

2025 Annual Meeting

November 9-13

Metro Toronto Convention Centre **Toronto, Ontario, Canada**

astmh.org ajtmh.org #TropMed25

in



>








POCKET GUIDE

Medscape



Breaking Dengue's Grip

Epidemiology, Immune Responses, and Vaccine Advances

TUESDAY, NOVEMBER 11, 2025 | 6:15 pm − 8:00 pm et IN-PERSON (3)

CONVENTION CENTRE | ROOM: 718A | Dinner buffet will be served!

Moderator/Course Director: Davidson H. Hamer, MD | Boston, Massachusetts, United States

AGENDA

- · Welcome and Introductions
- Medscape Quiz Show: Dengue, A Public Health Concern
- Immune Responses During Dengue Infection
- Overview of the Currently Available Dengue Vaccines
- Bridging the Gap: Understanding Risk and Vaccine Acceptance
- · Panel Discussion
- Summary and Audience Q&A



This sponsored symposium is held in conjunction with the 2025 ASTMH Annual Meeting

For more information and to register, visit: www.medscape.org/symposium/dengue-epidemiology-ir-vaccination

Supported by an independent educational grant from Takeda.

Produced by Medscape LIVE!



denotes Livestream Session



denotes Educational Content

Sunday, November 9

Monday, November

10

Tuesday, November 11

Wednesday, November 12

Thursday, November 13

Convention Center and Hotel Floor Plans

Welcome to the ASTMH 2025 Annual Meeting!

The American Society of Tropical Medicine and Hygiene, founded in 1903, is the largest international scientific organization of experts dedicated to reducing the worldwide burden of tropical infectious diseases and improving global health. We accomplish this through generating and sharing scientific evidence, informing health policies and practices, fostering career development, recognizing excellence, and advocating for investment in tropical medicine/global health research.



Become an ASTMH Member

ASTMH is the largest interdisciplinary global health scientific society, representing a large network of international scientists, clinicians and global health professionals. By joining ASTMH, you can connect with respected leaders in the field and share the latest data, engage in scientific discourse and collaborate on Society activities through committee work, and gain access to the *American Journal of Tropical Medicine and Hygiene* or one of the Society's five specialty subgroups.

Visit www.astmh.org for ASTMH membership information or use this QR code



Become an Affiliate Member

Affiliate Membership offers a cost-effective way for universities, university programs, NGOs, research groups and professional societies throughout the world that have an interest in clinical and basic tropical medicine, infectious diseases and global public health to join and lend their voice to a Society that is a leader in its field.

Thank you to our current Affiliate Contributor Members
Clemson University
Columbia University Irving Medical Center
Hind Hamad Alrowais (Consultant)
University of Vermont College of Medicine







Meeting App

Use the Meeting App to search the Annual Meeting program:

- Search the full session schedule, including Poster Sessions and presenters
- Search by speaker, abstract or topic
- Learn about sponsors and exhibitors participating in the Annual Meeting
- Network with peers



Use this QR code to download the Meeting App

Content Tags for Symposium Sessions and Scientific Sessions

In order to assist attendees in searching for specific content, content tags appear at the end of the descriptions for Symposia and Scientific Sessions in the Meeting App.


Sessions Designated for Educational Content

Educational content is increasingly relevant to all disciplines within ASTMH, as well as to those at all career stages. Throughout this Pocket Guide, you will find sessions labeled as **Educational Content** that feature an instructive/didactic format on specialized topics by field experts, reviews of novel therapeutics and diseases, and public policy content. In addition, you can search sessions in the Meeting App using the Educational Content filter.



Continuing Education Credit

- If you did not pre-register for CME credit or Veterinarian CE credit, visit the Registration Desk to register and make payment of documentation fee of \$200 US.
- Claim CME/Veterinarian CE credit for one session during a period of concurrent sessions.
- For CME credit, complete the CME Survey and CME Claim Form by Monday, November 24 here: astmh.org/annual-meeting/continuing-education-credit
- For Veterinarian CE credit, complete the Claim Form by Monday, November 24 here:
 astmh.org/annual-meeting/2025RegPacket



AJTMH — Get to know the Journal at the 2025 Annual Meeting

Be sure to look for the *Journal* table near the Poster Hall, *AJTMH* editors will be available to discuss manuscript submissions, advertising, supplements, etc. Check out AJTMH.org for more information.





THE AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Official Journal of the American Society of Tropical Medicine and Hygiene

Social Media at the 2025 Annual Meeting

Connect with ASTMH year-round on LinkedIn and our new BlueSky account, in addition to Facebook, Instagram and X (Twitter). Visit astmh.org to access all social media outlets as follows:

in











Follow the American Society of Tropical Medicine and Hygiene on LinkedIn. Raise your professional profile when you promote your Annual Meeting presentation, attendance, award or ASTMH membership.

On BlueSky, follow ASTMH at @astmh.bsky.social and on X at @ASTMH. During the conference, you can follow what your colleagues are posting on BlueSky, X and Facebook by using the #TropMed25 and #IamTropMed hashtags. Also follow @AJTMH on X for Journal updates.

ASTMH also has a **YouTube channel**. Enjoy archived video from past Annual Meetings, Alan Magill Symposia, webinars and interviews with pioneers in the tropical medicine and global health field.



Travel the Exhibit Hall with the Exhibitor Passport!

Use your Exhibitor Passport to visit participating exhibit booths and become eligible for a chance to win a free ASTMH membership. This fun and interactive activity will maximize your exposure with exhibitors and provide invaluable networking opportunities. You can find a map to all of our exhibitors in the Meeting App.

Registration Hours

Convention Center - Level 600

Sunday, November 9	8 a.m 7:30 p.m.
Monday, November 10	7 a.m 5 p.m.
Tuesday, November 11	7 a.m 5 p.m.
Wednesday, November 12	7 a.m 5 p.m.
Thursday, November 13	7 a.m 10:30 a.m.



Questions?

Scan to view a list of the **Most Frequently Asked Questions**about the Annual Meeting.

Speaker Ready Room Hours

Convention Center - Room 703 (Level 700)

Submit your slides to the Speaker Ready Room at least 24 hours in advance of your scheduled session.

Sunday, November 9	Noon – 6 p.m.
Monday, November 10	7 a.m. – 6 p.m. (Closed Noon – 1 p.m.)
Tuesday, November 11	7 a.m 5 p.m. (Closed 11:30 a.m 12:30 p.m.)
Wednesday, November 12	7 a.m. – 7 p.m. (Closed 10:30 a.m 11:30 a.m.)
Thursday, November 13	7 a.m. – Noon

Poster Session Schedule

Convention Center - Poster Hall (Level 800)

Poster Session A - Monday, November 10

Set-Up	7 a.m. – 7:30 a.m.
Viewing	7:30 a.m. – 12:30 p.m.
Presentations	12:30 p.m. – 2:15 p.m.
Viewing	2:15 p.m. – 4 p.m.
Dismantle	4 p.m. – 6:45 p.m.

Presenters are responsible for dismantling posters. Posters left behind at the close of the dismantle period will be disposed of and are not the responsibility of ASTMH or the Metro Toronto Convention Centre.

Poster Session B - Tuesday, November 11

Set-Up	7 a.m 7:30 a.m.	
Viewing	7:30 a.m. – Noon	
Presentations	Noon – 1:45 p.m.	
Viewing	1:45 p.m. – 3:30 p.m.	
Dismantle	3:30 p.m. – 6:15 p.m.	

Poster Session C - Wednesday, November 12

Set-Up	7 a.m. – 7:30 a.m.
Viewing	7:30 a.m. – 11 a.m.
Presentations	11 a.m. – 12:45 p.m.
Viewing	12:45 p.m. – 2:30 p.m.
Dismantle	2:30 p.m. – 5:15 p.m.

Check out these new events at the 2025 Annual Meeting!

Fever Feud Educational Quiz Show

A Tropical Medicine Spin on TV's "Family Feud"

Monday, November 10 6:45 p.m. - 8:15 p.m.

Convention Center - Hall F/G (Level 800)



Mentorship Pop-Up Sessions — Expanded program!

Convention Center - Level 600 Lobby (Level 600)

Mentorship Pop-Up Sessions are designed to foster meaningful interactions among emerging innovators, early-career professionals and seasoned experts across various fields. This space will provide a unique opportunity for networking, knowledge exchange and collaboration, contributing to the advancement of innovative solutions in global health.

Attend a Mentorship Pop-Up Session!

Convention Center - Level 600 Lobby (Level 600)

Mentorship Pop-Up Sessions are designed to foster meaningful interactions among emerging innovators, early career professionals and seasoned experts across various fields. This space will provide a unique opportunity for networking, knowledge exchange, and collaboration, contributing to the advancement of innovative solutions in global health. These sessions will be held in the Mentorship Pop-Up area located in the Lobby on Level 600 of the Metro Toronto Convention Centre.

Monday, November 10

10:15 a.m11:15 a.m.	Global Health Innovation in 60 Seconds: Pitch & Connect
1:15 p.m 2:15 p.m.	AI for Global Health: Techniques for Impact
5:15 p.m 6:15 p.m.	Professional Development Needs of Mid-Career Professionals in Tropical Medicine and Global Health

Tuesday, November 11

7:30 a.m 9 a.m.	This Week in Parasitology (TWiP) Podcast Taping 1
9 a.m 10 a.m.	This Week in Virology (TwiV): Clinical Update with Dr. Daniel Griffin Podcast Taping 2

10 a.m 11 a.m.	Green up Your Lab, Clinic and Field Work with the ASTMH Green Task Force!
11:15 a.m 12:15 p.m.	Global Health Politics: A View from the Social Sciences
1:30 p.m 2:30 p.m.	African Voices of Science (AVoS): Amplifying African Leadership in Global Health Research & Innovation
5:15 p.m 6:15 p.m.	Missing Data, Missed Opportunities: Integrating Sex and Gender in Global Health R&D

Wednesday, November 12

8:45 a.m 9:45 a.m.	Rotary and Malaria – How Rotary Interacts with Global Malaria Efforts
10:15 a.m11:15 a.m.	Anchored in Africa: Building Local Leadership in Women's Health R&D
12:30 p.m 1:30 p.m.	Equitable Partnership in Health and Beyond
2 p.m 3 p.m.	Career Chats: Scientific Job Hunting in Industry - Differentiating Yourself from the Crowd
3 p.m 4 p.m.	Clinical Syndromes Around the World
4 p.m 5 p.m.	Youth Voices Driving Advocacy Impact: Making the Case for Noma

Sponsored Symposia Sponsors



Breaking Dengue's Grip: Epidemiology, Immune Responses and Vaccine Advances



Malaria Fradication in our Lifetime: Don't Stop Believing



Outbreaks Without Headlines: Surveillance, Reporting, and Vaccination Against Chikungunya



MERCK

Towards Next-Generation Prevention Tools to Combat Malaria: Long-Acting Antimalarials and Chemovaccination



SC Johnson Healthier World



Spatial Repellents: A New Frontier in Vector Control



Critical Diagnostic Decisions in Tropical Fever: Evolving Approaches with Fast **Diagnostics Testing**



Elimination at Scale: India's Integrated Model to Beat Vector Borne Diseases. with a Focus on Lymphatic Filariasis and Visceral Leishmaniasis

Towards next-generation prevention tools to combat malaria – long-acting antimalarials and chemovaccination



SPEAKERS



Ally Olotu, MD, PhD

Director of Science, Ifakara Health Institute Bagomoyo, Tanzania



Justin Boddey, PhD

Associate Professor, Laboratory Head, Walter and Eliza Hall Institute of Medical Research (WEHI) • Melbourne, Australia



Cristina Donini, PharmD, PhD

Executive Vice President, Head of Research Early Development and Modeling, Medicines for Malaria Venture (MMV) • Geneva, Switzerland METRO TORONTO CONVENTION CENTRE ROOM 717 • TORONTO, CANADA

Tuesday, 11 November 2025 • 07:00 – 08:45 AM (EST)

Symposium sponsored by Merck

Held in conjunction with the 2025 Annual Meeting

Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.



JOIN OUR SPONSORED BREAKFAST SYMPOSIUM

Outbreaks Without Headlines: Surveillance, Reporting, and Vaccination against Chikungunya



The symposium will address current chikungunya hotspots, traveler risks, under-reporting and surveillance gaps, the significance of diagnosing and reporting chikungunya cases, and the latest data on approved vaccines and their practical uses

SPEAKERS

Kamran Khan, MD, MPH, FRCPC, University of Toronto, Toronto, Canada Marta Díaz Menéndez, MD, PhD, Hospital La Paz-Carlos III, Madrid, Spain

TUESDAY, NOVEMBER 11TH - 7:00AM - 8:45AM ROOM 713, CONVENTION CENTER



Are you unable to attend our symposium?

Contact us to receive the recording!

medical.affairs@bavarian-nordic.com



INNOVATIVE DIAGNOSTICS FOR CHALLENGING TROPICAL DISEASES



BIOFIRE FILMARRAY TROPICAL FEVER PANEL

1 Test. 6 Targets. ~50 Minutes.

VISIT US BOOTH 307 SYMPOSIUM
TO FIND OUT MORE

TUESDAY, NOVEMBER 11TH 7 - 8.45 a.m. Room **715**

CRITICAL DIAGNOSTIC DECISIONS IN TROPICAL FEVER: EVOLVING APPROACHES WITH FAST DIAGNOSTICS TESTING

BREAKFAST PROVIDED VENUE: CONVENTION CENTER

BIOFIRE® FILMARRAY® Tropical Fever Panel is not approved by Health Canada in Canada This Sponsored Symposium is held in conjunction with the 2025 Annual Meeting



American Society of Tropical Medicine and Hygiene

241 18th Street South, Suite 501 Arlington, VA 22202 USA Phone: +1-571-351-5409 Email: info@astmh.org

Advancing Global Health Since 1903















BECOME AN ASTMH MEMBER

Become part of the global health community dedicated to reducing the worldwide burden of tropical infectious diseases and improving global health. Being a member of ASTMH means access to research on the latest diseases and treatments, a standing within your global community, learning about clinical cases and field work, and finding collaborators.

To join, visit ASTMH at astmh.org



Malaria eradication in our lifetime: don't stop believing

Bending the malaria burden curve towards zero by combining breakthrough technologies, strategies and leadership from endemic countries and their supporters.

Wednesday, 12 November 7:00 – 8:45am* Location:

Convention Centre,
Room 717
South

Building

* Breakfast will be served from 6:45am

Co-chairs:

- Dr Jean-Luc Bodmer, Gates Foundation, USA
- → Dr Cristina Donini, Medicines for Malaria Venture, Switzerland

Speakers:

- → Prof. Richard Amewu, University of Ghana
- → Dr Busiku Hamainza, Ministry of Health, Zambia
- Prof. Justice Nonvignon, Management Sciences for Health, USA and University of Ghana
- Prof. Melissa Penny, The Kids Research Institute Australia
- → Dr Tim Wells. Medicines for Malaria Venture. Switzerland

Gates Foundation and MMV
ASTMH 2025 Annual Meeting.

Gates Foundation

This is a sponsored symposium by Gates Foundation and MMV and is held in conjunction with the ASTMH 2025 Annual Meeting.



Spatial Repellents: A New Frontier in Vector Control

JOIN US for a compelling session that traces the journey of SC Johnson's spatial repellent technology from concept to global impact, culminating in its historic inclusion as the first new tool in the WHO vector control toolbox in over a decade.

This sponsored symposium will spotlight the real-world effectiveness of spatial repellents and the lessons learned through deployments across diverse geographies.

Whether you're a researcher, policymaker, or implementer, this symposium offers a unique opportunity to engage with leaders shaping the next generation of vector control.

Featuring speakers from: United to Beat Malaria, SC Johnson Healthier World Initiative, as well as representatives from country programs, NGOs, and research partners.

The sponsored symposium will include Q&A. Coffee and light breakfast will be served.

Wednesday, November 12

7:00 - 8:45 a.m. | Room 713 | Convention Center

We look forward to seeing you there!

This sponsored symposium is being held in conjunction with the 2025 Annual Meeting.



SC Johnson Healthier World United to BEAT MALARIA















VISIT US AT ROOM 602

Snacks and beverages will be served from 7:00 am

MODEL TO BEAT VECTOR BORNE DISEASES,
WITH A FOCUS ON LYMPHATIC FILARIASIS
AND VISCERAL LEISHMANIASIS

Tuesday, November 11, 2025 7:00 a.m. - 8:45 a.m. Convention Centre Room 602

Gates Foundation and CHAI are the sponsors of this symposium. This sponsored symposium is being held in conjunction with the ASTMH 2025 Annual Meeting.

Supporting Partners

















Medscape GLOBAL



Breaking Dengue's Grip

Epidemiology, Immune Responses, and Vaccine Advances

TUESDAY, NOVEMBER 11, 2025 | 6:15 PM – 8:00 PM ET IN-PERSON (*)

CONVENTION CENTRE | ROOM: 718A | Dinner buffet will be served!

Moderator/Course Director: Davidson H. Hamer, MD | Boston, Massachusetts, United States

Panelists: Julio Croda, MD, PhD | Campo Grande, Brazil Albert I. Ko, MD | New Haven, Connecticut, United States Sujan Shresta, PhD | La Jolla, California, United States



This sponsored symposium is held in conjunction with the 2025 ASTMH Annual Meeting

For more information and to register, visit: www.medscape.org/symposium/dengue-epidemiology-ir-vaccination

Sunday, November 9		Room Name
7 a.m 7 p.m.	Nursing Mothers Room Please pick up the room key at the Registration Desk, Level 600	Convention Center – Room 702 (Level 700)
7 a.m 7 p.m.	Prayer Room	Convention Center - Room 810 (Level 800)
8 a.m 7:30 p.m.	Registration	Convention Center - Registration Lobby Area (Level 600)
8:15 a.m 5 p.m.	Update Course in Clinical Tropical Medicine and Travelers' Health	InterContinental Hotel - Caledon (Upper Level)
8:30 a.m 3:45 p.m.	Parasitology Pre-Meeting Course: Learning with the Innovators: Global Health Transformation Through Basic Science Interventions	Offsite at University of Toronto
8:30 a.m 5 p.m.	Clinical Pre-Meeting Course: Challenges in the Treatment of Tropical Diseases: Emerging Resistance and Difficult to Manage Infections	InterContinental Hotel - Oakville Room (Upper Level)
9 a.m 2 p.m.	Young Investigator Award Session A	Convention Center - Room 701A (Level 700)

6693: A COMPARATIVE ANALYSIS OF DENGUE, CHIKUNGUNYA, AND ZIKA MANIFESTATIONS IN A PEDIATRIC COHORT...
6700: PARENTS' EXPECTATIONS FOR THE MANAGEMENT OF PEDIATRIC DIARRHEA IN THE CLINICAL SETTING...
6904: DEVELOPING A CORE OUTCOME SET FOR TRIALS IN THE TREATMENT OF SEVERE MALARIA
7035: ASSESSMENT OF DISEASE SEVERITY SCORE TRAJECTORY IN A CONTROLLED HUMAN INFECTION MODEL CHALLENGE...
7064: INTERSECTING EPIDEMICS: THE CO-OCCURRENCE OF DIABETES AND LYMPHATIC FILARIASIS IN SOUTH INDIA
7131: DIARRHOEAL PATHOGEN DIVERSITY AMONG CHILDREN UNDER FIVE YEARS IN COASTAL ANLOGA DISTRICT OF GHANA

7424: MONITORING GHANA'S PROGRESS TOWARDS ELIMINATING HEPATITIS B AS A PUBLIC HEALTH THREAT: A BASELINE ASSESSMENT...

7494: HYPOXIC BRAIN INJURY FINDINGS ON MRI IN CHILDREN WITH CEREBRAL MALARIA: CLINICAL RISK FACTORS. OUTCOMES...

7643: PREVALENCE AND FACTORS ASSOCIATED WITH PREHOSPITAL DELAYS IN SEEKING CARE AMONG SEPSIS PATIENTS...

7793: PREVENTING POSTPARTUM MALARIA: A STUDY OF ARTEMISININ COMBINATION THERAPY AT TIME OF DELIVERY TO IMPROVE...

7843: WEATHER VARIABLES AS PREDICTORS OF CRYPTOSPORIDIUM-ATTRIBUTED ACUTE DIARRHEA AMONGST CHILDREN IN LMICS

7844: CLINICAL PREDICTION MODEL FOR VIRAL ETIOLOGY OF ACUTE DIARRHEA IN US CHILDREN PRESENTING FOR EMERGENCY CARE

7855: CEREBROSPINAL FLUID TAU ASSOCIATION WITH PROLONGED COMA AND NEUROLOGICAL DEFICIT AT DISCHARGE...

7916: SAFETY PROFILE, CLINICAL RESPONSES AND OUTCOMES FROM A FIRST-IN-HUMAN SALMONELLA TYPHIMURIUM...

9 a.m. - 2 p.m.

Young Investigator Award Session B

Convention Center - Room 701B (Level 700)

6075: BLOOD RNA TRANSCRIPTS FOR DIAGNOSING AND PREDICTING THE OUTCOMES OF FEBRILE ILLNESSES...

6247: ADVANCING DENGUE SERODIAGNOSTICS: LEVERAGING EPITOPE INSIGHTS FOR PEPTIDE-BASED TEST DEVELOPMENT

6319: GEOGRAPHICAL DISTRIBUTION AND TEMPORAL TRENDS OF ANTIMALARIAL DRUG RESISTANCE MARKERS IN UGANDA: 2023-24

6580: PERFORMANCE OF A RAPID URINARY POINT-OF-CARE ASSAY FOR NEUROCYSTICERCOSIS DIAGNOSIS...

6626: SPATIAL TRANSCRIPTOMICS AND MULTIPLEX IMAGING REVEAL DISTINCT BLOOD-BRAIN BARRIER SIGNATURES...

6662: CANDIDATE AUTOANTIBODIES AS BIOMARKERS OF THERAPEUTIC RESPONSE FOLLOWING BENZNIDAZOLE TREATMENT...

6668: IDENTIFYING ANTIBODY BIOMARKERS THAT PREDICT PROGRESSION OF CHAGAS CARDIOMYOPATHY

6672: MACHINE LEARNING IDENTIFIES METABOLIC BIOMARKERS OF POST-EBOLA SYNDROME

6934: GENOMIC SURVEILLANCE OF MALARIA REVEALS EMERGENCE AND RISE OF THE K13 P441L CANDIDATE MARKER...

7111: COMMUNITY-LED SCHISTOSOMIASIS DIAGNOSTICS: THE FOLDSCOPE AND MICROFLUIDIC SLIDES IN RURAL NIGERIA

Room Name

7234: INTEGRATING PLASMODIUM KNOWLESI-SPECIFIC SEROLOGICAL MARKERS OF RECENT EXPOSURE IN A MULTIPLEX PANEL...

7237: DEPLOYING MOLECULAR MALARIA FIELD TESTING TO RURAL AFRICA: A LAMP-BASED APPROACH...

7476: ASSESSING THE RISK OF EXISTING AND EMERGING PFKELCH13 AND PFCORONIN VARIANTS CONFERRING ARTEMISININ RESISTANCE...

9 a.m. - 2 p.m.

Young Investigator Award Session C

Convention Center - Room 714 (Level 700)

6001: FECAL AND WATERBORNE ZOONOTIC PATHOGENS AND ASSOCIATED RISK FACTORS IN PEOPLE, DOMESTIC ANIMALS, AND LEMURS...

6042: INTEGRATED SEROSURVEILLANCE AND SPATIAL EPIDEMIOLOGY OF VACCINE PREVENTABLE DISEASES...

6615: EXPLORING THE USE OF ELECTRONIC HEALTH RECORD DATA TO EXAMINE CHAGAS DISEASE IN THE UNITED STATES

6635: MODELING THE IMPACT OF LOW-COST VENTILATION INTERVENTIONS ON NOSOCOMIAL RESPIRATORY INFECTION RISK...

6637: BEYOND SENSITIVITY AND SPECIFICITY: USING MACHINE LEARNING (ML) TO ENHANCE CHOLERA RAPID DIAGNOSTIC TEST...

6720: UNVEILING THE CAUSES OF WOMEN'S DEATHS DUE TO INFECTIOUS DISEASES IN BANGLADESH INSIGHTS...

6982: EVALUATING THE DUAL HEALTH AND EDUCATIONAL BENEFITS OF MALARIA CHEMOPREVENTION IN SCHOOL-AGED CHILDREN...

7032: ANTIBIOTIC RESISTANT COAGULASE-NEGATIVE STAPHYLOCOCCI ISOLATED FROM STILLBIRTHS AND POSTMORTEM NEONATAL..

7282: TROPICAL OCEAN TEMPERATURE ANOMALIES PREDICT DENGUE TRENDS IN ASIA AND THE AMERICAS

7753: PRENATAL AND POSTNATAL ENVIRONMENTAL INFLUENCES ON CHILD GROWTH TRAJECTORIES: AN ANALYSIS...

7757: INTER-RATER AGREEMENT OF METHODS TO EVALUATE HAND CLEANLINESS TO STUDY TRACHOMA RISK...

7912: POST-INTRODUCTION IMPACT OF THE TYPHOID CONJUGATE VACCINE ON TYPHOID FEVER IN MALAWI - MITIMA STUDY RESULTS

7945: RISING DENGUE RISK WITH INTENSIFIED CLIMATE MODES AND TELECONNECTIONS UNDER GREENHOUSE WARMING

Convention Center - Room 715 (Level 700) 6022: IMMUNE DYSREGULATION AND NEUTROPHIL RESPONSES IN FRYTHEMA NODOSIIM I EPROSIIM

6280: B CELL RECEPTOR DEPENDENT ENHANCEMENT OF DENGUE VIRUS INFECTION

6281: CELL INTRINSIC MECHANISMS OF ANTIBODY-DEPENDENT ENHANCEMENT OF DENGUE VIRUS INFECTION

6284: ANTIBODY RESPONSE TO AFDES AFGYPTI D7I 1+2 SALIVARY PROTFINS AS MARKER OF AGGREGATE VECTOR EXPOSURE AND...

6440: OVERCOMING HLA RESTRICTION AND PARASITE DIVERSITY IN PLASMODIUM FALCIPARUM VACCINE DESIGN...

6669: A NEW THREAT IN THE TROPICS: MODELING REEMERGENT 2024 OROPOUCHE VIRUS PATHOGENESIS...

6685: INTEGRATING MULTI-OMICS APPROACHES TO UNCOVER MARKERS OF MALARIA DISEASE SEVERITY...

6861: ROTAVIRUS VP6-SPECIFIC T-CELL RESPONSES AND CELLULAR IMMUNOPHENOTYPES IN ZAMBIAN INFANTS...

6898: ANTIPI ASMODIAL ACTIVITY OF PROBIOTIC BACTERIUM ENTEROCOCCUS LACTIS ISOLATED FROM FULANI FERMENTED MILK IN PLASMODIUM...

7156 PARADOXICAL FEFECTS OF ASCARIS-INDUCED PYLORIC METAPLASIA: REDUCING ASCARIS REINFECTION BUT CREATING HELICOBACTER...

7769: EXTRACELLULAR VESICLES OF TAENIA SOLIUM SUPPRESSES REACTIVE OXYGEN SPECIES PRODUCTION IN NEUTROPHILS AND...

7924: IT'S COMPLICATED: MODELLING THE IMMUNE EVASION PHENOTYPIC IMPACT OF MABS TO RH5 IN THE CONTEXT OF MIXED ALLELES...

7933: DISTINCT AND CONTRASTING NEUTROPHIL PHENOTYPES AND FUNCTIONAL PROFILES IN HUMAN INFECTIONS...

9 a.m. - 2 p.m. Young Investigator Award Session E

Convention Center - Room 716 (Level 700)

Room Name

6372: GLOBAL CHARACTERIZATION OF DIVERSITY AND SELECTIVE PRESSURES IN FIVE LOCI IDENTIFIED BY WHOLE-GENOME SIEVE ANALYSIS ..

6629: WIDESPREAD GENE FUSION ARTIFACTS IN HEI MINTH GENOMES

6650: POWASSAN VIRUS ELICITS DIFFERENTIAL HOST IMMUNE RESPONSES DURING NATURAL TICK-MEDIATED TRANSMISSION

7137: PLASMODIUM FALCIPARUM UBIQUITIN-PROTEASOME SYSTEM (UPS) MODULATING ANTIMALARIAL RESISTANCE

Sunday, November 9

7194: PREDICTING NOVEL MOLECULAR MARKERS ASSOCIATED WITH REDUCED SENSITIVITY OF PLASMODIUM FALCIPARUM TO...

7288: GENOMIC SURVEILLANCE REVEALS GEOGRAPHICAL HETEROGENEITY AND DIFFERENCES IN KNOWN AND NOVEL...

7488: HIGH-DENSITY TEMPORAL AND SPATIAL SURVEILLANCE IN RWANDA REVEALS INCREASING VALIDATED...

7544: GENOMIC CHARACTERIZATION OF PLASMODIUM FALCIPARUM TRANSMISSION NETWORKS ACROSS ANGOLA>S DIVERSE...

7609: STRUCTURE OF MALARIA SPOROZOITE-STAGE ANTIBODY 3C1 AND POTENTIAL THERAPEUTIC APPLICATIONS

7626: INVESTIGATION OF MICRONUTRIENT AND ENERGY METABOLISM DIFFERENCES IN LATENT AND CLINICAL LEPROSY...

7777: CHARACTERIZATION OF CIRCULATING VIRAL ISOLATES OF POWASSAN VIRUS LINEAGE II

7829: CONSERVED RESIDUES IN THE ORTHOFLAVIVIRUS ENVELOPE PROTEIN SERVE A DUAL PURPOSE...

7853: NEUREGULIN-1 MITIGATES HEME-INDUCED INJURY IN IPSC-DERIVED ENDOTHELIAL CELLS FROM CHILDREN WITH VARIOUS...

7874: DEEP LEARNING-GUIDED CARTOGRAPHY METHOD FOR ANALYZING PATTERNS AND MOLECULAR DETERMINANTS...

7955: PFAPIAT2 MEDIATES PROLINE TRANSPORT AND IS ESSENTIAL FOR OOCYST DEVELOPMENT AND TRANSMISSION...

9 a.m. - 2 p.m.

Young Investigator Award Session F

Convention Center - Room 717 (Level 700)

6208: COMPARATIVE ATTRACTION OF ANOPHELES QUADRIANNULATUS AND ANOPHELES ARABIENSIS TO HUMANS ESTIMATED...

6216: ANOPHELES SUBPICTUS, AN EMERGING VECTOR IN MALARIA TRANSMISSION IN THE WESTERN PART OF INDIA...

6217: ADULT ANOPHELES FUNESTUS FROM DIFFERENT GEOGRAPHICAL LOCATIONS EXPRESS VARIABLE MATING RESPONSES TO IDENTICAL.

6219: FORECASTING WEST NILE VIRUS IN MARICOPA COUNTY USING CLIMATE FACTORS

6250: UNMASKING AN UNDERREPORTED EPIDEMIC: SEROPREVALENCE AND SEASONAL TRENDS OF DENGUE VIRUS IN NIGERIA

Noon – 2 p.m	. ACCTMTH Clinical Research Award Session 6073: DEFINING THE EPIDEMIOLOGY OF ACUTE FEBRILE ILLNESS IN RURAL SOUTH AND SOUTH	Convention Center - Room 713 (Level 700)		
Noon - 2 p.m.	American Committee on Arthropod-Borne Viruses and Zoonotic Viruses (ACAV) SIRACA Subcommittee Meeting	Convention Center - Room 604 (Level 600)		
11 a.m Noo	American Committee on Arthropod-Borne Viruses and Zoonotic Viruses (ACAV) SIE Subcommittee Meeting	Convention Center - Room 604 (Level 600)		
	7773: RETROSPECTIVE GENOMIC SURVEILLANCE OF ST. LOUIS ENCEPHALITIS VIRUS IN TEXAS,	USA FROM 2009-2024 REVEALED		
	7742: FROM DEMONSTRATION TO SUSTAINABILITY: EVALUATING THE POST-ELIMINATION PHASE	E OF THE MALARIA ELIMINATION		
	7455: ARBOVIRUS PREVALENCE IN MOSQUITOES ACROSS DIFFERENT LAND USE HABITATS IN T	THE GAMBIA		
	7438: ECOLOGICAL MODELING OF ASSOCIATIONS BETWEEN CONFLICT, ENVIRONMENTAL FACTO	RS, AND DENGUE INCIDENCE IN SUDAN		
	7219: INVESTIGATING OPPORTUNITIES FOR TARGETED LARVAL SOURCE MANAGEMENT IN RURA	ESTIGATING OPPORTUNITIES FOR TARGETED LARVAL SOURCE MANAGEMENT IN RURAL COMMUNITIES WHERE MALARIA		
	6835: DEFINING THE GEOGRAPHIC DISTRIBUTION OF ORTHOFLAVIVIRUS SEROPOSITIVITY IN NO	DRTHERN VICTORIA, AUSTRALIA		
	6670: GENOMIC CHARACTERIZATION OF ARBOVIRUSES DISCOVERED BETWEEN THE 1950S AND	1980S		
	6630: ESTIMATING THE GLOBAL BURDEN OF SCRUB TYPHUS			
	6410: MODEL-BASED ASSESSMENT OF CHLORFENAPYR-ALPHA-CYPERMETHRIN NETS VERSUS	STANDARD PYRETHROID NETS		
	6361: PREVALENCE AND RISK FACTORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIE	NCY AMONG A <i>PLASMODIUM VIVAX</i> MALARIA		
	6350: FINE SCALE SPATIAL MAPPING OF URBAN MALARIA PREVALENCE FOR MICROSTRATIFICA	TION IN AN URBAN AREA OF GHANA		

Room Name

6073: DEFINING THE EPIDEMIOLOGY OF ACUTE FEBRILE ILLNESS IN RURAL SOUTH AND SOUTHEAST ASIAN PRIMARY CARE
6268A: TEMPORAL TRENDS AND PREDICTIVE MODELING OF ROTAVIRUS-ATTRIBUTABLE HOSPITALIZATIONS IN CHILDREN UNDER...
6700: PARENTS' EXPECTATIONS FOR THE MANAGEMENT OF PEDIATRIC DIARRHEA IN THE CLINICAL SETTING...

Sunday,

7553: COORDINATED IMMUNITY: CYTOKINE PROFILES REVEAL KEY DYNAMICS UNDERLYING CLINICAL OUTCOMES...

7758: COMPARATIVE EVALUATION OF ENVIRONMENTAL SURVEILLANCE METHODS FOR DETECTING SALMONELLA TYPHI IN...

7878: PNEUMOCOCCAL SEROTYPE REPLACEMENT IN THE POST-PCV ERA; IMPLICATIONS FOR VACCINE POLICY IN BANGLADESH

Noon - 5 p.m.	Press Room	Convention Center - Room 704 (Level 700)
Noon - 6 p.m.	Speaker Ready Room	Convention Center - Room 703 (Level 700)
1 p.m 4 p.m.	AJTMH Meet the Editors and Writing Workshop (advance registration required)	Convention Center - Room 718B (Level 700)
1 p.m 2 p.m.	Point-of-Entry: First-Time Attendee Orientation	Convention Center - Room 602 (Level 600)
2 p.m 3 p.m.	ACCTMTH Clinical Research Award Committee Meeting	Convention Center - Room 713 (Level 700)
2 p.m 3:30 p.m.	Young Investigator Award Committee Meeting	Convention Center - Room 714 (Level 700)
2 p.m 3:30 p.m.	American Committee on Arthropod-Borne Viruses and Zoonotic Viruses (ACAV) SALS Subcommittee Meeting	Convention Center - Room 604 (Level 600)
2:30 p.m 3:30 p.m.	Student Reception	Convention Center - Room 501 (Level 500)
3:30 p.m 5:30 p.m.	American Committee on Arthropod-Borne Viruses and Zoonotic Viruses (ACAV) Council Meeting	Convention Center - Room 604 (Level 600)
3:30 p.m 5:30 p.m.	Clinical Group (American Committee on Clinical Tropical Medicine and Travelers' Health - ACCTMTH) Council Meeting	Convention Center - Room 802A (Level 800)
3:30 p.m 5:30 p.m.	ASTMH Committee on Global Health (ACGH) Council Meeting	Convention Center - Room 711 (Level 700)
3:30 p.m 5:30 p.m.	ASTMH Committee on Global Health (ACGH) Council Meeting	Convention Center - Room 711 (

Sunday, November 9		Room Name
3:30 p.m 5:30 p.m.	American Committee of Medical Entomology (ACME) Council Meeting	Convention Center - Room 709 (Level 700)
3:30 p.m 5:30 p.m.	American Committee of Molecular, Cellular and Immunoparasitology (ACMCIP) Council Meeting	Convention Center - Room 606 (Level 600)
3:45 p.m 4:30 p.m.	Young Investigator Award Reception	Convention Center - Room 718A (Level 700)
	SPONSORED BY Pfizer	
5:30 p.m 7 p.m.	Plenary Session 1: Plenary Session I: Opening Keynote and Awards Program	Convention Center - Hall F/G (Level 800)
5:30 p.m.	WELCOMING REMARKS	
5:45 p.m.	KEYNOTE ADDRESS: CAN HIV TRANSFORM GLOBAL HEALTH? LESSONS LEARNED	AND CURRENT CHALLENGES
6:05 p.m.	AWARDS CEREMONY	
7 p.m 9:30 p.m.	Opening Reception	Convention Center - Hall D (Level 800) (Exhibit Hall)
7 p.m 9:30 p.m.	Exhibit Hall Open	Convention Center - Hall D (Level 800) (Exhibit Hall)

Monday, November 1	0	Room Name
7 a.m 5 p.m.	Registration	Convention Center - Registration Lobby Area (Level 600)
7 a.m 5 p.m.	TropStop - Student/Trainee Lounge	Convention Center - Room 401 (Level 400) (TropStop)
7 a.m 6 p.m.	Speaker Ready Room (Closed Noon - 1 p.m.)	Convention Center - Room 602B (Level 600)
7 a.m 7 p.m.	Meeting Sign-Up Room	Convention Center - Room 711 (Level 700)
7 a.m 7 p.m.	Nursing Mothers Room Please pick up the room key at the Registration Desk, Level 600	Convention Center – Room 702 (Level 700)
7 a.m 7 p.m.	Prayer Room	Convention Center - Room 810 (Level 800)
7 a.m 7:30 a.m.	Poster Session A Set-Up	Convention Center - Hall E (Level 800) (Poster Hall)
7:30 a.m 12:30 p.m.	Poster Session A Viewing	Convention Center - Hall E (Level 800) (Poster Hall)
7:30 a.m 8:15 a.m.	((*))) Plenary Session 2: Plenary Session II: Fred L. Soper Lecture	Convention Center - Hall F/G (Level 800)
7:30 a.m.	INTRODUCTION	
7:45 a.m.	FRED L. SOPER LECTURE: VALUE OF GLOBAL HEALTH INVESTMENTS TO THE UNITED STATES	
7:45 a.m 5 p.m.	Press Room	Convention Center - Room 704 (Level 700)
8:15 a.m 8:30 a.m.	Break	



Symposium 3: Responding to Recent Outbreaks of Emerging and Re-emerging Viruses

Convention Center - Hall F/G (Level 800)

TREAMING CONTENT		
	8:30 a.m.	INTRODUCTION
	8:40 a.m.	MEASLES RESURGENCE, CHALLENGES AND OPPORTUNITIES FOR CONTROL
	8:55 a.m.	INSIGHTS INTO THE YELLOW FEVER OUTBREAK IN SOUTH AMERICA
	9:10 a.m.	CHIKUNGUNYA OUTBREAK IN THE INDIAN OCEAN
	9:25 a.m.	BIOTHREATS EMERGENCE, ANALYSIS, AND COMMUNICATIONS NETWORK
	9:40 a.m.	UTILITY OF MULTI-PATHOGEN SEROSURVEILLANCE PLATFORMS TO DETECT EMERGING AND RE-EMERGING INFECTIOUS
cientific Se	ssion 4: One Health	I: The Interface of Humans, Ecosystems and Animal Health Convention Center - Room 701A (Level 700)
	8:30 a.m.	6000: HIDDEN THREAT TO URBAN PUBLIC HEALTH: METAGENOMIC EVIDENCE OF HIGH RISK ZOONOTIC PATHOGENS IN PET
	8:40 a.m.	6001: FECAL AND WATERBORNE ZOONOTIC PATHOGENS AND ASSOCIATED RISK FACTORS IN PEOPLE, DOMESTIC ANIMALS
	8:50 a.m.	6002: GENOMIC CHARACTERIZATION OF ORAL-RECTAL ESKAPE PATHOGENS, ISOLATED FROM BATS SPECIES SAMPLED
	9 a.m.	6003: PRELIMINARY RESULT ON THE PREVALENCE OF <i>SALMONELLA, E. COLI,</i> AND L. <i>MONOCYTOGENES</i> AT ONE HEALTH
	9:10 a.m.	6004: HUMAN-BAT INTERACTIONS IN BANGLADESH: A ONE HEALTH PERSPECTIVE ON PERCEIVED BENEFITS
	9:20 a.m.	6005: WASTEWATER-BASED BIOSURVEILLANCE OF PATHOGENS CAUSING ILLNESS IN US MILITARY TRAINING CENTERS
	9:30 a.m.	6006: SYNTHESIZING EVIDENCE REGARDING THE PREVALENCE OF ZOONOSES ACROSS SPECIES AND THE ENVIRONMENT
	9:40 a.m.	6007: ASSOCIATIONS BETWEEN ANIMAL OWNERSHIP AND MALARIA PREVALENCE OVER SPACE AND TIME IN SUB
	9:50 a.m.	6008: MATHEMATICAL MODELING METHODS DESCRIBING THE TRANSMISSION DYNAMICS OF ZOONOSES USING
	10 a.m.	6009: INTEGRATING SOCIOBEHAVIORAL APPROACHES TO CHARACTERIZE THE RISK PERCEPTION OF LIVESTOCK

Monday, November 10 Room Name

ntific Session 5: Malaria	- Surveillance and Data Use	Convention Center - Room 701B (Level 70)
8:30 a.m.	6010: USING ROUTINE HEALTH FACILITY DATA TO EVALUATE THE RET	ROSPECTIVE IMPACT OF LONG-LASTING
8:40 a.m.	6011: ENHANCING HEALTH CENTRE SURVEILLANCE TO MEASURE TH	COMBINED IMPACT OF RTS,S MALARIA VACCINE
8:50 a.m.	6012: EVALUATING THE REAL-WORLD IMPACT OF SEASONAL MALARIA	A CHEMOPREVENTION (SMC) IN BURKINA FASO
9 a.m.	6013: OPTIMIZATION OF SMC CAMPAIGNS THROUGH DIGITALIZED MIC	RO-PLANNING IN DHIS2: PILOT PHASE IN MALI
9:10 a.m.	6014: EVALUATING THE PERFORMANCE OF MALARIA SENTINEL SURV	EILLANCE SITES IN THE DRC
9:20 a.m.	6015: PRIVATE SECTOR CASE MANAGEMENT IN NIGERIA: FINDINGS FI	ROM THE 2024 ACTWATCH LITE SURVEY
9:30 a.m.	6016: REVOLUTIONIZING MALARIA RISK: DATA FUSION MODELLING A	PPROACHES FOR DEVELOPING ROBUST MALARIA
9:40 a.m.	6017: QUANTIFYING RESIDUAL PLASMODIUM VIVAX TRANSMISSION I	N THE PHILIPPINES USING SEROLOGICAL MARKERS
9:50 a.m.	6018: TARGETED MOLECULAR SURVEILLANCE TO CHARACTERIZE A M	IULTI- <i>PLASMODIUM</i> SPECIES OUTBREAK
10 a.m.	LIGHTNING TALKS	
	7582: PERSPECTIVES OF KEY STAKEHOLDERS ON THE USE OF INFRA	RED SPECTROSCOPY FOR MALARIA SURVEILLANCE
	7583: DRIVERS OF QUALITY OF ROUTINE HEALTH FACILITY MALARIA	DATA IN UGANDA
	7587: LEVERAGING MALARIA CAMPAIGN DATA TO INFORM POPULATION ESTIMATES ON BIOKO ISLAND	
	7585: SPATIAL EXPLORATION OF THE IMPACT OF LIVESTOCK ON MALARIA TRANSMISSION USING DATA	
	7584: MALARIA OUTBREAK PREDICTION AT THE SUB-DISTRICT LEVEL IN ZAMBIA USING REMOTE SENSING SATELLITE	
ntific Session 6: Clinical	Tropical Medicine: Bacterial Infections and Antibiotics	Convention Center - Room 713 (Level 700)
8:30 a.m.	6019: ULCERATIVE SKIN LESIONS: INVESTIGATION OF AN OUTBREAK IN MBANG HEALTH DISTRICT, EAST REGION	

	Room Name	
6020: POINT-OF-CARE COMPATIBLE MULTIPLEX/MULTI PARALLEL MOL	ECULAR DIAGNOSTICS FOR SKIN NEGLECTED	
6021: BACTERIAL CLEARANCE IN BURULI ULCER LESIONS FROM PATIE	NTS IN A CLINICAL TRIAL TO SHORTEN BURULI	
6022: IMMUNE DYSREGULATION AND NEUTROPHIL RESPONSES IN ERY	THEMA NODOSUM LEPROSUM: INSIGHTS	
6023: EFFECTIVENESS OF CLINICAL ALGORITHMS COMBINED WITH PO	INT OF CARE TESTING TO IMPROVE ANTIBIOTIC	
6024: COMPARISON OF CLINICAL PROFILE AND OUTCOMES OF SCRUB	TYPHUS AND SPOTTED FEVER IN INDIA	
6025: LEPTOSPIROSIS INCIDENCE IN JUNGLE WARFARE TRAINEES		
6026: UNCOVERING HIDDEN MORTALITY INSIGHTS IN TROPICAL SETTIN	NGS USING VERBAL AUTOPSY: LESSONS FROM A	
6027: PREVALENCE AND ASSOCIATED FACTORS OF TRACHOMA IN SCH	OOL IN THE TOKOMBERÉ HEALTH DISTRICT	
6028: SERO-EPIDEMIOLOGY OF SCRUB TYPHUS IN U.S. ACTIVE DUTY S	ERVICEMEMBERS DURING MILITARY TRAVEL	
nvironmental Cleaning: What Works	Convention Center - Room 714 (Level 700)	
INTRODUCTION		
NIGERIA CDC POLICIES AND STRATEGIES FOR IMPROVING ENVIRONMENTAL CLEANING		
IMPACT OF A MULTI-COMPONENT TRAINING INTERVENTION (CLEAN FRONTLINE) ON MICROBIOLOGICAL CLEANLINESS		
LESSONS LEARNED FROM A DECADE OF RESEARCH, IMPLEMENTATION AND POLICY IN IMPROVING HEALTHCARE		
IMPROVING ENVIRONMENTAL CLEANING COMPLIANCE IN HIGH-RISK U	INITS AS PART OF ANTIMICROBIAL RESISTANCE	
esearch Gaps in Chemoprevention Targeting School-Aged Children	Convention Center - Room 715 (Level 700)	
INTRODUCTION		
DIRECT AND INDIRECT IMPACT OF EXTENDED-AGE SMC IN BURKINA FA	450	
FEASIBILITY AND ACCEPTABILITY OF EXTENDED-AGE SMC IN BURKINA	A FASO	
	6021: BACTERIAL CLEARANCE IN BURULI ULCER LESIONS FROM PATIE 6022: IMMUNE DYSREGULATION AND NEUTROPHIL RESPONSES IN ERY 6023: EFFECTIVENESS OF CLINICAL ALGORITHMS COMBINED WITH PO 6024: COMPARISON OF CLINICAL PROFILE AND OUTCOMES OF SCRUB 6025: LEPTOSPIROSIS INCIDENCE IN JUNGLE WARFARE TRAINEES 6026: UNCOVERING HIDDEN MORTALITY INSIGHTS IN TROPICAL SETTII 6027: PREVALENCE AND ASSOCIATED FACTORS OF TRACHOMA IN SCH 6028: SERO-EPIDEMIOLOGY OF SCRUB TYPHUS IN U.S. ACTIVE DUTY S INTRODUCTION NIGERIA CDC POLICIES AND STRATEGIES FOR IMPROVING ENVIRONME IMPACT OF A MULTI-COMPONENT TRAINING INTERVENTION (CLEAN FE LESSONS LEARNED FROM A DECADE OF RESEARCH, IMPLEMENTATION IMPROVING ENVIRONMENTAL CLEANING COMPLIANCE IN HIGH-RISK U RESEARCH Gaps in Chemoprevention Targeting School-Aged Children INTRODUCTION DIRECT AND INDIRECT IMPACT OF EXTENDED-AGE SMC IN BURKINA FA	

Monday, November 10		Room Name
9:20 a.m.	MEASURING THE HOUSEHOLD LEVEL IMPACT OF IPTSC IN MALAWI	
9:40 a.m.	EVALUATING THE DUAL HEALTH AND EDUCATIONAL BENEFITS OF MALARIA CHEMOPREVENTION IN SCHOOL-AGED	
10 a.m.	UPTAKE AND IMPLEMENTATION OF MALARIA CHEMOPREVENTION TARGETING SCHOOL-AGE CHILDREN	
	mmittee of Molecular, Cellular and Immunoparasitology (ACMCIP) Symposium I: ug Discovery: Discovering New Targets and Beating Resistance	Convention Center - Room 716 (Level 700)
8:30 a.m.	INTRODUCTION	
8:35 a.m.	EVALUATING GSK3SS AS A THERAPEUTIC TARGET IN PARASITIC DISEASES	
8:55 a.m.	ADAPTATIVE MECHANISMS TO G6PDH INHIBITION IN T. CRUZI: AN EXOMETABOLOMIC AND TRANSCRIPTOMIC	
9:15 a.m.	LEVERAGING SMALL MOLECULES TO INVESTIGATE THE STRUCTURE AND FUNCTION OF PLASMODIUM MOLECULAR	
9:35 a.m.	PESTICIDE TOXIFICATION BY CYTOCHROME P450S	
9:55 a.m.	TARGETS FOR ANTIMALARIAL DRUG DISCOVERY—WHAT WE HAVE LEARNED	AND NEXT STEPS
Symposium 10: Bold	Diplomacy: The Need for an Active Scientific Voice in Global Health Diplomacy	Convention Center - Room 717 (Level 700)
8:30 a.m.	INTRODUCTION	
8:40 a.m.	WELCOME AND OVERVIEW	
8:45 a.m.	SPEAKING TRUTH TO POWER IN A POST-TRUTH WORLD	
8:55 a.m.	INVESTING IN CAPACITY BUILDING IN LMICS TO FOSTER GLOBAL HEALTH DI	PLOMACY: EXPLORING THE ROLE OF A
9:05 a.m.	BOLD DIPLOMACY IN THE BIOMEDICAL SCIENCES: BUILDING A DIVERSE WORKFORCE TO ADVANCE THE VACCINE	

Monday, November 10		Room Name
9:15 a.m.	THE ROLE OF EFFECTIVE COMMUNICATION AND ENGAGEMENT WITH	PUBLIC AUDIENCES IN A BOLD DIPLOMACY
9:25 a.m.	SCIENCE DIPLOMACY IN A DISRUPTIVE ERA	
9:35 a.m.	WRAP UP COMMENTS	
9:40 a.m.	PANEL DISCUSSION AND Q&A	
Symposium 11: Long-lasting Genetics to Inform Vector Co	Insecticidal Nets in Africa: Combining Experimental Huts and ntrol Tool Choice	Convention Center - Room 718A (Level 700)
8:30 a.m.	INTRODUCTION	
8:40 a.m.	THE RAPID SCALE-UP OF DUAL-ACTIVE INGREDIENT LONG-LASTING INSECTICIDAL NETS (LLINS) IN SUB-SAHARAN AFRICA	
8:50 a.m.	GENETIC SURVEILLANCE OF INSECTICIDE RESISTANCE IN AFRICAN ANOPHELES POPULATIONS TO INFORM MALARIA	
9 a.m.	ENTOMOLOGICAL RESULTS (VECTOR BINOMICS, INSECTICIDE RESISTANCE AND BEHAVIOR) OF A MULTI-CENTER	
9:15 a.m.	TRANSCRIPTOMIC SIGNATURES OF VECTOR RESPONSES TO LLINS DURING THE EXPERIMENTAL HUT TRIALS	
9:35 a.m.	n. GENOMIC SIGNATURES OF VECTOR RESPONSES TO LLINS DURING THE EXPERIMENTAL HUT TRIALS	
9:55 a.m.	MATHEMATICAL MODELS INTEGRATING GENETIC DATA TO INFORM LL	IN PROCUREMENT BY NATIONAL MALARIA
Scientific Session 12: Measur	res for Control and Elimination of Neglected Tropical Diseases I	Convention Center - Room 718B (Level 700)
8:30 a.m.	6029: ORAL IVERMECTIN IS SAFE IN CHILDREN WEIGHING 5 TO LESS	THAN 15 KG - A MULTICENTER TRIAL
8:40 a.m.	6030: SUCCESS OF AND LESSONS ON ONCHOCERCIASIS ELIMINATION	THROUGH COMMUNITY-DIRECTED TREATMENT
8:50 a.m.	6031: TOWARD ERADICATION: THE FIRST FIELD DEPLOYMENT AND EV	ALUATION OF A SEROLOGICAL DIAGNOSTIC ASSAY
9 a.m.	6032: STEPS FOR INTEGRATING NEGLECTED TROPICAL DISEASES INT	O THE HEALTH SYSTEM. FEASIBILITY STUDY IN KILIFI
9:10 a.m.	6033: PERSISTENTLY HIGH SOIL-TRANSMITTED HELMINTHIASIS PREV	ALENCE AFTER 15 YEARS OF MASS DRUG
9:20 a.m.	6034: THREE YEARS OF POST-TREATMENT SURVEILLANCE AFTER STO	PPING MASS DRUG ADMINISTRATION FOR

Monday, November 1	0	Room Name
9:30 a.m.	6035: SYNCHRONIZED TRACHOMA SURGERY AND MASS DRUG A	ADMINISTRATION IN MOBILE AND MIGRATORY
9:40 a.m.	6036: HEALTH SYSTEMS CAPACITY FOR LYMPHATIC FILARIASIS	MORBIDITY MANAGEMENT IN COASTAL KENYA:
9:50 a.m.	6037: TARGETED SOCIAL MOBILIZATION INTERVENTIONS TO BOX	OST DRUG COMPLIANCE FOR LYMPHATIC FILARIASIS
10 a.m.	6038: ADAPTIVE PROGRAMMING: CONDUCTING MASS DRUG ADM	MINISTRATION (MDA) IN INSECURE AREAS OF
Scientific Session 13: Glo	bal Health: Community Health, NTDs and NCDs	Convention Center - Room 801A (Level 800,
8:30 a.m.	6039: THE HEALTH AND WELLNESS IMPACTS OF HOPE GROUPS	FOR PEOPLE WITH LYMPHATIC FILARIASIS IN EBONYI
8:40 a.m.	6040: APPLYING THE IDARE METHODOLOGY: ADVANCING GENDE	R EQUITY AND SOCIAL INCLUSION TO STRENGTHEN MASS
8:50 a.m.	6041: INTEGRATED SEROSURVEILLANCE AS A TOOL FOR MONITO	ORING OF NEGLECTED TROPICAL DISEASE MONITORING IN
9 a.m.	6042: INTEGRATED SEROSURVEILLANCE AND SPATIAL EPIDEMIC	OLOGY OF VACCINE PREVENTABLE DISEASES AND
9:10 a.m.	6043: COMBINING FORCES: INTEGRATING INFECTIOUS DISEASE	AND NCD SURVEILLANCE DURING NIUE'S NATIONAL
9:20 a.m.	6044: FOOD SECURITY AND NON-COMMUNICABLE DISEASE RISH	K IN UGANDA: A SECONDARY ANALYSIS OF
9:30 a.m.	6045: A DESCRIPTIVE ANALYSIS OF MORTALITY IN RURAL WEST	ERN KENYA USING HEALTH AND DEMOGRAPHIC
9:40 a.m.	6046: TEN-YEAR TRENDS IN ADULT MORTALITY IN THE GAMBIA:	CAUSE OF DEATH ANALYSIS USING
9:50 a.m.	6047: HYGIENE INDEX FOR PREDICTING RISK OF PODOCONIOSIS	IN ENDEMIC COMMUNITIES
10 a.m.	6048: IMPACT OF TRACHOMA SAFE INTERVENTIONS IN SOUTH S	SUDANESE REFUGEE CAMPS IN SUDAN
Symposium 14: The 100-	Day Mission: Are We Ready for Nipah?	Convention Center - Room 801B (Level 800)
8:30 a.m.	INTRODUCTION	

Monday, November 10		Room Name	
8:40 a.m.	NIPAH IN BANGLADESH: RESPONSE AND CHALLENGES		
8:50 a.m.	NIPAH IN INDIA: RESPONSE AND CHALLENGES		
9 a.m.	ADVANCES IN DIAGNOSTICS FOR NIPAH VIRUS		
9:10 a.m.	ADVANCES IN THERAPEUTICS FOR NIPAH VIRUS		
9:20 a.m.	ADVANCES IN VACCINES FOR NIPAH VIRUS		
9:30 a.m.	STOPPING SPILLOVER: ONE HEALTH AND NPI STRATEGIES FOR NIF	PAH PREPAREDNESS	
9:40 a.m.	HEALTH SYSTEMS STRENGTHENING AND OPERATIONAL PREPAREI	DNESS FOR NIPAH RESPONSE	
9:50 a.m.	ADVANCING NIPAH VIRUS COUNTERMEASURES: CEPI'S STRATEGI	CINITIATIVES	
Scientific Session 15: Moso	uitoes- Bionomics, Behavior and Surveillance	Convention Center - Room 803 (Level 800)	
8:30 a.m.	6049: THE VECTOR ATLAS: PROVIDING DATA AND EVIDENCE-BASE	MAPS FOR MALARIA VECTOR CONTROL	
8:40 a.m.	6050: MAPPING AFRICA'S MALARIA VECTORS THROUGH UPDATED	DATA AND MODELS	
8:50 a.m.	6051: SEASONAL VARIATION OF AEDES AEGYPTI DAILY BITING ACT	IVITY AND RESTING BEHAVIOR ACROSS AN	
9 a.m.	6052: URBANIZATION GRADIENTS SHAPE AEDES MOSQUITO ECOLO	GY AND BEHAVIOR: AGE STRUCTURE, HOST-SEEKING	
9:10 a.m.	6053: VARIABILITY IN TEMPERATURE-DEPENDENT TRANSMISSIBIL	ITY OF WEST NILE VIRUS BY GEOGRAPHICALLY	
9:20 a.m.	6054: CLOSE-KIN MARK-RECAPTURE METHODS TO ESTIMATE DISP	ERSAL PARAMETERS AND BARRIER STRENGTH FOR	
9:30 a.m.	6055: USING IDX, AN IMAGING AND DEEP LEARNING BASED VECTO	R IDENTIFICATION TOOL, TO DIFFERENTIATE	
9:40 a.m.	6056: MOSQUITO-BORNE DISEASES IN NORTH BORNEO SABAH MAI	AYSIA: DEVELOPMENT OF A MACHINE LEARNING	
9:50 a.m.	6057: ADAPTIVE MOSQUITO SURVEILLANCE: EVALUATION OF DEPL	OYMENT STRATEGIES IN EUROPE AND AFRICA	
10 a.m.	6058: FIELD VALIDATION OF A SINGLE CLOSED-TUBE SYBR GREEN	ASSAY FOR AGE-GRADING CULEX QUINQUEFASCIATUS	

Monday,	November 10		Room Name
		Approaches to Deliver the United Nations General Assembly Political Commitments on and Preventing Resistance	Convention Center - Room 602 (Level 600
	8:30 a.m.	INTRODUCTION	
	8:35 a.m.	THE INDEPENDENT PANEL FOR EVIDENCE FOR ACTION ON AMR (IPEA): HOW THE	IPEA WILL FACILITATE THE
	8:55 a.m.	THE AVERTABLE BURDEN FROM IMPROVED AND APPROPRIATE ACCESS TO ANTIE	BIOTICS
	9:15 a.m.	OPTIMAL LEVELS OF AWARE ANTIBIOTIC USE - TAKING A POPULATION HEALTH A	PPROACH
	9:35 a.m.	CLOSING THE KNOW-DO GAP: GENERATING EVIDENCE FOR THE INTRODUCTION A	ND APPROPRIATE USE OF RESERVE
	9:55 a.m.	LEVERAGING DATA TO IMPROVE ACCESS TO ANTIBIOTICS: EXPLORING HOW DATA	-DRIVEN APPROACHES CAN SUPPORT
10 a.m. – 4	4:30 p.m.	Exhibit Hall Open	Convention Center - Hall D (Level 800) (Exhibit Hall)
10:15 a.m.	10:45 a.m.	Coffee Break	Convention Center - Hall D (Level 800) (Exhibit Hall)
10:15 a.m.	11:15 a.m.	Mentorship Pop-Up Session: Global Health Innovation in 60 Seconds: Pitch & Connect	Convention Center – Level 600 Lobby (Level 600)
		J. Magill Malaria Eradication Symposium: Malaria Delenda Est- How Innovation Is owards Malaria Eradication	Convention Center - Hall F/G (Level 800)
SUF	PPORTED WITH F	UNDING FROM Gates Foundation	
	10:45 a.m.	INTRODUCTION	

Monday, November 10		Room Name
10:50 a.m.	A NEW GENERATION OF MALARIA VECTOR CONTROL TOOLS - STAYING A	HEAD IN THE INSECTICIDE RESISTANCE ARMS RACE
11:10 a.m.	A NEW GENERATION OF MALARIA VECTOR CONTROL TOOLS - STAYING A	HEAD IN THE INSECTICIDE RESISTANCE ARMS RACE
11:30 a.m.	AI AND ANTIMALARIA DRUG DEVELOPMENT	
11:50 a.m.	AI AND MALARIA DIAGNOSTICS	
Scientific Session 18: One He	alth II: The Interface of Humans, Ecosystems and Animal Health	Convention Center - Room 701A (Level 700)
10:45 a.m.	6059: A ONE HEALTH PERSPECTIVE ON DOMESTIC ANIMAL GUINEA WOR	M INFECTIONS IN CHAD FROM 2012 TO 2023
10:55 a.m.	6060: RIFT VALLEY FEVER SEROPREVALENCE IN UGANDAN LIVESTOCK	INCREASED BY 4% OVER THREE YEARS: INSIGHTS
11:05 a.m.	6061: EMERGING AN REEMERGING ZOONOTIC VIRUSES WITH SPILLOVEF	R POTENTIAL IN BRAZIL A SCOPING REVIEW
11:15 a.m.	6062: DEVELOPING A COORDINATED RESPONSE PLAN FOR HIGHLY PATH	OGENIC AVIAN INFLUENZA (H5N1)
11:25 a.m.	6063: REDUCING ANTIBIOTICS USE IN FISH AND SHRIMP FARMING: A MI	XED SOCIAL MARKETING APPROACH IN
11:35 a.m.	6064: EVALUATING ZOONOTIC MALARIA TRANSMISSION AND AGRICULTU	JRAL LAND USE IN INDONESIA: ZOOMAL STUDY
11:45 a.m.	6065: SHIFTING WATER CYCLE, WATER MANAGEMENT, AND ZOONOTIC D	ISEASES RISK: SOCIOENVIRONMENTAL DRIVERS
11:55 a.m.	6066: UNUSUAL ETIOLOGIES OF BACTERAEMIA IN UNDER-5 CHILDREN: A	A CASE FOR ONE-HEALTH DIAGNOSTIC APPROACHES
12:05 p.m.	6067: ENGAGING COMMUNITIES TO ADDRESS ANTIMICROBIAL RESISTAN	ICE FROM A ONE HEALTH PERSPECTIVE: RESULTS
12:15 p.m.	6068: SOCIETAL DEVELOPMENT AND TRANSITIONS IN ENTERIC DISEASE	CONTROL: EMERGING EVIDENCE AND POLICY
Symposium 19: The Role of F	ood Hygiene in Preventing Pathogens Transmission in Low- and Middle-Income C	ountries Convention Center - Room 701B (Level 700)
10:45 a.m.	INTRODUCTION	
10:50 a.m.	ADDRESSING THE SPECIFIC PATHWAYS OF INFECTION IN YOUNG CHILD	REN THROUGH FOOD HYGIENE INTERVENTIONS
11:10 a.m.	IMPACTS OF FOOD HYGIENE INTERVENTIONS ON STREET FOOD VENDOR	S AND CONSUMERS IN LOW RESOURCE SETTINGS

Monday, November 10 Room Name 11:30 a.m. FOOD HYGIENE IN SUB-SAHARAN AFRICA: LESSONS FROM BENIN AND STRATEGIC PERSPECTIVES FOR SAFER FOOD... 11:50 a.m. FOOD SAFETY IN POULTRY MARKETS IN MOZAMBIQUE: THE CHEEP CHEEP STUDY Scientific Session 20: Clinical Tropical Medicine: Febrile Illness Diagnosis and Epidemiology Convention Center - Room 713 (Level 700) 10:45 a.m. 6069: EVALUATION OF NUCLEIC ACID AMPLIFICATION TESTING IN SALIVA AND URINE FOR DENGUE DIAGNOSIS IN COLOMBIA 10:55 a.m. 6070: AN AI-POWERED SMARTPHONE APPLICATION FOR UNIVERSAL STANDARDIZED LATERAL FLOW ASSAYS... 11:05 a.m. 6071: ETIOLOGICAL PROFILING OF PEDIATRIC FEBRILE ILLNESS USING METAGENOMIC NEXT-GENERATION SEQUENCING... 11:15 a.m. 6072: DETERMINING THE INFECTIOUS CAUSES OF ACUTE FEBRILE ILLNESS IN RURAL LAOS, THAILAND, AND BANGLADESH... 11:25 a.m. 6073: DEFINING THE EPIDEMIOLOGY OF ACUTE FEBRILE ILLNESS IN RURAL SOUTH AND SOUTHEAST ASIAN PRIMARY CARE 11:35 a.m. 6074: PERFORMANCE OF A RAPID MOLECULAR DIAGNOSTIC PLATFORM AT DIFFERENTIATING DENGUE AND LEPTOSPIROSIS... 11:45 a.m. 6075: BLOOD RNA TRANSCRIPTS FOR DIAGNOSING AND PREDICTING THE OUTCOMES OF FEBRIL FILL NESSES IN LOW- AND... 11:55 a.m. 6076: MAPPING THE PREVALENCE OF NON-MALARIAL FEBRILE II LINESS IN AREAS WITH VARYING MALARIA BURDENS IN... 12:05 p.m. 6077: TEMPORAL TRENDS IN NON-MALARIA FEBRILE ILLNESS IN MAINLAND TANZANIA: EVIDENCE FROM HEALTH FACILITY... 12:15 p.m. 6078: ADVANCING CLINICAL TROPICAL MEDICINE IN RURAL AND CONFLICT-AFFECTED COMMUNITIES IN CAMEROON... Symposium 21: New Drugs for Treatment of Filarial Infections Convention Center - Room 714 (Level 700) INTRODUCTION 10:45 a.m. 10:55 a.m. CORALLOPYRONIN A: FROM PRECLINICAL DEVELOPMENT INTO PHASE I CLINICAL TRIAL 11:10 a.m. ANTI-WOLBACHIA REGISTERED ANTIBIOTICS AND THEIR RE-PURPOSING OPPORTUNITIES: FROM THE A-WOL PIPELINE...

Monday, November 10		Room Name	
11:25 a.m.	OXFENDAZOLE: A BASKET TRIAL FOR STH AND FILARIAL INFECTIONS		
11:40 a.m.	EMODEPISDE: RESULTS FROM THE PHASE II PART I CLINICAL TRIAL AND WA	Y FORWARD	
11:55 a.m.	MOXIDECTIN: RESULTS FROM AN INITIAL CLINICAL TRIAL IN LYMPHATIC FILA	ARIASIS	
12:10 p.m.	MOXIDECTIN: INSIGHTS FROM THE FIRST ROUND OF MDA WITH MOXIDECTIN FOR ONCHOCERCIASIS IN GHANA		
Symposium 22: Urban Futur	es: Rethinking Mosquito-borne Disease Risks in Cities	Convention Center - Room 715 (Level 700)	
10:45 a.m.	INTRODUCTION		
10:55 a.m.	IMPACT OF URBANIZATION ON AEDES VECTORS AND HUMAN DENGUE EXPO	SURE IN URBAN, PERI-URBAN AND RURAL	
11:10 a.m.	EFFECT OF DIFFERENT URBAN ENVIRONMENTS ON TWO ARBOVIRUS VECTO	RS AEDES AEGYPTI AND AE ALBOPICTUS IN	
11:25 a.m.	DECONSTRUCTING URBANIZATION: HOW URBANIZATION GRADIENTS SHAPE	AEDES MOSQUITO ECOLOGY AND BEHAVIOR	
11:40 a.m.	DOES URBANIZATION MODIFY MOSQUITO LONGEVITY AND MALARIA TRANSM	MISSION? FINDINGS FROM COTE D'IVOIRE	
11:55 a.m.	RETHINKING MALARIA, MOSQUITOES AND CITIES: WHAT ARE WE LEARNING	FROM SURVEYS FOR ANOPHELES STEPHENSI	
12:05 p.m.	RETHINKING MALARIA, MOSQUITOES AND CITIES: WHAT ARE WE LEARNING	FROM SURVEYS FOR ANOPHELES	
Symposium 23: American Co Trager, Trainees and Take-of	mmittee of Molecular, Cellular and Immunoparasitology (ACMCIP) Symposium II: f!	Convention Center - Room 716 (Level 700)	
10:45 a.m.	WELCOME		
10:50 a.m.	INTRODUCTION OF WILLIAM TRAGER AWARD FOR BASIC PARASITOLOGY REC	CIPIENT	
10:55 a.m.	WILLIAM TRAGER AWARD FOR BASIC PARASITOLOGY: WHAT DOES IT MEAN	TO BE AN ESSENTIAL GENE?	
11:20 a.m.	INTRODUCTION OF 3-MINUTE THESIS WINNERS		
11:25 a.m.	3-MINUTE THESIS WINNER: MALARIA MOLECULAR SURVEILLANCE IN NAMIB	BIA: EVIDENCE OF INCREASING K13-MEDIATED	

Monday, November	10	Room Name
11:35 a.n	n. 3-MINUTE THESIS WINNER: TEPINOM: AN IMMI	UNOINFORMATICS FRAMEWORK TO IDENTIFY CONSERVED
11:45 a.n	n. 3-MINUTE THESIS WINNER: PARASITE HIDDEN	POWER: NEUROCYSTICERCOSIS ANTIGENS SPECIFICALLY MODULATE
11:55 a.n	n. INTRODUCTION OF TAKE-OFF AWARD IN PARA	SITOLOGY RESEARCH RECIPIENT
Noon	TAKE-OFF AWARD IN PARASITOLOGY RESEARC	CH: CIRCADIAN RHYTHMS IN PARASITIC DISEASES
12:15 p.n	n. ANNUAL BUSINESS MEETING	
12:25 p.n	n. NETWORKING RECEPTION	
10:45 a.m. – 12:30 p.m.	Symposium 24: Strategic Advocacy During Turbu	lent Times Convention Center - Room 717 (Level 700)
10:45 a.n	n. PANEL DISCUSSION	
Scientific Session 26: N	Measures for Control and Elimination of Neglected Tropical D	iseases II Convention Center - Room 718B (Level 700)
10:45 a.n	n. 6079: EFFICACY OF DOXYCYCLINE AND HYGIEN	E MEASURES IN THE MANAGEMENT OF PODOCONIOSIS - A DOUBLE
10:55 a.n	n. 6080: A FRAMEWORK FOR ASSESSING INTEGR.	ATED DISEASE CONTROL POTENTIAL IN MULTIPATHOGEN CONTEXTS: CASE
11:05 a.n	n. 6081: PREVALENCE OF OCULAR <i>CHLAMYDIA TR</i>	ACHOMATIS INFECTION AND ANTIBODIES IN THREE TRACHOMA-TREATMENT
11:15 a.n	n. 6082: ENHANCING INTEGRATED SKIN DISEASE	MANAGEMENT THROUGH DIGITAL TOOLS AND PERSON-CENTERED
11:25 a.n	n. 6083: TRACHOMA ELIMINATION IN NIGER: SCRI	EENING OF TRACHOMATOUS TRICHIASIS CASES BY COMMUNITY RELAYS
11:35 a.n	n. 6084: ASSESSING FACE WASHING BEHAVIOR C	CHANGE: FINDINGS FROM THE STRONGER-SAFE CLUSTER
11:45 a.n	n. 6085: A RANDOMIZED TRIAL OF THREE FACE W	ASHING METHODS FOR THE REMOVAL OF CHLAMYDIA TRACHOMATIS FROM

Monday, Novemb	er 10		Room Name
11:55	a.m.	6086: SEROLOGICAL MONITORING OF CHLAMYDIA TRACHOMATIS ANTIBODI	ES IN LOW-PREVALENCE DISTRICTS
12:05	p.m.	6087: EVALUATING INTERVENTIONS FOR GUINEA WORM ERADICATION: A S	IMULATION MODELING APPROACH
12:15	p.m.	6088: COLLABORATION ACROSS MULTIPLE SECTORS AND COMMUNITIES FO	OR MOSQUITO SURVEILLANCE TO EXPEDITE
Scientific Session 2	7: Global He	alth: Improved Health Care Service Delivery and Health Systems Strengthening	Convention Center - Room 801A (Level 800)
10:45	a.m.	6089: GOOD FOR HEARTS, BETTER FOR BUDGETS: A COST-EFFECTIVENESS	EVALUATION OF SCREENING FOR CHAGAS
10:55	a.m.	6090: INNOVATIONS IN MOBILE DATA CAPTURE FOR MULTI-COUNTRY IMPL	EMENTATION OF A LONGITUDINAL MALARIA
11:05	a.m.	6091: PRIORITIZATION OF MALARIA INSECTICIDE-TREATED NET DISTRIBUT	ON TO MAXIMIZE HEALTH IMPACT AND EQUITY
11:15	a.m.	6092: OPERATIONAL MANAGEMENT OF IMMUNIZATION CAMPAIGNS USING	NEAR-REAL TIME DATA IN HARD-TO-REACH
11:25	a.m.	6093: DEVELOPMENT AND VALIDATION OF A MULTIPLEX LATERAL FLOW AS	SAY FOR SIMULTANEOUS POINT-OF-CARE
11:35	a.m.	6094: ASSESSING THE AGREEMENT BETWEEN MATERNAL AND PERINATAL	DEATH SURVEILLANCE AND RESPONSE
11:45	a.m.	6095: CATMAT'S APPROACH TO EVIDENCE ASSESSMENT AND GUIDELINE D	EVELOPMENT IN TRAVEL MEDICINE IN CANADA
11:55	a.m.	6096: STRENGTHENING VACCINE DELIVERY SYSTEMS THROUGH ENGAGING	PRIVATE PROVIDERS IN URBAN SLUMS OF
12:05	p.m.	6097: REACHING SPECIAL POPULATIONS IN SOUTH SUDAN: EXPERIENCES	FROM MASS DRUG ADMINISTRATION
12:15	p.m.	6098: ECONOMIC EVALUATION OF INTERFERON-GAMMA RELEASE ASSAYS	AS A VALID TEST FOR LATENT TUBERCULOSIS
Scientific Session 2 Survillance and Spi		Field and Ecological Studies of Viruses Including and Emergence	Convention Center - Room 801B (Level 800)
10:45	a.m.	6099: PERSISTING NEUROCOGNITIVE/NEUROSENSORY SEQUELAE IN ADUL	T EBOLA SURVIVORS FROM THE 2018-2020
10:55	a.m.	6100: SEROPREVALENCE OF VIRAL HEMORRHAGIC FEVERS IN ECOLOGICAL	LY DISTINCT REGIONS OF GUINEA BETWEEN
11:05	a.m.	6101: ASSESSING ZOONOTIC SPILLOVER RISK OF HENIPAVIRUSES AMONG	BORDER SECURITY PERSONNEL IN THE
11:15	a.m.	6102: HORSESHOE BAT SPECIES DELIMITATION AND BAT-ASSOCIATED COR	ONAVIRUS DIVERSITY IN EASTERN UGANDA

Monday, November 10		Room Name	
11:25 a.m.	6103: TRAVEL-RELATED DENGUE, ZIKA AND CHIKUNGUNYA IN CANADA, 2	2012-2023: RESULTS FROM A FEASIBILITY PILOT	
11:35 a.m.	6104: NEXT GENERATION SEQUENCING DIAGNOSTICS TO IDENTIFY ETIOLO	OGIES OF ACUTE UNDIFFERENTIATED FEVER	
11:45 a.m.	6105: IDENTIFICATION OF POTENTIAL VECTORS AND DETECTION OF RIFT	VALLEY FEVER VIRUS IN MOSQUITOES	
11:55 a.m.	6106: DISTRIBUTION OF JAPANESE ENCEPHALITIS IN BANGLADESH 2017-	-2023: AN UPDATE FROM ACUTE ENCEPHALITIS	
12:05 p.m.	6107: VIROME COMPOSITION OF AMBLYOMMA MIXTUM AND IXODES CF. B	BOLIVIENSIS: EXPLORING POTENTIAL EMERGENT	
12:15 p.m.	6108: SILENT CIRCULATION OF CRIMEAN-CONGO HAEMORRHAGIC FEVER	VIRUS IN NORTHERN NIGERIA: INSIGHTS FROM	
Scientific Session 29: Arthro	pods: Arthropods/Entomology - Other	Convention Center - Room 803 (Level 800)	
10:45 a.m.	6109: SCRUB TYPHUS PATIENTS DEVELOP ANTIBODIES SPECIFIC TOWARDS	CHIGGER MITE, LEPTOTROMBIDIUM PALLIDUM	
10:55 a.m.	6110: METAGENOMIC SURVEY OF TICK RNA VIRUSES FROM SELECT PAST	TORAL REGIONS OF KENYA, 2022-2024	
11:05 a.m.	6111: ENTOMOLOGICAL IMPACT ASSESSMENT OF MASS DRUG ADMINIST	RATION AGAINST ONCHOCERCIASIS IN BENIN	
11:15 a.m.	6112: GENOME ASSEMBLY OF SIMULIUM DAMNOSUM FROM GHANA: IMPL	LICATIONS FOR ONCHOCERCIASIS TRANSMISSION	
11:25 a.m.	6113: STUDIES ON SIMULIUM BLACK FLIES AND ONCHOCERCA PARASITE	S TO DECIPHER THE TRANSMISSION DYNAMICS	
11:35 a.m.	6114: ENTOMOLOGICAL ASSESSMENTS FOR ONCHOCERCA VOLVULUS IN	GECHI-BORICHA-DIDESSA AND GIMBO	
11:45 a.m.	6115: COMPARISON AND CALIBRATION OF SIMULIUM CATCHES BETWEEN	I HUMAN LANDING CATCH AND ESPERANZA	
11:55 a.m.	6116: MULTI-COUNTRY EVALUATION OF THE PERFORMANCE OF A MODIFI	ED HUMAN LANDING COLLECTION METHOD FOR	
12:05 p.m.	6117: MODELLING THE SPATIAL DISTRIBUTION OF BLACKFLY ENTOMOLO	GICAL INDICES TO GUIDE ONCHOCERCIASIS	
12:15 p.m.	6118: SPATIAL DYNAMICS OF ONCHOCERCIASIS TRANSMISSION INDICES	AND THEIR IMPLICATIONS FOR ENTOMOLOGICAL	

Monday,	November 10		Room Name
Symposiu	m 30: Pushing the	Boundaries of Leprosy Research to Tackle this Ancient Disease	Convention Center - Room 602 (Level 600)
	10:45 a.m.	INTRODUCTION	
	10:55 a.m.	EPIDEMIOLOGY OF LEPROSY IN THE US: A FLORIDA PERSPECTIVE	
	11:10 a.m.	MOLECULAR CHARACTERIZATION OF THE LEPROSY AGENTS	
	11:25 a.m.	IMMUNODIAGNOSTICS AND GLOBAL PERSPECTIVE IN THE DETECTION OF I	DISEASE AND INFECTION
	11:40 a.m.	IMPLEMENTATION OF THE ZERO LEPROSY PLANNING IN TANZANIA	
	11:55 a.m.	ONGOING CLINICAL TRIALS FOR THE DEVELOPMENT OF NEW REGIMENS A	GAINST <i>M. LEPRAE</i>
	12:10 p.m.	PANEL DISCUSSION ON THE ADVANCEMENTS OF LEPROSY	
12:15 p.m.	2:15 p.m.	Poster Session 31: Poster Session A Presentations	Convention Center - Hall E (Level 800) (Poster Hall)
12:30 p.m.	2:15 p.m.	Exhibit Hall - Light Lunch	Convention Center - Hall D (Level 800) (Exhibit Hall)
12:45 p.m.	1:45 p.m.	Ben Kean Fellowship Committee Meeting	Convention Center - Room 604 (Level 600)
12:45 p.m.	1:45 p.m.	Centennial Travel Award Committee Meeting	Convention Center - Room 606 (Level 600)
12:45 p.m.	1:45 p.m.	Membership Committee/Trainee Membership Committee/ International Membership Committee Meeting	Convention Center - Room 605 (Level 600)
12:45 p.m.	1:45 p.m.	Travel Award Luncheon	Convention Center - Room 718B (Level 700)
12:45 p.m.	2 p.m.	Lecture Committee Meeting	InterContinental - Wentworth Room (Upper Level)

Monday, November 10		Room Name
12:45 p.m 2 p.m.	American Committee of Medical Entomology (ACME) Trainee Networking Event - Grab Your Lunch and Bring It!	Convention Center - Room 707 (Level 700)
12:45 p.m 2 p.m.	Late-Breaker Abstract Session 32: Late-Breakers in Basic Science	Convention Center - Room 801A (Level 800)
12:45 p.m 2 p.m.	Meet the Professors Session 33: Meet the Professors: Cases from South Asia	Convention Center - Room 801B (Level 800)
1:15 p.m. – 2:15 p.m.	Mentorship Pop-Up Session: AI for Global Health: Techniques for Impact	Convention Center – Level 600 Lobby (Level 600)
2:15 p.m 4 p.m.	Poster Session A Viewing	Convention Center - Hall E (Level 800) (Poster Hall)
2:15 p.m 4 p.m. CONTENT C	Symposium 34: Pathways to Success: Highlighting Exceptional Careers in Tropical Medicine and Global Health	Convention Center - Hall F/G (Level 800)
2:15 p.m.	PANEL DISCUSSION	
Symposium 35: Evaluating Zoon	otic Malaria in Western Indonesia: The ZOOMAL Project	Convention Center - Room 701A (Level 700)
2:15 p.m.	INTRODUCTION	
2:25 p.m.	A MULTI-CRITERIA FRAMEWORK ENCOMPASSING PREDICTIVE RISK MAPPING FO	R DISEASE SURVEILLANCE SITE
2:35 p.m.	DESIGN AND INTEGRATION OF MULTIPLEX SEROLOGICAL TOOLS FOR ZOONOTIC	AND HUMAN MALARIA SURVEILLANCE
2:45 p.m.	HEALTH FACILITY SURVEYS FOR POPULATION-LEVEL ZOONOTIC MALARIA INFEC	TION AND EXPOSURE PREVALENCE IN
2:55 p.m.	UNDERSTANDING THE DISTRIBUTION, BIONOMICS AND ZOONOTIC PLASMODIUM	INFECTION PREVALENCE OF ANOPHELES
3:05 p.m.	OCCUPANCY MODELLING OF MACACA NEMSTRINA AND MACACA FASCICULARIS	N DIFFERENT LAND TYPES IN WESTERN

Monday, November 10	Room Name
3:15 p.m.	A QUALITATIVE APPROACH TO UNDERSTANDING LAND USE AND HUMAN BEHAVIOR IN AREAS AT RISK FOR ZOONOTIC
3:25 p.m.	HOUSEHOLD COSTS OF ILLNESS OF ASSOCIATED WITH ZOONOTIC MALARIA IN INDONESIA
3:35 p.m.	GENOMIC ANALYSIS OF PLASMODIUM KNOWLESI ACROSS SOUTHEAST ASIA, WITH INSIGHTS INTO INDONESIAN
Scientific Session 36: Malaria	a - Prevention I Convention Center - Room 701B (Level 700)
2:15 p.m.	6571: CHILDREN'S EXPOSURE TO INSECTICIDES LINKED TO VECTOR CONTROL IN BENIN
2:25 p.m.	6572: ROLE OF IMPROVED HOUSING IN REDUCING MALARIA PREVALENCE AMONG SCHOOL-AGED CHILDREN IN
2:35 p.m.	6573: TAFENOQUINE AND G6PD TEST IMPLEMENTATION IN ETHIOPIA: PARTIAL STUDY RESULTS
2:45 p.m.	6574: ENTOMOLOGICAL INSIGHTS ON SCALING UP DUAL ACTIVE INGREDIENT INSECTICIDE TREATED NET IN AREA
2:55 p.m.	6575: OPTIMAL COVERAGE CAN MEAN LOWER COVERAGE: THE FUTURE OF INSECTICIDE-TREATED NETS WHEN
3:05 p.m.	6576: EFFICACY AND SAFETY OF INTERMITTENT PREVENTIVE TREATMENT OF MALARIA IN SCHOOL-AGE CHILDREN USING
3:15 p.m.	6577: INTER-CLUSTER CONTAMINATION: A SEMIVARIANCE ANALYSIS OF COMMUNITY EFFECT RANGES OF MALARIA
3:25 p.m.	6578: INTENSIVE SUPERVISION OF COMMUNITY HEALTH WORKERS BY MOBILE NURSE TO BETTER PREVENT, DIAGNOSE
3:35 p.m.	6579: BUILDING AN EVIDENCE BASE TO INFORM THE OPTIMIZATION OF INSECTICIDE-TREATED NET DISTRIBUTION IN
3:45 p.m.	LIGHTNING TALKS
	7559: PERCEPTIONS OF VOLUNTEERS ON THE USE OF PERSONAL DEVICES FOR ELECTRONIC DATA COLLECTION DURING
	7575: LOGISTICS PREPAREDNESS: ENSURING TIMELY COMMODITY AVAILABILITY FOR LARGE-SCALE ITN AND SMC
	7556: DATA-DRIVEN ITN REPRIORITIZATION STRATEGY FOR SELECTED GLOBAL FUND-ASSISTED STATES IN NIGERIA WITH
	7558: DETERMINANTS OF ITN PHYSICAL DURABILITY IN SUB-SAHARAN AFRICA: SECONDARY ANALYSIS OF DATA
	7561: ESTIMATING THE SPATIAL AND TEMPORAL VARIATION IN THE EPIDEMIOLOGICAL IMPACT OF INSECTICIDE-TREATED

Room Name



Symposium 37: American Committee on Clinical Tropical Medicine and Travelers' Health (Clinical Group - ACCTMTH) Symposium I: Vincenzo Marcolongo Lecture: Navigating Malaria Risk for International Travel: Advances in Prevention, Diagnosis, and Treatment

Convention Center - Room 713 (Level 700)

SUPPORTED WITH FUNDING FROM



2:15 p.m.	INTRODUCTION
2:20 p.m.	NAVIGATING MALARIA RISKS FOR INTERNATIONAL TRAVEL: ADVANCES IN PREVENTION, DIAGNOSIS AND TREATMENT
2:40 p.m.	NAVIGATING MALARIA RISKS FOR INTERNATIONAL TRAVEL: ADVANCES IN PREVENTION, DIAGNOSIS AND TREATMENT
3 p.m.	ACCTMTH BUSINESS MEETING
3:30 p.m.	NETWORKING RECEPTION

Scientific Session 38: American Committee of Molecular Cellular and Immunoparasitology (ACMCIP): New Diagnostics and Surveillance of Parasitic Diseases

Convention Center - Room 714 (Level 700)

SUPPORTED WITH FUNDING FROM

BURROUGHS WELLCOME FUND

2:15 p.m.	p.m. 6580: PERFORMANCE OF A RAPID URINARY POINT-OF-CARE ASSAY FOR NEUROCYSTICERCOSIS DIAGNOSIS IN A	
2:30 p.m. 6581: DEVELOPING A MULTIPLEX RECOMBINANT PROTEIN-BASED ELISA FOR DIAGNOSING <i>TOXOCARA</i> INFECTIONS		

Monday, November 10		Room Name
2:45 p.m.	6582: DIGITALIZATION OF CLINICAL SPECIMENS BY MICROSCOPIC SCAN	NERS IN COMBINATION WITH ARTIFICIAL
3 p.m.	6583: METAGENOMIC NEXT-GENERATION SEQUENCING FOR THE IDENTIF	FICATION OF CIRCULATING CELL FREE
3:15 p.m.	6584: MOLECULAR SURVEILLANCE OF HELMINTHS IN WILD RODENTS IN	NIGERIA: IMPLICATIONS FOR HUMAN HEALTH
3:30 p.m.	6585: GENOMIC EPIDEMIOLOGY RESULTS LEAD TO NEW UNDERSTANDIN	IG OF STRAIN DIVERSITY AND
3:45 p.m.	6586: IMPACT OF A COMMUNITY-WIDE MASS DRUG ADMINISTRATION IN	TERVENTION ON ENVIRONMENTAL RESERVOIRS
	ountry Genomic Surveillance of Malaria Across Sub-Saharan Africa: nsights from Local NOMADS Nanopore Sequencing in Five Countries	Convention Center - Room 715 (Level 700)
2:15 p.m.	INTRODUCTION	
2:25 p.m.	ACCELERATING CONTINENTAL-SCALE GENOMIC SURVEILLANCE OF P. F.	ALCIPARUM MALARIA WITH RAPID
2:40 p.m.	IMPLEMENTATION OF IN-COUNTRY NANOPORE SEQUENCING FOR ROUT	INE GENOMIC SURVEILLANCE OF MALARIA IN
2:55 p.m.	SURVEILLANCE OF MOLECULAR MARKERS FOR ANTIMALARIAL DRUG R	ESISTANCE IN THE SOUTH KIVU REGION, DRC
3:10 p.m.	IMPLEMENTATION OF THE NOMADS ASSAY IN WESTERN KENYA	
3:25 p.m.	ESTABLISHING INDEPENDENT NANOPORE-BASED SEQUENCING CAPACI	TY TO IMPLEMENT GENOMIC SURVEILLANCE OF
3:40 p.m.	TRACKING DRUG RESISTANCE AND GENETIC DIVERSITY IN PLASMODIU	M FALCIPARUM MALARIA ACROSS NIGERIA USING
3:50 p.m.	ESTABLISHING NANOPORE SEQUENCING FOR MALARIA VECTOR SURVE	ILLANCE IN KENYA: PROGRESS AND OPPORTUNITIES
	ommittee of Medical Entomology (ACME) Symposium I: entions to Tackle Vector Borne Diseases	Convention Center - Room 716 (Level 700)
2:15 p.m.	INTRODUCTION	
2:25 p.m.	MOSQUITO POPULATION REPLACEMENT GENE DRIVES FOR MALARIA CO	ONTROL
2:45 p.m.	ANTI-MICROBIAL PEPTIDES (AMPS) AS ANTI-MALARIA EFFECTORS IN A	NOPHELES FUNESTUS MOSQUITOES

Monday, November 10		Room Name
3:05 p.m.	CRISPR-BASED STRATEGIES FOR MANAGING MOSQUITOES AND FIGHTING	G VECTOR-BORNE DISEASES
3:25 p.m.	GENOME EDITING OF PROSTRIATE AND METASTRIATE TICK SPECIES	
3:40 p.m.	TRANSGENIC TARGETING OF HUMAN PATHOGENS IN THEIR MOSQUITO VE	ECTORS
Symposium 41: Analyz	ing Anti-science Attacks to Defend our Field	Convention Center - Room 717 (Level 700)
2:15 p.m.	INTRODUCTION	
2:25 p.m.	IMPACT OF THE INFODEMIC	
2:40 p.m.	HOW COVID-19 ORIGINS CONSPIRACIES DERAILED RESEARCH, AND HOW	TO DEAL WITH THEM
2:55 p.m.	WHAT CAN PUBLIC HEALTH SCIENTISTS LEARN FROM CLIMATEGATE?	
3:15 p.m.	HOW TO RESPOND TO LEGAL THREATS, LAWSUITS, AND GOVERNMENTAL	INQUIRIES
3:35 p.m.	HOW GOVERNMENT EMPLOYEES ARE BEING TARGETED AND UNDERMINE	D BY DISINFORMATION
Symposium 42: Plasmodium	Ovale Species in Sub-Saharan Africa: Curiosity or Emerging Threat?	Convention Center - Room 718A (Level 700)
2:15 p.m.	INTRODUCTION	
2:25 p.m.	OVALE MALARIA: HISTORICAL, EPIDEMIOLOGICAL AND EVOLUTIONARY CO	ONSIDERATIONS
2:35 p.m.	LONGITUDINAL ASSESSMENT OF MORBIDITY DUE TO PLASMODIUM OVAL	E WALLIKERI AND PLASMODIUM OVALE CURTISI
2:50 p.m.	PLASMODIUM OVALE SPP. RECURRENCE AND RELAPSE: A LONGITUDINAI	L COHORT IN BAGAMOYO, TANZANIA
3:05 p.m.	DIVERSITY OF PLASMODIUM SPECIES IN HUMANS AND MOSQUITOES ASS	SOCIATED WITH DIFFERENT ANOPHELES SPECIES
3:20 p.m.	GENOMIC ANALYSES OF PLASMODIUM OVALE SPP.: POPULATION STRUCT	TURE, DEMOGRAPHIC HISTORY, AND SIGNATURES

Monday, November 10		Room Name
	Unprecedented Goal: Development of a Single Dose, High Efficacy, Replication Competent, erythrocytic Stage Malaria Vaccine for <i>Plasmodium falciparum</i> Elimination	Convention Center - Room 718B (Level 700)
2:15 p.m.	INTRODUCTION	
2:25 p.m.	FROM EARLY ARRESTING TRIPLE GENE DELETION (GAP3KO) TO LATE ARRESTING	SINGLE GENE (LARC1=GA2) AND THEN
2:45 p.m.	SAFETY, IMMUNOGENICITY, AND VACCINE EFFICACY OF PFSPZ-LARC2 VACCINE, A	ATTENUATED BY DELETION OF TWO
3 p.m.	SAFETY, IMMUNOGENICITY, AND VACCINE EFFICACY OF PFSPZ-LARC2 VACCINE, A	ATTENUATED BY DELETION OF TWO
3:15 p.m.	INCREASING THE CHANCES OF DURABLE, >90% SINGLE DOSE VACCINE EFFICACY	AGAINST HETEROLOGOUS
3:35 p.m.	HOW MUCH VACCINE EFFICACY FOR HOW LONG AGAINST P. FALCIPARUM INFECT	TION WILL BE REQUIRED TO HALT
Scientific Session 44: Globa Infectious Diseases and Pa	l Health: Global Health Security, Emerging andemic Preparedness	Convention Center - Room 801A (Level 800)
2:15 p.m.	6587: ENHANCING DETECTION AND RESPONSE CAPACITIES OF NATIONAL SURVE	ILLANCE SYSTEMS IN A CHANGING
2:25 p.m.	6588: DEVELOPING, SUSTAINING AND GROWING A MULTI-STAKEHOLDER PARTNE	RSHIP FOR MULTI-JURISDICTIONAL
2:35 p.m.	6589: CONTAINMENT THROUGH SURVEILLANCE AND LABORATORY TESTING UGA	NDA'S EBOLA RESPONSE EXPERIENCE
2:45 p.m.	6590: LEVERAGING PRE-EXISTING VILLAGE HEALTH TEAMS TO IMPLEMENT AN AC	CTIVE COMMUNITY-BASED DISEASE
2:55 p.m.	6591: THE ROLE OF WHO FIELD TEAMS AT THE SUBNATIONAL LEVEL IN PUBLIC H	IEALTH EMERGENCY RESPONSE
3:05 p.m.	6592: MPOX GENOMIC SURVEILLANCE IN THE DEMOCRATIC REPUBLIC OF THE CO	NGO (DRC) FROM 2017 - 2025: HIGH
3:15 p.m.	6593: A FRAMEWORK TO UNDERSTAND TIMELINESS IN CANINE RABIES OUTBREA	K REPORT AND RESPONSE
3:25 p.m.	6594: TASK FORCE FOR GLOBAL HEALTH'S POLIO SURGE CAPACITY PROGRAM: A	GAME CHANGER IN RESPONDING TO
3:35 p.m.	6595: COVID-19 VACCINE EFFECTIVENESS AND SARS-COV-2 VARIANTS IN NEPAL:	TEST-NEGATIVE CASE-CONTROL
3:45 p.m.	6596: ANALYSIS OF ONE-YEAR SURVEILLANCE DATA FOR ENHANCED DISEASE SU	IRVEILLANCE AND PUBLIC HEALTH

Monday, November 10 Room Name

Scientific Session	45: Viruses -	Immunology	Convention Center - Room 801B (Level 800,
2:1	5 p.m.	6597: POLIOVIRUS IMMUNITY AMONG CHILDREN AGED 6-11 AND 12-23 MONTHS	IN POLIO HIGH-RISK DISTRICTS OF
2:2	5 p.m.	6598: INFECTING SEROTYPE AND ZIKA VIRUS IMMUNITY INFLUENCE NEUTROPH	IIL INVOLVEMENT IN SECONDARY
2:3!	5 p.m.	6599: SINGLE-CELL MULTI-OMIC PROFILING OF HUMAN INFLUENZA CHALLENGE	UNCOVERS DYNAMIC PERIPHERAL
2:4	5 p.m.	6600: EXPERIMENTAL PRIMARY DENV-1 AND DENV-3 INFECTIONS PROVIDE DUR	ABLE AND STERILIZING IMMUNITY
2:5	5 p.m.	6601: CHARACTERIZATION OF DENV E-DIMER-SPECIFIC MEMORY B CELLS AND A	NTIBODIES
3:0!	5 p.m.	6602: LONGITUDINAL ANALYSIS OF THE CELLULAR IMMUNE RESPONSE TO EBOL	A VIRUS DISEASE
3:1!	5 p.m.	6603: DETAILED SEROLOGICAL PROFILING AND IDENTIFICATION OF IMMUNOREA	CTIVE EPITOPES FROM A DENV1
3:25	5 p.m.	6604: PROTEOMIC DECONVOLUTION OF THE PLASMA ANTIBODY RESPONSE TO SECONDARY DENGUE VIRUS INFECTIO	
3:3!	5 p.m.	6605: LONG-TERM IMMUNE MEMORY RESPONSE FROM VENEZUELIAN EQUINE EI	NCEPHALITIS AND MADARIAGA VIRUSES
3:4	5 p.m.	LIGHTNING TALKS	
		7460: MAGNITUDE AND LONG-TERM PERSISTENCE OF HOMOTYPIC AND HETERO	TYPIC DENGUE VIRUS ANTIBODIES
		7458: SEROTYPE-DEPENDENT VARIATION IN FUSION LOOP ANTIBODY RESPONSE	S IN DENGUE VIRUS INFECTIONS
		7463: LONGITUDINAL CHARACTERIZATION OF SARS-COV-2 ANTIBODY LANDSCAF	PES
		7465: ANTI-MPXV IGG PROFILES ARE CORRELATED WITH NEUTRALIZING ANTIBO	DY TITERS AMONG MPOX PATIENTS LIVING
Symposium 46: A	Addressing the	Rising Threat of Scrub Typhus	Convention Center - Room 803 (Level 800)
2:1	5 p.m.	INTRODUCTION	

Monday, November 10			Room Name	
	2:25 p.m.	IMPACT OF CLIMATE CHANGE ON SCRUB TYPHUS ECOLOGY AND EPIDEMIC	LOGY: THE INDIAN EXPERIENCE	
	2:45 p.m.	ESTIMATING THE GLOBAL BURDEN OF SCRUB TYPHUS		
	3:10 p.m.	A NEGLECTED PATHOGEN AND A WINDOW INTO BACTERIAL INNOVATION		
	3:35 p.m.	STRATEGIES OF SCRUB TYPHUS VACCINE DEVELOPMENT		
Scientific Se	ession 47: Kineto	plastida and Other Opportunistic and Anaerobic Protozoa: Epidemiology	Convention Center - Room 602 (Level 600)	
	2:15 p.m.	6606: TRANSMISSIBILITY OF <i>LEISHMANIA DONOVANI</i> FROM HUMAN TO SAI	ND FLIES IN AN AREA ENDEMIC FOR VISCERAL	
	2:25 p.m.	6607: THE TEST STUDIES: TRANSLATING EPIDEMIOLOGY TO SCREENING FO	R <u>TRYPANOSOMA CRUZI</u> (CHAGAS DISEASE)	
	2:35 p.m.	6608: INVESTIGATION OF THE VISCERAL LEISHMANIASIS OUTBREAK IN TH	E ENDEMIC REGION OF INDIA	
	2:45 p.m.	6609: URBANIZATION OF CHAGAS DISEASE IN BOLIVIA		
	2:55 p.m.	6610: CUTANEOUS LEISHMANIASIS: A ELEVEN YEARS REPORT OF A CLINIC	AL AND INVESTIGATION CENTER IN SOUTH	
	3:05 p.m.	6611: DATA QUALITY GAPS THREATEN VISCERAL LEISHMANIASIS ELIMINA	TION EFFORTS IN KENYA: FINDINGS FROM	
	3:15 p.m.	6612: ELIMINATION OF VISCERAL LEISHMANIASIS AS A PUBLIC HEALTH PF	ROBLEM IN KENYA: PROGRESS, CHALLENGES	
	3:25 p.m.	6613: LEISHMANIA INFANTUM TRANSMISSION DYNAMICS TO SAND FLIES V	VITHIN IMPORTANT RESERVOIRS IN BRAZIL	
	3:35 p.m.	6614: TRYPANOSOMA CRUZI DTU TCI AND ITS ROLE IN CLINICAL OUTCOME	S AND DISEASE PROGRESSION: INSIGHTS	
	3:45 p.m.	6615: EXPLORING THE USE OF ELECTRONIC HEALTH RECORD DATA TO EXA	MINE CHAGAS DISEASE IN THE UNITED STATES	
3:30 p.m 4	:30 p.m.	Career Chats: Leading with Purpose - Science Diplomacy and Enduring Collaborations	Convention Center - Room 401 (Level 400) (TropStop)	
4 p.m 6:45	p.m.	Poster Session A Dismantle	Convention Center - Hall F/G (Level 800)	
4 p.m 4:30) p.m.	Coffee Break	Convention Center - Hall D (Level 800) (Exhibit Hall)	

Monday, November 10 Room Name

LIVE	Symposium 48: Presi Pathogenesis and Cor	dent's Symposium: Global Efforts to Elucidating Malaria nbatting Multidrug-resistant <i>P. falciparum</i>	Convention Center - Hall F/G (Level 800)
	4:30 p.m.	INTRODUCTION	
	4:35 p.m.	THE PATHOGENESIS OF FATAL CEREBRAL MALARIA: A FEW MORE PIECES (F THE PUZZLE
	4:50 p.m.	MALARIA IN PREGNANCY AND ITS IMPACT ON OFFSPRING	
	5:05 p.m.	BUILDING A PAN-AFRICAN PLATFORM OF MALARIA RESEARCH AND GENOM	IIC SURVEILLANCE
	5:20 p.m.	MALARIA TREATMENT AND PREVENTION: A VITAL ROLE FOR THE WHO	
	5:35 p.m.	TRIPLE COMBINATION THERAPIES TO COMBAT DRUG-RESISTANT MALARIA	
	5:50 p.m.	INNOVATIONS IN DISCOVERING AND DEVELOPING THE NEXT GENERATION OF ANTIMALARIAL DRUGS	
		cation Crosshairs: A One Health Examination of Guinea Worm onment Nexus, and the Use of Resulting Evidence for Action	Convention Center - Room 701A (Level 700
-	4:30 p.m.	INTRODUCTION	
	4:40 p.m.	INTERRUPTING GUINEA WORM TRANSMISSION IN A CONTEXT WITH HIGH E	BURDEN OF DISEASE AMONGST DOMESTICATED
	4:55 p.m.	THE POPULATION GENETIC CASE FOR APPLYING THE ONE HEALTH PARADI	GM TO GUINEA WORM ERADICATION
	5:10 p.m.	CLOSING GAPS FOR ENVIRONMENTAL DETECTION OF GUINEA WORM DISEA	ASE: MOLECULAR TESTING FOR DRACUNCULUS
	5:25 p.m.	INTO THE WILD: BABOON TRACKING, TRAPPING, AND EVALUATION FOR EN	HANCED GUINEA WORM SURVEILLANCE
	5:40 p.m.	DEVELOPMENT AND VALIDATION OF NOVEL DIAGNOSTIC TOOLS TO ENHAN	OF CLIDYFILL ANOT OF OUNEA MODAL DICEACE

Monday, November 10 Room Name Scientific Session 50: Malaria: Clinical and Population Epidemiology Convention Center - Room 701B (Level 700) 4:30 p.m. 6616: TRAVEL AND MALARIA QPCR POSITIVITY IN NDOLA DISTRICT, ZAMBIA 4:40 p.m. 6617: SPATIOTEMPORAL MULTIVARIATE MODELS TO ASSESS MALARIA INTERVENTIONS AND TRENDS IN BURKINA FASO... 4:50 p.m. 6618. EVALUATING THE IMPACT OF MALARIA COMMUNITY CASE MANAGEMENT IN MALAWI 6619: PLASMODIUM SPECIES POSITIVITY RATES ACROSS REGIONS WITH DIFFERENT MALARIA TRANSMISSION... 5 p.m. 5:10 p.m. 6620: FINE SCALE TEMPORAL PATTERNS OF MOSQUITO DENSITY, PLASMODIUM FALCIPARUM SPOROZOITE RATE IN... 5:20 p.m. 6621: RESURGENCE OF MALARIA IN MYANMAR A REGIONAL CRISIS FUELED BY CONFLICT AND HEALTH SYSTEM COLLAPSE 5:30 p.m. 6622: MALARIA IN THEIR WORDS: THEMATIC ANALYSIS OF ONLINE NARRATIVES FROM SUB-SAHARAN AFRICA 6623: IDENTIFYING AND CHARACTERIZING HOTSPOT DISTRICTS OF PLASMODIUM VIVAX MALARIA IN INDIA IMPLICATIONS... 5:40 p.m. 6624: ASYMPTOMATIC PLASMODIUM INFECTIONS AMONG PREGNANT WOMEN AT FIRST ANTENATAL CARE CONTACT IN... 5:50 p.m. LIGHTNING TALKS 6 p.m. 7518: MODELLING THE GLOBAL BURDEN OF PREGNANCY-ASSOCIATED MALARIA DEATHS - UPDATES SINCE 2017 7530: UNDERSTANDING IMPORTED MALARIA DEATHS TO IMPROVE CARE: THE UK CONFIDENTIAL AUDIT INTO MALARIA... 7519: IMPROVING ACCESS TO CARE IN UNDERSERVED AREAS: CONTRIBUTION OF MOBILE CLINICS TO MALARIA CONTROL.. 7517: RISK FACTORS AND EPIDEMIOLOGY OF BLACKWATER FEVER IN UGANDA: HOST AND ENVIRONMENT 7516: ASSOCIATIONS BETWEEN EREQUENCY OF MALARIA INFECTIONS DURING THE FIRST YEAR OF LIFE AND FARLY... Convention Center - Room 713 (Level 700) Symposium 51: American Committee on Clinical Tropical Medicine and Travelers' Health (Clinical Group - ACCTMTH) Symposium II: Science Communication for Healthcare Professionals 4:30 p.m. INTRODUCTION PODCASTING FOR HEALTHCARE PROFESSIONALS 4:35 p.m.

Monday, November 10			Room Name	
	5 p.m.	ENGAGING WITH MAINSTREAM AND SOCIAL MEDIA		
	5:25 p.m.	USING SOCIAL INNOVATION FOR COMMUNITY ENGAGEMENT		
	5:50 p.m.	MARRYING TROPICAL MEDICINE AND JOURNALISM		
		can Committee of Molecular Cellular and Immunoparasitology (ACMCIP): Revealed by 'Omics	Convention Center - Room 714 (Level 700)	
SUPPOR	TED WITH FUNDIN	BURROUGHS WELLCOME FUND®		
	4:30 p.m.	7958: SEE MEETING APP FOR PRESENTATION DETAILS		
	4:45 p.m.	7959: SEE MEETING APP FOR PRESENTATION DETAILS		
	5 p.m.	6625: IMMUNE-DISABLING PLASMODIUM FALCIPARUM VARIANT SURFACE	ANTIGENS ARE DIFFERENTIALLY EXPRESSED IN	
	5:15 p.m.	6626: SPATIAL TRANSCRIPTOMICS AND MULTIPLEX IMAGING REVEAL DIST	FINCT BLOOD-BRAIN BARRIER SIGNATURES IN	
	5:30 p.m.	6627: IDENTIFYING THE SOURCES OF PROINFLAMMATORY MEDIATORS IN	SUBARACHNOID NEUROCYSTICERCOSIS USING	
	5:45 p.m.	6628: SPATIAL AUTOCORRELATION AND TEMPORAL TRENDS IN HOOKWOR	M-MALARIA CO-ENDEMICITY: MAPPING	
	6 p.m.	6629: WIDESPREAD GENE FUSION ARTIFACTS IN HELMINTH GENOMES		
	ım 53: Mitigating M nting, and Monitori	falaria Epidemics During Humanitarian Emergencies: Preparing, Planning, ng Responses	Convention Center - Room 715 (Level 700)	
	4:30 p.m.	INTRODUCTION		

londay, November 10		Room Name	
4:40 p.m.	OVERVIEW OF MALARIA BURDEN AND RESPONSES IN FRAGILE AND CONFLI	CT-AFFECTED SETTINGS	
4:55 p.m.	PREPARING, PLANNING, AND MONITORING RESPONSES TO HUMANITARIAN	EMERGENCIES IN MOZAMBIQUE	
5:15 p.m.	ADAPTING MALARIA CONTROL STRATEGIES AMID HUMANITARIAN EMERGEN	ICIES IN BURKINA FASO	
5:35 p.m.	GETTING BACK ON TRACK TO MALARIA ELIMINATION AMID CONFLICT IN MY	ANMAR	
	mmittee of Medical Entomology (ACME) Symposium II: Annual Business Meeting, al Medal Presentation, and Networking Reception	Convention Center - Room 716 (Level 700	
4:30 p.m.	INTRODUCTION AND WELCOME		
4:35 p.m.	ACME ANNUAL BUSINESS MEETING		
	ACME AWARDS CEREMONY I: YOUNG INVESTIGATOR TRAVEL AWARD (TRAVI	EL AWARD COORDINATOR: NSA DADA)	
4:55 p.m.	PRESENTATION OF YOUNG INVESTIGATOR TRAVEL AWARD		
	ACME AWARDS CEREMONY II: ACME AWARD OF DISTINCTION AND HOOGSTR	AAL MEDAL	
5 p.m.	PRESENTATION OF ACME AWARD OF DISTINCTION		
5:05 p.m.	AWARD OF DISTINCTION RECIPIENT		
5:10 p.m.	HARRY HOOGSTRAAL MEDAL PRESENTATION		
5:15 p.m.	HARRY HOOGSTRAAL MEDAL RECIPIENT PLENARY ADDRESS		
5:40 p.m.	PASSING OF THE GAVEL		
5:45 p.m.	ACME NETWORKING AND SOCIALIZING SESSION, CELEBRATING ACME'S 40TH	BIRTHDAY WITH CAKE	
ymposium 55: Enteric Patho	ogen Genomics and Evolution	Convention Center - Room 717 (Level 700	
4:30 p.m.	INTRODUCTION		
4:40 p.m.	IMPLICATIONS OF GENOMICS FOR CONTROL OF SHIGELLOSIS IN ENDEMIC S	ETTINGS	

Monday, November 10		Room Name	
4:55 p.m.	EVOLUTIONARY PATHS SHAPING THE EMERGENCE OF PANDEMIC VIB.	RIO CHOLERAE	
5:20 p.m.	HOST SPECIFICITY OF VIBRIO PHAGES ACROSS EVOLUTIONARY LINEA	AGES OF <i>V. CHOLERAE</i> 01 WITH DISTINCT ANTI	
5:45 p.m.	GENETIC DETERMINANTS OF AMR IN ENTERIC INFECTIONS IN LEBANC	DN-SALMONELLA AND CHOLERA OUTBREAKS	
, , , , , , , , , , , , , , , , , , , ,	ssion Fitness of African Artemisinin-resistant Parasites and the eir Transmission to Mosquitoes	Convention Center - Room 718A (Level 700,	
4:30 p.m.	INTRODUCTION		
4:40 p.m.	EVIDENCE FOR PARTIAL RESISTANCE TO ARTEMISININS IN MALARIA F	PARASITES IN EAST AFRICA	
4:55 p.m.	THE IMPACT OF VALIDATED PARTIAL ARTEMISININ MARKERS, R561H	AND C469Y, ON FITNESS AND TRANSMISSION	
5:10 p.m.	ELUCIDATING THE GENETIC DETERMINANTS OF EMERGING ARTEMET	HER-LUMEFANTRINE RESISTANCE IN UGANDAN	
5:25 p.m.	OCCURRENCE OF ARTEMISININ RESISTANT PARASITES IN MULTICLON	NAL INFECTIONS IN UGANDA AND THEIR	
5:40 p.m.	GAMETOCYTE CARRIAGE AND TRANSMISSION TO ANOPHELES ARABIE	ENSIS MOSQUITOES AFTER TREATMENT OF	
Symposium 57: Evidence to 0	Guide the Implementation of Effective P. vivax Radical Cure	Convention Center - Room 718B (Level 700	
4:30 p.m.	INTRODUCTION		
4:40 p.m.	THE NATIONAL ROLL-OUT OF TAFENOQUINE IN THE BRAZILIAN AMAZO	DN: LESSONS LEARNED	
4:55 p.m.	DETERMINING THE FEASIBILITY OF IMPLEMENTING A NEW DIAGNOST	IC AND TREATMENT APPROACH FOR P. VIVAX	
5:10 p.m.	SCOPE STUDY OUTLINE AND THE SAFETY OF HIGH DOSE SHORT COUF	RSE PRIMAQUINE FOR <i>P. VIVAX</i> MALARIA	
5:25 p.m.	FEASIBILITY AND IMPACT OF IMPLEMENTING G6PD TESTING AND HIG	H DAILY DOSE PRIMAQUINE - INSIGHTS FOR SCALE UP	
5:40 p.m.	UNDERSTANDING COMMUNITY, PATIENT AND HEALTH WORKER PERS	PECTIVES ON <i>P. VIVAX</i> RADICAL CURE IN INDONESIA	

Monday, November 10		Room Name	
5:45 p.m.	UNDERSTANDING COMMUNITY, PATIENT AND HEALTH WORKER PERSF	PECTIVES ON <i>P. VIVAX</i> RADICAL CURE IN PNG	
5:50 p.m.	IMPACT OF G6PD ACTIVITY THRESHOLDS ON RADICAL CURE TREATME	NT OPTIONS AND COVERAGE	
Scientific Session 58: Global Epidemiology and Global Hea	Health: Modeling, AI and Advanced Methods Applied to Disease Ith Issues	Convention Center - Room 801A (Level 800)	
4:30 p.m.	6630: ESTIMATING THE GLOBAL BURDEN OF SCRUB TYPHUS		
4:40 p.m.	6631: POST-MARKET SURVEILLANCE TO COMBAT SUBSTANDARD AND	FALSIFIED ANTIMALARIALS AND ANTIBIOTICS: A	
4:50 p.m.	6632: CREATION AND APPLICATION OF A HEALTH CAMPAIGN INTEGRAT	TION OPTIMIZATION ALGORITHM	
5 p.m.	6633: POTENTIAL IMPACT OF VACCINE INTRODUCTION ON MALARIA CA	ASES AND DEATHS IN SUB-SAHARAN AFRICA	
5:10 p.m.	6634: TYPHOIDSIM: AN OPEN-SOURCE TRANSMISSION MODEL TO EVAL	LUATE TYPHOID CONJUGATE VACCINE SCHEDULES	
5:20 p.m.	6635: MODELING THE IMPACT OF LOW-COST VENTILATION INTERVENTI	IONS ON NOSOCOMIAL RESPIRATORY INFECTION	
5:30 p.m.	6636: NON-P. FALCIPARUM AND P. FALCIPARUM MALARIA IS BACK IN T	THE CENTRAL HIGHLAND OF MADAGASCAR	
5:40 p.m.	6637: BEYOND SENSITIVITY AND SPECIFICITY: USING MACHINE LEARN	ING (ML) TO ENHANCE CHOLERA RAPID	
5:50 p.m.	6638: CASCADES OF EFFECTIVENESS OF NEW-GENERATION INSECTICE	DE-TREATED NETS AGAINST MALARIA, FROM	
6 p.m.	6639: ANTICIPATING REGIONAL SPREAD OF MEASLES FROM TEXAS US	ING A PARAMETER-FREE MOBILITY MODEL	
Scientific Session 59: Viruses	s - Therapeutic, Antiviral Drugs and Vaccine Clinical Trials	Convention Center - Room 801B (Level 800)	
4:30 p.m.	6640: PROPHYLACTIC OR THERAPEUTIC NEUTRALIZING MONOCLONAL	ANTIBODY TREATMENT PREVENTS LETHAL	
4:40 p.m.	6641: A MULTIVALENT NUCLEOSIDE-MODIFIED MRNA VACCINE AGAINS	ST WEST NILE VIRUS	
4:50 p.m.	6642: AN UNPRECEDENTED MODE-OF-ACTION AND A CMAX-DRIVEN EF	FICACY OF A YELLOW FEVER ANTIVIRAL DRUG	
5 p.m.	6643: GENERATION OF THERAPEUTIC HUMAN IGG MONOCLONAL ANTIE	BODIES AGAINST SEVERE FEVER WITH	

Monday, November 10	Room Name
5:10 p.m.	6644: LONG-TERM IMMUNOGENICITY OF INTRADERMAL JAPANESE ENCEPHALITIS VACCINATION
5:20 p.m.	6645: FIVE-YEAR EFFICACY AND SAFETY OF A LIVE, ATTENUATED TETRAVALENT DENGUE VACCINE PRODUCED BY
5:30 p.m.	6646: PHASE 1 TRIAL TO SAFELY MODEL PRIMARY, SECONDARY, AND TERTIARY DENGUE
5:40 p.m.	6647: MAGNITUDE OF VACCINE-INDUCED T CELL RESPONSE CANNOT BE INFERRED FROM NEUTRALIZING ANTIBODY TITERS
5:50 p.m.	6648: EFFICACY OF THE LIVE ATTENUATED TETRAVALENT DENGUE VACCINE TV003 OR PREVIOUS ZIKA INFECTION
6 p.m.	6649: SAFETY, LONG-TERM IMMUNE RESPONSE AND BOOSTER IMPACT OF THE TETRAVALENT DENGUE VACCINE TAK-003
Scientific Session 60: Ectopa	rasite-Borne Diseases Convention Center - Room 803 (Level 800)
4:30 p.m.	6650: POWASSAN VIRUS ELICITS DIFFERENTIAL HOST IMMUNE RESPONSES DURING NATURAL TICK-MEDIATED
4:40 p.m.	6651: HISTORIC CIRCULATION OF POWASSAN VIRUS IN THE AMERICAN DOG TICK, DERMACENTOR VARIABILIS
4:50 p.m.	6652: ANTIBODIES TO TICK SALIVARY ANTIGENS AV422 AND CALRETICULIN IN PATIENTS WITH SPOTTED FEVER GROUP
5 p.m.	6653: DIVERSE HOSTS MAINTAIN ANAPLASMA PHAGOCYTOPHILUM ON MASSACHUSETTS ISLANDS
5:10 p.m.	6654: IMPACT OF A RESERVOIR-TARGETED BORRELIA BURGDORFERI ORAL VACCINE ON INFECTION PREVALENCE
5:20 p.m.	6655: EXTRAVASATION OF BORRELIA BURGDORFERI IN A 3D TISSUE-ENGINEERED MICROVESSEL MODEL
5:30 p.m.	6656: FIRST DETECTION OF YERSINIA PESTIS IN XENOPSYLLA BRASILIENSIS IN MADAGASCAR EVIDENCE FROM
5:40 p.m.	6657: POLYFUNCTIONAL MEMORY CD8 T CELLS CORRELATE WITH VACCINE-INDUCED PROTECTION AGAINST FATAL
5:50 p.m.	6658: ECO-EPIDEMIOLOGY OF VECTOR-BORNE PATHOGENS IN HUMANS, RODENTS AND THEIR ECTOPARASITES IN RURAL
6 p.m.	6659: ELEVATED SERUM CREATININE AS A PREDICTOR OF MORTALITY AMONG SCRUB TYPHUS PATIENTS ADMITTED TO A

Scientific Se	ession 61: Kinetoplas	stida and Other Opportunistic and Anaerobic Protozoa:	Convention Center - Room 602 (Level 600)
Diagnosis a	nd New Detection To	ols 6660: LYOPHILIZED COLORIMETRIC AND FLUOROMETRIC LOOP-MEDIATED ISO	THEDMAL AMDI IFICATION (LAMD): A DOINT
	4:30 p.m. 4:40 p.m.	6661: AI-POWERED DIGITAL MICROSCOPY FOR ENHANCED DIAGNOSIS AND MC	
	4:50 p.m.	662: CANDIDATE AUTOANTIBODIES AS BIOMARKERS OF THERAPEUTIC RESP	
	5 p.m.	663: SPECIES-SPECIFIC DIRECT DETECTION OF LEISHMANIA USING A CAS12-	
	5:10 p.m.	6664: LONGITUDINAL EVALUATION OF <i>LEISHMANIA DONOVANI</i> TRANSMISSION	
	5:20 p.m.	6665: IMPROVING THE DIAGNOSIS OF VISCERAL LEISHMANIASIS IN ETHIOPIA	
	5:30 p.m.	6666: EARLY ASSESSMENT OF ANTIBODY DECLINE AND TREATMENT DISCRIMI	NATION IN CHAGAS PATIENTS USING THE
	5:40 p.m.	6667: IMPLEMENTATION OF A THREE-TEST ALGORITHM FOR CLINICAL SEROLO	GICAL TESTING FOR CHAGAS DISEASE
	5:50 p.m. 6668: IDENTIFYING ANTIBODY BIOMARKERS THAT PREDICT PROGRESSION OF CHAGAS CARDIOMYOPATHY		CHAGAS CARDIOMYOPATHY
4:30 p.m 6	:15 p.m.	Special Session 62: ASTMH Committee on Global Health (ACGH) Networking and Lightning Presentations	Convention Center - Room 707 (Level 700)
5:15 p.m. – (6:15 p.m.	Mentorship Pop-Up Session: Professional Development Needs of Mid-Career Professionals in Tropical Medicine and Global Health	Convention Center – Level 600 Lobby (Level 600)
6:15 p.m 6	5:45 p.m.	Break	
6:45 p.m 8	3:15 p.m.	Special Session 63: Fever Feud Educational Quiz Show: A Tropical Medicine Spin on "Family Feud"	Convention Center - Hall F/G (Level 800)

Tuesday, November 1	1	Room Name
7 a.m 5 p.m.	Registration	Convention Center - Registration Lobby Area (Level 600)
7 a.m 5 p.m.	Speaker Ready Room (Closed 11:30 a.m 12:30 p.m.)	Convention Center - Room 703 (Level 600)
7 a.m 5 p.m.	TropStop- Student/Trainee Lounge	Convention Center - Room 401 (Level 400) (TropStop)
7 a.m 7 p.m.	Meeting Sign-Up Room	Convention Center - Room 711 (Level 700)
7 a.m 7 p.m.	Nursing Mothers Room Please pick up the room key at the Registration Desk, Level 600	Convention Center – Room 702 (Level 700)
7 a.m 7 p.m.	Prayer Room	Convention Center - Room 810 (Level 800)
7 a.m 7:30 a.m.	Poster Session B Set-Up	Convention Center - Hall E (Level 800) (Poster Hall)
7:30 a.m Noon	Poster Session B Viewing	Convention Center - Hall E (Level 800) (Poster Hall)
7 a.m. – 8:45 a.m.	Sponsored Symposium: Elimination at Scale: India's Integrated Model to Beat Vector Borne Diseases, with a Focus on Lymphatic Filariasis and Visceral Leishmar	Convention Center - Room 602 (Level 600)
	SPONSORED BY	

Tuesday, November 1	1	Room Name
7 a.m. – 8:45 a.m.	Sponsored Symposium: Outbreaks Without Headlines: Surveillance, Reporting, and Vaccination against Chikungunya	Convention Center - Room 713 (Level 700)
	SPONSORED BY BAVARIAN NORDIC	
7 a.m. – 8:45 a.m.	Sponsored Symposium: Critical Diagnostic Decisions in Tropical Fever: Evolving Approaches with Fast Diagnostics Testing	Convention Center - Room 715 (Level 700)
	SPONSORED BY	
7 a.m. – 8:45 a.m.	Sponsored Symposium: Towards Next-Generation Prevention Tools to Combat Malaria: Long-Acting Antimalarials and Chemovaccination	Convention Center - Room 717 (Level 700)
	SPONSORED BY	
7:30 a.m 9 a.m.	Mentorship Pop-Up Session: This Week in Parasitology (TWiP) Podcast Taping 1	Convention Center – Level 600 Lobby (Level 600)
7:45 a.m 5 p.m.	Press Room	Convention Center - Room 704 (Level 700)
7:45 a.m 8:45 a.m.	AJTMH Editorial Board Meeting	Convention Center - Room 604 (Level 600)

Tuesday, November 11		Room Name
9 a.m 10 p.m.	Mentorship Pop-Up Session: This Week in Virology (TwiV): Clinical Update with Dr. Daniel Griffin Podcast Taping 2	Convention Center – Level 600 Lobby (Level 600)
9 a.m 9:45 a.m.	Plenary Session 64: Plenary Session III: President's Address	Convention Center - Hall F/G (Level 800)
9 a.m.	INTRODUCTION	
9:15 a.m.	PRESIDENT'S ADDRESS: LEVERAGING SCIENCE IN THE GLOBAL EFFORT TO ELIM UNPRECEDENTED CHALLENGES	IINATE MALARIA IN AN ERA OF
9:30 a.m. – 4 p.m.	Exhibit Hall Open	Convention Center - Hall D (Level 800) (Exhibit Hall)
9:45 a.m 10:15 a.m.	Coffee Break	Convention Center - Hall D (Level 800) (Exhibit Hall)
10 a.m. – 11 a.m.	Mentorship Pop-Up Session: Green Up Your Lab, Clinic and Field Work with the ASTMH Green Task Force!	Convention Center – Level 600 Lobby (Level 600)
Symposium 65: Malaria V	faccines in a New Era of Malaria Control and Elimination: earch and Real-world Implementation	Convention Center - Hall F/G (Level 800)
10:15 a.m.	INTRODUCTION	
10:25 a.m.	OVERVIEW OF THE RTS,S AND R21 MALARIA VACCINES -IMPACT ON UNCOMPLIC	CATED AND SEVERE MALARIA
10:55 a.m.	BEYOND THE MALARIA VACCINE IMPLEMENTATION PROGRAMME (MVIP): WHAT	HAVE WE LEARNED FROM THE PHASE
11:25 a.m.	EXPERIENCE AND LESSONS LEARNED FROM R1 MALARIA VACCINE INTRODUCTION	ON IN NIGERIA

Tuesday, November 11		Room Name
10:55 a.m.	ACCELERATING MALARIA VACCINATION ROLL-OUT IN AFRICA T	HROUGH CROSS-COUNTRY EXPERIENCE SHARING
11:25 a.m.	WHAT IS NEXT FOR MALARIA VACCINES- SECOND GENERATION	VACCINES
Scientific Session 66: Viruses	cientific Session 66: Viruses - Emerging Viral Diseases Convention Center - Room 701A (Leve	
10:15 a.m.	6669: A NEW THREAT IN THE TROPICS: MODELING REEMERGEN	T 2024 OROPOUCHE VIRUS PATHOGENESIS AND
10:25 a.m.	6670: GENOMIC CHARACTERIZATION OF ARBOVIRUSES DISCOV	ERED BETWEEN THE 1950S AND 1980S
10:35 a.m.	6671: CRIMEAN-CONGO HEMORRHAGIC FEVER OUTBREAK IN PO	DDOR, NORTHERN SENEGAL IN 2022
10:45 a.m.	6672: MACHINE LEARNING IDENTIFIES METABOLIC BIOMARKER	S OF POST-EBOLA SYNDROME
10:55 a.m.	6673: FETAL AND MATERNAL OUTCOMES ASSOCIATED WITH DE	NGUE IN PREGNANCY: EVIDENCE FROM THE CHILD HEALTH
11:05 a.m.	6674: EVIDENCE OF CIRCULATION OF MULTIPLE ENDEMIC ARBO	OVIRUSES IN HUMANS BASED ON SYNDROMIC SENTINEL
11:15 a.m.	6675: EBOLAVIRUS EVOLUTION AND EMERGENCE ARE ASSOCIA	TED WITH LAND USE CHANGE
11:25 a.m.	6676: EXTENSIVE SILENT TRANSMISSION OF OROPOUCHE VIRU	S DURING THE 2024 OUTBREAK IN SALVADOR, BRAZIL
11:35 a.m.	6677: PRE-CLADE IIB HUMAN CASES: MPOX VIRUS SEROPREVA	LENCE IN GHANA
11:45 a.m.	6678: OROPOUCHE VIRUS COUNTRY RISK ESTIMATION: VALIDA	TING CONNECTIVITY MODELLING WITH 2024 TRAVEL
Scientific Session 67: Malaria	- Genetics, Genomics and Evolution	Convention Center - Room 701B (Level 700)
10:15 a.m.	6679: INTEGRATING PARASITE GENOMICS AND EPIDEMIOLOGICA	AL DATA TO QUANTIFY MALARIA IMPORTATION IN
10:25 a.m.	6680: TEMPORAL AND SPATIAL DYNAMICS OF MALARIA PARASI	TE GENETIC RELATEDNESS IN SENEGAL: ANALYSES OF
10:35 a.m.	6681: BENCHMARKING THE POTENTIAL FOR QUANTITATIVE INF	ERENCE USING GENOMIC EPIDEMIOLOGY APPROACHES
10:45 a.m.	6682: ESTIMATING PROBABILITIES OF MALARIA IMPORTATION I	N SOUTHERN MOZAMBIQUE THROUGH <i>P. FALCIPARUM</i>
10:55 a.m.	6683: USING GENETICS TO ASSESS SUB-NATIONAL MALARIA TF	RANSMISSION INTENSITY AND INCIDENCE IN SENEGAL

Tuesday, November 11 Room Name 11:05 a.m. 6684: INTEGRATIVE GENOMIC AND TRANSCRIPTOMIC ANALYSIS OF PLASMODIUM KNOWLESI TO ELUCIDATE DRIVERS OF... 11:15 a.m. 6685: INTEGRATING MULTI-OMICS APPROACHES TO UNCOVER MARKERS OF MALARIA DISEASE SEVERITY... 11:25 a.m. 6686: CYP2D GENETIC VARIATION MODULATES PLASMODIUM VIVAX INFECTION RISK: INSIGHTS FROM A LONGITUDINAL... 11:35 a.m. 6687: APIAP2-I, MODULATES THE STRESS RESPONSE IN MALARIA PARASITES 11:45 a.m. LIGHTNING TALKS 7535: HOST INFECTIVITY AND CSP GENETIC STRUCTURE INDEPENDENCE OF PLASMODIUM VIVAX DURING MALARIA... 7536: MOLECULAR INVESTIGATION OF MALARIA RESURGENCE IN ETHIOPIA 7538: FIELD-DEPLOYABLE TARGETED NANOPORE SEQUENCING TO ASSESS MOLECULAR MARKERS OF ANTI-MALARIAL... 7534: STREAMLINING MALARIA GENOMIC ANALYSIS: OPEN-SOURCE. INTEROPERABLE PIPELINES FOR ANTIMALARIAL... Scientific Session 68: Clinical Tropical Medicine: Parasites, Viruses and Others Convention Center - Room 713 (Level 700) 10:15 a.m. 6688: NEED FOR ANTIVENOM QUALITY CONTROL: PRECLINICAL RESULTS REVEAL THE POTENTIAL AND DEFICIENCIES OF... 10:25 a.m. 6689: CHALLENGES AND OPPORTUNITIES FOR SETTING UP ACTIVE PREGNANCY PHARMACOVIGILANCE IN SUB-... 10:35 a.m. 6690: EVOLUTION OF FLUID MANAGEMENT IMPROVES DENGUE OUTCOME OVER 20 YEARS IN TWO STUDIES IN NICARAGUA 10:45 a.m. 6691: REAL-TIME HAEMODYNAMIC ASSESSMENT IN DENGUE SHOCK USING CONTINUOUS PHYSIOLOGICAL MONITORING 10:55 a.m. 6692' TRAINING THE NEXT GENERATION OF TROPICAL MEDICINE SPECIALISTS: A 12-YEAR ANALYSIS OF BAYLOR'S... 11:05 a.m. 6693: A COMPARATIVE ANALYSIS OF DENGUE, CHIKUNGUNYA, AND ZIKA MANIFESTATIONS IN A PEDIATRIC COHORT OVER... 11:15 a.m. 6694: ASSOCIATION OF PERSISTENT ASYMPTOMATIC GIARDIA COLONIZATION IN INFANCY WITH FALTERED LINEAR... 11:25 a.m. 6695: RISK OF MALARIA IN ADULTS WITH TYPE 2 DIABETES FOLLOWED FOR A ONE-YEAR PERIOD: RESULTS FROM A...

Tuesday, November 11		Room Name
11:35 a.m.	6696: "CALL, PHOTO, TREAT": AN ON-DEMAND HOME TREATMENT ALGORITHM M	IITIGATES BENZNIDAZOLE-RELATED RASH
11:45 a.m.	6697: CEREBRAL MALARIA AND SEVERE MALARIAL ANEMIA, BUT NOT OTHER FO	ORMS OF SEVERE MALARIA, ARE
10:15 a.m Noon	Meet the Professors Session 69: Meet the Professors: Trainee Case Competition	Convention Center - Room 714 (Level 700)
Symposium 70: Antimalaria	l Drug Resistance in Africa: Will We Miss the Train Again?	Convention Center - Room 715 (Level 700)
10:15 a.m.	INTRODUCTION	
10:25 a.m.	RELATIONSHIP BETWEEN PFKELCH13 MUTATIONS AND PARASITOLOGICAL OUT	COMES IN UNCOMPLICATED MALARIA
10:40 a.m.	IMPACT OF PFKELCH13 MUTATIONS ON CLINICAL OUTCOMES IN SEVERE MALA	RIA
10:55 a.m.	PHARMACOMETRIC ASSESSMENT OF SEASONAL MALARIA CHEMOPREVENTION	I
11:15 a.m.	WHAT IS A SUITABLE ANTIMALARIAL CHEMOPREVENTION IN PREGNANCY?	
11:35 a.m.	MAPPING THE SPREAD OF DRUG RESISTANCE IN AFRICA	
Symposium 71: Spatial Biol	ogy Applications in Immunology and Infectious Diseases	Convention Center - Room 716 (Level 700)
10:15 a.m.	INTRODUCTION	
10:25 a.m.	SPATIAL BIOLOGY APPLICATIONS IN IMMUNOLOGY AND INFECTIOUS DISEASES	
10:30 a.m.	IMAGING-BASED SPATIAL PROTEO/TRANSCRIPTOMICS APPLIED TO INFECTIOU	S DISEASES RESEARCH
10:55 a.m.	NOVEL SPATIAL OMICS AND DEEP LEARNING TOOLS TO STUDY HOST-PARASITE	INTERACTIONS IN THE PLASMODIUM
11:20 a.m.	SPATIOTEMPORAL INSTRUCTION OF T CELL TISSUE IMMUNITY	
11:40 a.m.	INVESTIGATING BLOOD-BRAIN BARRIER SIGNATURES IN CEREBRAL MALARIA U	JSING SPATIAL TRANSCRIPTOMICS AND

Tuesday, November 11 Room Name

Sympos	ium 72: Case Manag	ement of Typhoid Fever	Convention Center - Room 717 (Level 700)
	10:15 a.m.	INTRODUCTION	
	10:25 a.m.	GLOBAL AND REGIONAL BURDEN OF DRUG-RESISTANT ENTERIC FEVER, EPI	DEMIOLOGICAL TRENDS, AND SURVEILLANCE
	10:40 a.m.	MOLECULAR MECHANISMS OF RESISTANCE IN S. TYPHI	
	10:55 a.m.	EFFECTIVENESS OF CURRENT DIAGNOSTIC TOOLS FOR ENTERIC FEVER AN	D FUTURE POTENTIAL OPTIONS
	11:10 a.m.	TREATMENT OF DRUG RESISTANT TYPHOID	
	11:25 a.m.	ARE TWO DRUGS BETTER THAN ONE FOR THE TREATMENT OF UNCOMPLICA	ATED ENTERIC FEVER: SHARING THE RESULTS
Sympos	nposium 73: Next Generation Malaria Diagnostics - Harnessing New Biomarkers for Parasite Detection Convention Center - Room 718A (L		Convention Center - Room 718A (Level 700)
	10:15 a.m.	INTRODUCTION	
	10:25 a.m.	LANDSCAPE OF NEW BIOMARKERS AND NEXT GENERATION DIAGNOSTIC TE	STS FOR MALARIA
	10:30 a.m.	PLASMODIUM BIOMARKER DISCOVERY THROUGH -OMICS, AI AND PROTEIN	ENGINEERING
	10:50 a.m.	PROFILING HUMAN SCENT FINGERPRINTS TO ACCELERATE MALARIA DIAGN	IOSIS AND CONTROL
	11:10 a.m.	DEVELOPMENT OF A BREATHALYZER FOR DETECTION OF LOW PARASITE IN	FECTIONS
	11:30 a.m.	EXTRACELLULAR VESICLES AS NEW BIOMARKERS FOR P. VIVAX CRYPTIC IN	NFECTIONS, AND SPLENIC RESERVOIR
	11:45 a.m.	DIFFERENTIALLY EXPRESSED MIR-3158-3P MICRORNA IN SEVERE MALARIA	: FROM DISCOVERY TO VALIDATION
Sympos	ium 74: Al for One H	ealth: Creative Use of Data and AI for Pandemic and Epidemic Preparedness	Convention Center - Room 718B (Level 700
	10:15 a.m.	INTRODUCTION	
	10:20 a.m.	THE NEED FOR A UNIFIED PLATFORM TO COLLECT, ANALYZE, AND REPORT N	MALARIA SURVEILLANCE DATA POWERED BY
	-		

November 11		Room Name
10:30 a.m.	ARTIFICIAL INTELLIGENCE FOR MALARIA SURVEILLANCE THROUGH AN	ALYSIS OF MOSQUITO SOUNDS
10:50 a.m.	ARTIFICIAL INTELLIGENCE FOR PANDEMIC AND EPIDEMIC PREPAREDNE	ESS: EXAMPLES FROM THE GLOBAL SOUTH
11:10 a.m.	LEVERAGING ARTIFICIAL INTELLIGENCE AND UNCONVENTIONAL DATA I	FOR REAL-TIME SURVEILLANCE, FORECASTING
11:30 a.m.	ROLE OF FUNDERS IN SUPPORTING AND SCALING ARTIFICIAL INTELLIG	ENCE TOOLS FOR GLOBAL HEALTH
	•	Convention Center - Room 801A (Level 800)
10:15 a.m.	INTRODUCTION	
10:25 a.m.	GLOBAL NEWBORN HEALTH & SURVIVAL: CHALLENGES AND OPPORTU	NITIES
10:45 a.m.	WHAT CAN BE DONE FOR NEWBORN SURVIVAL: AN EVIDENCE REVIEW	
11:05 a.m.	CURRENT EVIDENCE ON INTERVENTIONS TO PREVENT AND CONTROL N	IEWBORN INFECTIONS, SEPSIS, AND AMR IN LOW
11:25 a.m.	CURRENT EVIDENCE ON INTERVENTIONS TO PREVENT AND CONTROL N	IEWBORN INFECTIONS, SEPSIS, AND AMR IN LOW
11:45 a.m.	NEWBORN HEALTH COUNTRY CASE STUDY: ZAMBIA	
ased Decision Mak	ring: SeroTracker Dashboard, Mapping and Data Tools, from	Convention Center - Room 801B (Level 800)
10:15 a.m.	INTRODUCTION	
10:25 a.m.	REVIEWING THE IMPACT OF THE SEROTRACKER INITIATIVE FOR SARS-	COV-2 SEROSURVEILLANCE AND BEYOND
10:40 a.m.	WHO UNITY STUDIES: THE DEVELOPMENT AND IMPLEMENTATION OF ST	TANDARDIZED PROTOCOLS AND A NETWORK OF
10:55 a.m.	SURVEILLANCE FOR ARBOVIRUSES SUCH AS ZIKA, DENGUE, CHIKUNG	UNYA, THE ARBOTRACKER DASHBOARD AND
	10:30 a.m. 10:50 a.m. 11:10 a.m. 11:30 a.m. 11:30 a.m. 10:05 a.m. 10:15 a.m. 10:25 a.m. 11:25 a.m. 11:45 a.m. 11:45 a.m. 11:45 a.m. 11:45 a.m. 11:45 a.m. 11:45 a.m. 10:15 a.m. 10:15 a.m. 10:25 a.m. 10:40 a.m.	10:30 a.m. ARTIFICIAL INTELLIGENCE FOR MALARIA SURVEILLANCE THROUGH AN 10:50 a.m. ARTIFICIAL INTELLIGENCE FOR PANDEMIC AND EPIDEMIC PREPAREDNE 11:10 a.m. LEVERAGING ARTIFICIAL INTELLIGENCE AND UNCONVENTIONAL DATA I 11:30 a.m. ROLE OF FUNDERS IN SUPPORTING AND SCALING ARTIFICIAL INTELLIGING INTELLIGING INTELLIGING INTELLIGING INTELLIGING INTELLIGING INTELLIGING INTELLIGING INTELLIGING INTERPRICE INTELLIGING INTELLIGI

11:10 a.m.

MIDDLE EAST RESPIRATORY SYNDROME SURVEILLANCE ACROSS SPECIES AND THE DEVELOPMENT OF THE...

Tuesday, November 11 Room Name

Noon – 1:45	p.m.	Poster Session 79: Poster Session B Presentations	Convention Center - Hall E (Level 800) (Poster Hall)
11:15 a.m	· 12:15 p.m.	Mentorship Pop-Up Session: Global Health Politics: A View from the Social Sciences	Convention Center – Level 600 Lobby (Level 600)
	11:20 a.m.	HUNGER IN THE TIME OF COVID-19: NUTRITION AND TB RISK IN INDIA DURING	THE PANDEMIC
	11 a.m.	LOCKED OUT OF CARE: UNDERNUTRITION AND TB IN BRAZIL'S PRISONS	
	10:40 a.m.	TB AND CLIMATE CHANGE: THE SOIL AND SEED FRAMEWORK	
	10:20 a.m.	SETTING THE TABLE: NUTRITION AS A CENTRAL DETERMINANT OF TUBERCULO	SIS
	10:15 a.m.	INTRODUCTION	
Symposium	78: Nutrition and	Tuberculosis: A Clear and Present Danger	Convention Center - Room 602 (Level 600)
	11:35 a.m.	TESTING PATHWAY FOR A SPLIT EFFECTOR/GENE DRIVE SYSTEM FOR ELIMINA	TING MALARIA TRANSMISSION IN TANZANIA
	11:10 a.m.	CONSIDERATIONS WHEN DESIGNING A FIELD TRIAL OF GENE DRIVE MOSQUITO	ES
	10:45 a.m.	FIELD TRIAL DESIGN FOR WOLBACHIA FOR DENGUE CONTROL	
	10:25 a.m.	WHAT IS GENE DRIVE AND WHY ARE GENE DRIVE MOSQUITOES NEEDED?	
	10:15 a.m.	INTRODUCTION	
Symposium	77: Gene Drive N	Aosquitoes for Malaria Control: Planning for Field Trials	Convention Center - Room 803 (Level 800)
	11:40 a.m.	FROM DATA TO DASHBOARD: SYNTHESIZING AND APPLYING SEROTRACKER'S D	ATA THROUGH VISUALIZATIONS, EVIDENCE.
	11:25 a.m.	MIDDLE EAST RESPIRATORY SYNDROME SURVEILLANCE ACROSS SPECIES AND	THE DEVELOPMENT OF THE

Tuesday, November 11		Room Name
11:45 a.m 1:45 p.m.	Exhibit Hall - Light Lunch	Convention Center - Hall D (Level 800) (Exhibit Hall)
12:15 p.m 1:15 p.m.	Burroughs Wellcome Fund - ASTMH Fellowship Committee Meeting	Convention Center - Room 606 (Level 600)
12:15 p.m 1:15 p.m.	CTropMed Exam Committee Meeting	Convention Center - Room 604 (Level 600)
12:15 p.m 1:15 p.m.	Green Task Force Committee Meeting	Convention Center - Room 709 (Level 700)
12:15 p.m 1:30 p.m.	Informal Lunch Discussion and Networking with the American Committee of Molecular, Cellular and Immunoparasitology (ACMCIP) Councilors	Convention Center - Room 707 (Level 700)
12:15 p.m 1:30 p.m.	Late-Breaker Abstract Session 80: Late-Breakers in Clinical and Applied Sciences I	Convention Center - Hall F/G (Level 800)
12:15 p.m 1:30 p.m.	Meet the Professors Session 81: Meet the Professors: Borders and Burdens: Clinical Dilemmas in Tropical Diseases Among Migrants and Frontline Indigenous and Rural Populations	Convention Center - Room 801B (Level 800)
1:15 p.m 2 p.m.	Diploma Course Directors Meeting	Convention Center - Room 604 (Level 600)
1:30 p.m. – 2:30 p.m.	Mentorship Pop-Up Session: African Voices of Science (AVoS): Amplifying African Leadership in Global Health Research & Innovation	Convention Center – Level 600 Lobby (Level 600)
1:45 p.m 3:30 p.m.	Poster Session B Viewing	Convention Center - Hall E (Level 800) (Poster Hall)
LIVE CATION CONTENT	82: Zoonotic Infections of the Arctic-Challenges in a Unique Ecosystem	Convention Center - Hall F/G (Level 800)
1:45 p.m.	INTRODUCTION	
1:55 p.m.	DIAGNOSTIC CHALLENGES OF PARASITIC ZOONOSIS	

Tuesday, November 11		Room Name
2:10 p.m.	TOXOPLASMA GONDII DNA IN TISSUES OF ARCTIC CHARR COLLECTED IN I	NUNAVIK, QUÉBEC
2:25 p.m.	ALVEOLAR AND CYSTIC ECHINOCOCCOSIS	
2:45 p.m.	CLINICAL AND PUBLIC HEALTH ASPECTS OF TRICHINOSIS AND BOTULISM	I IN THE ARCTIC REGION OF NUNAVIK, CANADA
3 p.m.	CLINICAL AND PUBLIC HEALTH ASPECTS OF TRICHINOSIS AND BOTULISM	I IN THE ARCTIC REGION OF NUNAVIK, CANADA
3:15 p.m.	STIGMA AND BARRIERS TO HEALTH-SEEKING IN NORTHERN INDIGENOUS	COMMUNITIES
Symposium 83: American Co Symposium I: Annual Busine	mmittee on Arthropod-Borne Viruses and Zoonotic Viruses (ACAV) ss Meeting	Convention Center - Room 701A (Level 700)
1:45 p.m.	INTRODUCTION	
1:55 p.m.	ACAV BUSINESS MEETING	
2:10 p.m.	ACAV AWARDS	
2:35 p.m.	OUTBREAK REPORT 1	
2:45 p.m.	OUTBREAK REPORT 2	
2:55 p.m.	OUTBREAK REPORT 3	
3:05 p.m.	NETWORKING RECEPTION	
Scientific Session 84: Malari	a - Deciphering Drug Resistance in <i>Plasmodium</i>	Convention Center - Room 701B (Level 700)
1:45 p.m.	7135: DOUBLE MUTATIONS IN KELCH13 DRIVE RESISTANCE TO NEXT-GE	NERATION ARTEMISININ DERIVATIVES IN
1:55 p.m.	7136: MITOCHONDRIAL DISRUPTION AND PFPRELI AS A RESISTANCE NO	DDE TO SERINE HYDROLASE INHIBITORS

Tuesday, November 11	Room Name
2:05 p.m.	7137: PLASMODIUM FALCIPARUM UBIQUITIN-PROTEASOME SYSTEM (UPS) MODULATING ANTIMALARIAL RESISTANCE
2:15 p.m.	7138: CELLULAR AND MOLECULAR BASIS OF PF CORONIN FUNCTION IN ARTEMISININ RESISTANCE IN PLASMODIUM
2:25 p.m.	7139: ARTEMISININ-RESISTANT PLASMODIUM FALCIPARUM KELCH13 MUTANT PROTEINS DISPLAY REDUCED HEME
2:35 p.m.	7140: IMPLEMENTING TAFENOQUINE-BASED RADICAL CURE FOR P. VIVAX MALARIA IN PERU: RESULTS FROM THE PAVE
2:45 p.m.	7141: METHAEMOGLOBINAEMIA IN PATIENTS WITH <i>PLASMODIUM VIVAX</i> MALARIA TREATED WITH PRIMAQUINE
2:55 p.m.	7142: PREVALENCE AND IMPACT OF PARASITE MUTATIONS IN PEDIATRIC PATIENTS IN AFRICA WITH UNCOMPLICATED
3:05 p.m.	7143: NATURAL IN VITRO SUSCEPTIBILITY OF PLASMODIUM FALCIPARUM TO PYRONARIDINE OVER 2009-2023 IN FRENCH
3:15 p.m.	7144: DISTINGUISHING REINFECTION FROM TREATMENT FAILURE IN A UGANDAN COHORT TO ESTIMATE THE REAL-WORLD
Scientific Session 85: Clini	cal Tropical Medicine: HIV and Co-Morbidities Convention Center - Room 713 (Level 700)
1:45 p.m.	7145: IMPACT OF LATENT TUBERCULOSIS ON IMMUNE REGULATION AND HIV RESERVOIR IN VIROLOGICALLY
1:55 p.m.	7146: FREQUENCY AND CORRELATES OF NON-DISCLOSURE OF MATERNAL HIV STATUS TO MALE PARTNERS IN DRC
2:05 p.m.	7147: DEPRESSION AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS IN THE MUANDA HEALTH ZONE
2:15 p.m.	7148: MAPPING THE GAP: SOCIOECONOMIC INEQUITIES IN HIV KNOWLEDGE ACROSS PERU
2:25 p.m.	7149: CAN SOCIAL MEDIA ADVOCACY END HIV STIGMA AMONG ADOLESCENTS?
2:35 p.m.	7150: CHARACTERIZATION OF THE EPIDEMIOLOGY OF HIV AND ASSOCIATED INFECTIONS IN GEORGIA AMIDST ONGOING
2:45 p.m.	7151: CLINICAL PRESENTATION, DIAGNOSIS, AND LABORATORY RESULTS OF CHILDREN WITH TUBERCULOSIS WITH
2:55 p.m.	7152: KNOWLEDGE, ATTITUDE AND PRACTICE OF HIV AND SEXUAL TRANSMITTED DISEASES AMONG LGBTQ+ AT A LARGE
3:05 p.m.	7153: HIGH PREVALENCE OF DYSLIPIDEMIA AND ASSOCIATED FACTORS AMONG ART NAÏVE PEOPLE LIVING WITH HIV
3:15 p.m.	7154: AN ANALYSIS OF SMOKING CESSATION RATES AND CESSATION RELATED FACTORS BY FOOD SECURITY STATUS

Room Name

EDU- CATION CONTENT	mposium 86: Nom	a: Current Knowledge and Future Directions	Convention Center - Room 714 (Level 700)
	1:45 p.m.	INTRODUCTION	
	1:55 p.m.	HIGH-LEVEL OVERVIEW OF THE AGENDA AND DATA FROM A RECENT SY	YSTEMATIC SCOPING REVIEW
	2:05 p.m.	OVERVIEW OF NOMA AND LESSONS LEARNED FROM INTEGRATED COM	MUNITY HEALTH INITIATIVES
	2:25 p.m.	THE CLINICAL PROGRESSION OF NOMA AND TREATMENT OPTIONS	
	2:40 p.m.	THE MICROBIOLOGY OF NOMA: INSIGHTS FROM A PILOT DEEP SHOTGU	N METAGENOMIC PROJECT
	3 p.m.	MY JOURNEY AS A NOMA SURVIVOR	
	3:10 p.m.	3:10 p.m. NOMA ON GLOBAL HEALTH AGENDAS: A PATH TO COMPREHENSIVE CARE AND PREVENTION	
Symposiu	ım 87: New Develo	pments Along the Continuum of Care for Severe Malaria Patients	Convention Center - Room 715 (Level 700)
	1:45 p.m.	INTRODUCTION	
	1:55 p.m.	IMPACT OF ROLLING OUT RAS ON ACCESS TO CARE AND UNDER 5 MOR	RTALITY IN AN ICCM PROGRAM AT POPULATION
	2:05 p.m.	HEALTH-SEEKING BEHAVIOR AND PATIENT ITINERARIES FOR CHILDRE	N AFTER IMPLEMENTATION OF RAS AND
	2:15 p.m.	CLINICAL EFFECTIVENESS OF RAS IN COMBINATION WITH ACT FOR CH	IILDREN UNDER 5 WITH SUSPECTED SEVERE
	2:25 p.m.	ACCEPTABILITY AND FEASIBILITY OF RAS IN AREAS WHERE PATIENTS ARE SELDOM REFERRED	
	2:35 p.m.	IMPLEMENTATION RESEARCH WITH RECTAL ARTESUNATE IN NIGERIA	
	2:45 p.m.	REAL-WORLD STABILITY TESTING OF ARTESUNATE RECTAL CAPSULES	UNDER HARSH CLIMATE CONDITIONS
	2:55 p.m.	A NEW, EASIER TO PREPARE FORMULATION OF INJECTABLE ARTESUM	ATE BASED ON ARGININE

Scientific Session 88: American Committee of Molecular Cellular and Immunoparasitology (ACMCIP): Modulation of Host Immunity by Parasites and Its Impact on Other Diseases

Convention Center - Room 716 (Level 700)

SUPPORTED WITH FUNDING FROM

BURROUGHS WELLCOME FUND®

1:45 p.m.	5 p.m. 7960: SEE MEETING APP FOR PRESENTATION DETAILS	
2 p.m.	7961: SEE MEETING APP FOR PRESENTATION DETAILS	
2:15 p.m.	7155: TAENIA SOLIUM CRUDE LYSATE SUPPRESSES HELICOBACTER PYLORI-INDUCED ONCOGENIC SIGNALING	
2:30 p.m.	7156: PARADOXICAL EFFECTS OF ASCARIS-INDUCED PYLORIC METAPLASIA: REDUCING ASCARIS REINFECTION BUT	
2:45 p.m.	7157: DOES CHRONIC LOIASIS AFFECT THE IMMUNE RESPONSE TO SARS-COV-2 INFECTION?	
3 p.m.	7158: SCHISTOSOMA JAPONICUM PROTEIN 40 PROMOTES WOUND HEALING IN A MURINE MODEL	
3:15 p.m.	7159: EFFECTS OF SCHISTOSOMA MANSONI AND OTHER GASTROINTESTINAL INFECTIONS ON THE IMMUNE RESPONSE	

Symposium 89: Data-Driven Strategies for Typhoid Prevention and Response: Modeling, Surveillance, and Innovative Methods

Convention Center - Room 717 (Level 700)

1:45 p.m.	INTRODUCTION
1:50 p.m.	STRENGTHENING TYPHOID SURVEILLANCE AROUND A MASS VACCINATION IN THE NORTHERN DIVISION OF FIJI
2:05 p.m.	PROJECTING THE IMPACT AND COST-EFFECTIVENESS OF TYPHOID BOOSTER VACCINATION STRATEGIES IN DIVERSE
2:20 p.m.	MODELING APPROACHES FOR IDENTIFYING AND DESPONDING TO TYPHOID OUTBREAKS
2:35 p.m.	TCV AND TYPHOID IN PAKISTAN

Tuesday, November 11		Room Name	
2:50 p.m.	EMPLOYING NOVEL GEOSPATIAL MODELLING METHODOLOGY TO CHARA	ACTERIZE THE SPATIAL VARIATION IN CLINICAL AND	
3:05 p.m.	MODERATOR		
Symposium 90: Coalescing Co	ommunity Resources for <i>Plasmodium</i> Genomic Epidemiology	Convention Center - Room 718A (Level 700)	
1:45 p.m.	INTRODUCTION		
1:55 p.m.	OVERVIEW OF PLASMOGENEPI OPEN-ACCESS DATA AND ANALYSIS		
2:15 p.m.	CURATING AND EVALUATING EXISTING ANALYTIC TOOLS TOWARDS HAP	RMONIZATION	
2:35 p.m.	GENOMIC SURVEILLANCE OF MALARIA IN WEST AFRICA		
2:55 p.m.	USING TERRA AS A CLOUD BASED PLATFORMS FOR BIOINFORMATICS A	AND ANALYTIC PIPELINES	
1:45 p.m. – 3:30 p.m.		Convention Center - Room 718B (Level 700)	
1:45 p.m.	PANEL DISCUSSION		
Scientific Session 92: Global H	Health: Women's, Maternal, Newborn, Child, and Adolescent Health	Convention Center - Room 801A (Level 800)	
1:45 p.m.	7160: INTRAVENOUS FERRIC CARBOXYMALTOSE VERSUS ORAL IRON IN	PREGNANCY AND INFANT GROWTH: EVIDENCE	
1:55 p.m.	7161: ASSOCIATION BETWEEN PLACENTA MALARIA PARASITES AND PR	EECLAMPSIA	
2:05 p.m.	7162: IMPACT OF FIRST-TRIMESTER ANTIMALARIAL TREATMENTS ON NE	EUROCOGNITIVE DEVELOPMENT	
2:15 p.m.	7163: RECURRENCE OF BAD OBSTETRIC OUTCOMES: PRELIMINARY FIND	DINGS FROM A PROSPECTIVE, LONGITUDINAL	
2:25 p.m.	7164: GUT MICROBIOME DISRUPTIONS IN POSTPARTUM ANEMIA, UNRA	VELING MICROBIAL SIGNATURES IN	
2:35 p.m.	7165: ASSOCIATIONS BETWEEN MATERNAL EXPERIENCE OF INTIMATE F	PARTNER VIOLENCE, MATERNAL DEPRESSIVE	

Tuesday, No	ovember 11		Room Name
	2:45 p.m.	7166: CAREGIVER SCREENING FOR RELAPSE AMONG CHILDREN RECENTLY RI	ECOVERED FROM SEVERE ACUTE
	2:55 p.m.	7167: BARRIERS TO ESSENTIAL PROGRAMME ON IMMUNIZATION COVERAGE	AND IMPLICATIONS FOR PERENNIAL
	3:05 p.m.	7168: ADOLESCENT BOYS' ATTITUDES TOWARDS MENSTRUATION IN SELECTE	ED HIGH SCHOOLS IN GHANA
	3:15 p.m.	LIGHTNING TALKS	
		7329: UNVEILING THE BURDEN AND DETERMINANTS OF BIRTH-RELATED PER	INEAL INJURIES IN RURAL BANGLADESH
		7319: INTEGRATION OF ADOLESCENT HEALTH SERVICES IN POPULATIONS AT	RISK FOR HPV, HIV AND FGS
		7318: ROLE OF BUBBLE CONTINUOUS POSITIVE AIRWAY PRESSURE IN CHILD	HOOD SEVERE PNEUMONIA AND HYPOXEMIA
		7336: MIXED METHODS STUDY ADDRESSING BARRIERS TO CONTRACEPTION I	IN REGIONS ENDEMIC FOR NEGLECTED
		7320: EXPLORING THE LONG-TERM SEROPREVALENCE OF SARS-COV-2 ANTIB	ODIES IN INFANTS BORN TO WOMEN
	3: Portable Dig Neglected Tropi	ital Microscopy: Harnessing Al and Molecular Tools to Revolutionize ical Infections	Convention Center - Room 801B (Level 800,
	1:45 p.m.	INTRODUCTION	
		INTRODUCTION	
	1:50 p.m.	DESIGN OF DEVICES FOR PORTABLE DIGITAL MICROSCOPY	
	1:50 p.m. 2:05 p.m.		
		DESIGN OF DEVICES FOR PORTABLE DIGITAL MICROSCOPY	
	2:05 p.m.	DESIGN OF DEVICES FOR PORTABLE DIGITAL MICROSCOPY LOA LOA QUANTIFICATION FOR TEST AND NOT TREAT (TANT) PROGRAMS	
	2:05 p.m. 2:20 p.m.	DESIGN OF DEVICES FOR PORTABLE DIGITAL MICROSCOPY LOA LOA QUANTIFICATION FOR TEST AND NOT TREAT (TANT) PROGRAMS AI FOR ADVANCING POINT-OF-CARE SCHISTOSOMIASIS DIAGNOSIS	
	2:05 p.m. 2:20 p.m. 2:30 p.m.	DESIGN OF DEVICES FOR PORTABLE DIGITAL MICROSCOPY LOA LOA QUANTIFICATION FOR TEST AND NOT TREAT (TANT) PROGRAMS AI FOR ADVANCING POINT-OF-CARE SCHISTOSOMIASIS DIAGNOSIS AI FOR ADVANCING POINT-OF-CARE SCHISTOSOMIASIS DIAGNOSIS (PART II)	

Tuesday, November 11 Room Name

: Session 94: Mosqu	uitoes- Epidemiology and Vector Control I	Convention Center - Room 803 (Level 800)
1:45 p.m.	7169: RAPID REDUCTION IN AEDES AEGYPTI POPULATION FOLLOWING STI	ERILE INSECT APPLICATION IN THE WEST VALLEY.
1:55 p.m.	7170: THE EVITA DENGUE TRIAL: DRIVERS OF SUSTAINED INTROGRESSION	N OF WOLBACHIA-INFECTED AEDES AEGYPTI IN
2:05 p.m.	7171: EFFICACY OF TARGETED INDOOR RESIDUAL SPRAYING IN PREVENTI	NG AEDES-BORNE DISEASES
2:15 p.m.	7172: A LONGITUDINAL COHORT STUDY OF ECOBIOTRAPS - AN ECOFRIEND	DLY BIODEGRADABLE LETHAL OVITRAP IN
2:25 p.m.	7173: TREATING WILD BIRDS WITH IVERMECTIN THROUGH BACKYARD BIR	RD FEEDERS TO REDUCE WEST NILE VIRUS
2:35 p.m.	7174: MODELING THE IMPACT OF IVERMECTIN-BASED STRATEGIES FOR OF	PTIMAL MALARIA CONTROL: THE ROLE OF
2:45 p.m.	7175: EVALUATING NOVEL MULTI-VECTOR CONTROL TOOLS FOR HUMANIT	TARIAN CRISES: THE ENTOMOLOGICAL
2:55 p.m.	7176: IN SILICO MODELLING OF A CRISPR-CAS9/GENE DRIVE SYSTEM FOR	R WOLBACHIA CIF TARGETING ANOPHELES
3:05 p.m.	7177: RAPID INFECTION DETECTION: THE POTENTIAL OF RAPID IONIZATION	N EVAPORATIVE MASS SPECTROMETRY FOR
3:15 p.m.	7178: PREDICTING MOSQUITO AGE AND SURVIVAL UNDER VARIABLE ENVI	IRONMENTAL CONDITIONS: INSIGHTS FROM
Session 95: Filaria	asis - Clinical, Immunology, and Diagnosis	Convention Center - Room 602 (Level 600)
1:45 p.m.	7179: SUSTAINED CLEARANCE OF ONCHOCERCA VOLVULUS SKIN MICROF	ILARIAE SIX MONTHS AFTER IVERMECTIN OR
1:55 p.m.	7180: TOLERABILITY OF NOVEL DRUG COMBINATION TREATMENTS FOR ON	NCHOCERCIASIS (TWO DOSES, 6 MONTHS APART)
2:05 p.m.	7181: DEVELOPMENT OF A NEW RAPID DIAGNOSTIC TEST TO SUPPORT ON	ICHOCERCIASIS ELIMINATION
2:15 p.m.	7182: EFFICACY OF MOXIDECTIN PLUS ALBENDAZOLE FOR LYMPHATIC FIL	ARIASIS AND ONCHOCERCIASIS; FOLLOW-UP
2:25 p.m.	7183: AN OPTIMIZED WUCHERERIA BANCROFTI WB123 ANTIGEN FOR USE	IN FIELD-DEPLOYABLE SEROLOGICAL ASSAYS
	1:45 p.m. 1:55 p.m. 2:05 p.m. 2:15 p.m. 2:25 p.m. 2:35 p.m. 2:35 p.m. 2:45 p.m. 3:05 p.m. 3:15 p.m. 3:15 p.m. 1:45 p.m. 1:55 p.m. 2:05 p.m.	1:55 p.m. 7170: THE EVITA DENGUE TRIAL: DRIVERS OF SUSTAINED INTROGRESSION 2:05 p.m. 7171: EFFICACY OF TARGETED INDOOR RESIDUAL SPRAYING IN PREVENTION 2:15 p.m. 7172: A LONGITUDINAL COHORT STUDY OF ECOBIOTRAPS - AN ECOFRIENT 2:25 p.m. 7173: TREATING WILD BIRDS WITH IVERMECTIN THROUGH BACKYARD BIR 2:35 p.m. 7174: MODELING THE IMPACT OF IVERMECTIN-BASED STRATEGIES FOR ON 2:45 p.m. 7175: EVALUATING NOVEL MULTI-VECTOR CONTROL TOOLS FOR HUMANIT 2:55 p.m. 7176: IN SILICO MODELLING OF A CRISPR-CAS9/GENE DRIVE SYSTEM FOR 3:05 p.m. 7177: RAPID INFECTION DETECTION: THE POTENTIAL OF RAPID IONIZATIO 3:15 p.m. 7178: PREDICTING MOSQUITO AGE AND SURVIVAL UNDER VARIABLE ENV Session 95: Filariasis - Clinical, Immunology, and Diagnosis 1:45 p.m. 7179: SUSTAINED CLEARANCE OF ONCHOCERCA VOLVULUS SKIN MICROF 1:55 p.m. 7180: TOLERABILITY OF NOVEL DRUG COMBINATION TREATMENTS FOR ON 2:05 p.m. 7181: DEVELOPMENT OF A NEW RAPID DIAGNOSTIC TEST TO SUPPORT ON 2:15 p.m. 7182: EFFICACY OF MOXIDECTIN PLUS ALBENDAZOLE FOR LYMPHATIC FIL

Tuesday, November 11		Room Name	
2:35 p.m.	7184: BRUGIA TEST PLUS (BT+), A FIELD-DEPLOYABLE, COST-EFFECTIVE, HIGHLY	SENSITIVE AND SPECIFIC RAPID	
2:45 p.m. 7185: MULTIBEAD BASED ASSAY PROVIDES ONE-STEP SPECIES-SPECIFICITY FO		R THE DIAGNOSIS OF FILARIAL	
2:55 p.m. 7186: AN ANTIBODY BIOMARKER ASSOCIATED WITH <i>ONCHOCERCA VOLVULUS</i> MIC		ROFILARIAE IDENTIFIED BY PROTEOMICS	
3:05 p.m. 7187: INVESTIGATING CO-EXPOSURE TO NEGLECTED TROPICAL DISEASES: PRELI		MINARY RESULTS FROM SENEGAL	
3:15 p.m.	7188: DEVELOPMENT AND INITIAL VALIDATION OF A NOVEL (NAS-14) ANTIGEN DI	AGNOSTIC ASSAY FOR LOIASIS	
3 p.m 4 p.m.	Career Chats: Presenting with Purpose - Communicating Science Across Audiences	SS Audiences Convention Center - Room 401 (Level 400) (TropStop)	
3:30 p.m 4 p.m. Coffee Break		Convention Center - Hall D (Level 800) (Exhibit Hall)	
3:30 p.m 6:15 p.m.	Poster Session B Dismantle	Convention Center - Hall E (Level 800) (Poster Hall)	
CI(ID)) LIVE EDU- CATION STREAMING CONTENT TO STREAMING TO STREAMI	: Innovations in Emerging Infectious Disease Surveillance and Response	Convention Center - Hall F/G (Level 800)	
4 p.m.	INTRODUCTION		
4:05 p.m.	INFECTIOUS DISEASE THREATS ON THE HORIZON		
4:20 p.m.	INFECTIOUS DISEASE THREATS ON THE HORIZON		
4:35 p.m. INNOVATION IN SURVEILLANCE TO SPEED INFECTIOUS DISEASE THREAT DE		TION	
4:50 p.m.	UPDATE ON VECTOR-BORNE DISEASE RESPONSE AND FUTURE TECHNOLOGIES F	OR VECTOR-BORNE DISEASE CONTROL	
5:05 p.m.	AVI ONE HEALTH APP AND WOLBACHIA		
5:20 p.m.	FROM ERADICATION TO REINTRODUCTION: NEW WORLD SCREWWORM		

Tuesday, November 1	1	Room Name	
	Symposium 97: American Committee on Arthropod-Borne Viruses and Zoonotic Viruses (ACAV) Symposium II: Convention Center - Room 701A (Level 700 Cooler Climate Arboviruses		
4 p.m.	INTRODUCTION		
4:10 p.m.	DON MCLEAN AND THE DISCOVERY OF POWASSAN		
4:30 p.m.	SALIVA-ASSISTED TICK-BORNE VIRUS TRANSMISSION		
4:50 p.m.	PATHOLOGY OF TICK-BORNE ENCEPHALITIS VIRUS		
5:10 p.m.	HISTORY OF ARBOVIRUSES IN CANADA		
Scientific Session 98: Mal	aria - Current Trends in Antimalarial Drug Resistance	Convention Center - Room 701B (Level 700)	
4 p.m.	7189: COMPREHENSIVE SPATIOTEMPORAL ANALYSIS OF ANTIMALARIAL DRUG	RESISTANCE MARKERS IN MALI: A	
4:10 p.m.	7190: GEOGRAPHICAL VARIATION IN SULFADOXINE-PYRIMETHAMINE RESISTA	NCE MARKERS AND IMPLICATIONS FOR	
4:20 p.m.	7191: PHENOTYPIC ASSESSMENT OF PLASMODIUM FALCIPARUM MOLECULAR	MARKERS ASSOCIATED WITH MALARIA	
4:30 p.m.	7192: ARTEMETHER-LUMEFANTRINE OR ARTEMETHER-LUMEFANTRINE PLUS	ATOVAQUONE-PROGUANIL TREATMENT	
4:40 p.m.	7193: DELAYED PARASITE CLEARANCE LINKED WITH PFKELCH13 R622I VARIA	NT IN A MULTISITE THERAPEUTIC EFFICACY	
4:50 p.m.	7194: PREDICTING NOVEL MOLECULAR MARKERS ASSOCIATED WITH REDUCE	D SENSITIVITY OF <i>PLASMODIUM</i>	
5 p.m.	7195: NEW EMERGENCE OF PFK13 MUTANTS IN GUYANA: IMPLICATIONS ON P.	FALCIPARUM RESISTANCE TO ARTEMISININ	
5:10 p.m.	7196: TREATMENT OF PARTIAL ARTEMISININ-RESISTANT PLASMODIUM FALCIF	PARUM MALARIA WITH PYRONARIDINE	
5:20 p.m.	7197: PRESENCE OF MUTANT PLASMODIUM FALCIPARUM PARASITES LACKING	G PFHRP2 GENES AND HIGH	

	5:30 p.m.	LIGHTNING TALKS	
		7468: SENSITIVE, SPECIFIC AND PRACTICAL: MULTIPLEXED AMPLICON SEQUENCIN	NG FOR EFFICACY DETERMINATION
	7471: EMERGENCE OF A VALIDATED P <i>LASMODIUM FALCIPARUM</i> KELCH 13 MUTATION (A675V) ASSOCIATED WITH		
	7470: IMPACT OF SEASONAL MALARIA CHEMOPREVENTION ON ANTIMALARIAL DRUG RESISTANCE AND THE		UG RESISTANCE AND THE
	7469: CLINICAL EFFECTIVENESS OF RECTAL ARTESUNATE IN COMBINATION WITH ARTEMISININ-BASED COMBINATION		
		7483: ASSESSING THE FUNCTIONAL ROLES OF PFKELCH13 MUTATIONS AND PFHR	P2/3 DELETIONS ON P. FALCIPARUM
Sympo CATION CONTENT	osium 99: Point-of-o	care Ultrasound for Infectious Diseases: Advancing Care Across the Globe	Convention Center - Room 713 (Level 700)
	4 p.m.	INTRODUCTION	
	4:10 p.m.	FOCUSED ASSESSMENT WITH SONOGRAPHY FOR HIV-ASSOCIATED TB (FASH)	
	4:25 p.m.	CORRELATION BETWEEN CHEST RADIOGRAPH AND LUNG ULTRASOUND FINDINGS	AMONG CHILDREN WITH SUSPECTED
	4:40 p.m.	PILOT ARTIFICIAL INTELLIGENCE MODELS DETECT DISTINGUISH BETWEEN TB AND	NON-TB LUNG ULTRASOUNDS
	4:55 p.m.	AI-AUGMENTED TB ULTRASOUND IN UGANDA	
	5:10 p.m.	ULTRASOUND IN ECHINOCOCCOSIS AND FILARIASIS	
	5:25 p.m.	IMPLEMENTING POCUS IN AN INFECTIOUS DISEASES AND TROPICAL MEDICINE SU	JBSPECIALTY TRAINING PROGRAM
Sympo	osium 100: Sustain	ing the Elimination of Visceral Leishmaniasis in South Asia	Convention Center - Room 714 (Level 700)
	4 p.m.	INTRODUCTION	
	4:10 p.m.	VISCERAL LEISHMANIASIS ELIMINATION IN INDIA AND NEPAL	

Tuesday, November 11		Room Name
4:25 p.m.	PROGRESS AND STATUS OF LEISHMANIASIS IN SRI LANKA	
4:40 p.m.	UNDERSTANDING LEISHMANIA VECTOR ECOLOGY TO PREVENT TRANSMI	SSION
4:55 p.m.	VECTOR CONTROL PROGRAM IN BIHAR STATE, INDIA	
5:10 p.m.	UPDATE ON THE USE OF VACCINES FOR THE PREVENTION AND TREATME	ENT OF LEISHMANIASIS WITH FOCUS ON VL AND
5:25 p.m.	DNDI EFFORTS IN LEISHMANIASIS CONTROL ACROSS THE INDIAN SUBCO	ONTINENT AND AFRICA
Symposium 101: Advances in	Human Cerebral Malaria: Mechanistic Insights and Translational Models	Convention Center - Room 715 (Level 700)
4 p.m.	INTRODUCTION	
4:10 p.m.	ELEVATED URIC ACID LEVELS, MORTALITY AND COGNITIVE IMPAIRMENT	IN CHILDREN WITH SEVERE MALARIA
4:25 p.m.	CEREBRAL MANIFESTATIONS OF FALCIPARUM MALARIA IN ADULTS: MOR	RE THAN MEETS THE EYE
4:40 p.m.	BREAKING BARRIERS: 3D BIOENGINEERED MODELS FOR CEREBRAL MALA	ARIA RESEARCH
4:55 p.m.	PLASMODIUM FALCIPARUM HEMOZOIN-ASSOCIATED LIPIDS INDUCE BRA	AIN ENDOTHELIAL CELL BARRIER DISRUPTION
5:10 p.m.	REVISING THE INTERPRETATION OF TRANSCRANIAL DOPPLER ULTRASOU	UND EXAMINATIONS IN PEDIATRIC CEREBRAL
5:20 p.m.	THE MRNA CONTENT OF PLASMA EXTRACELLULAR VESICLES PROVIDES	A WINDOW INTO MOLECULAR PROCESSES
5:30 p.m.	NILOTINIB ATTENUATES VASCULAR PATHOLOGY IN EXPERIMENTAL CERE	EBRAL MALARIA

Scientific Session 102: American Committee of Molecular Cellular and Immunoparasitology (ACMCIP): Parasite Cellular Immunity

Convention Center - Room 716 (Level 700)

SUPPORTED WITH FUNDING FROM

BURROUGHS WELLCOME FUND®

4 p.m.	7962: SEE MEETING APP FOR PRESENTATION DETAILS		
4:15 p.m.	7963: SEE MEETING APP FOR PRESENTATION DETAILS	7963: SEE MEETING APP FOR PRESENTATION DETAILS	
4:30 p.m.	7198: INVESTIGATING THE CONTRIBUTIONS OF HEMATOPOIETIC STEM AND PROGENITOR CELLS TO ANTIHELMINTH		
4:45 p.m.	7199: DEEP FUNCTIONAL ASSESSMENT OF HUMAN BASOPHILS IN TRICHURIS TRICHIURA INFECTION BY INTRACELLULAR		
5 p.m.	7200: INFLAMMATORY MONOCYTES CONTRIBUTE TO TREATMENT FAILURE IN PATIENTS WITH CUTANEOUS,,,		
5:15 p.m.	7201: CXCR6 RECRUITS TH2 CELLS AND PROMOTES LIVER FIBROSIS IN SCHISTOSOMIASIS JAPONICA		
5:30 p.m.	7202: MONOCYTES REGULATE PRO-INFLAMMATORY RESPONSE VIA MAPK SIGNALING IN NEUROCYSTICERCOSIS		
Compressions 102: Vin	come Managlange Calabustian Milestones in Traval Medicine	Convention Contan Doors 717 (Lavel 700)	



Symposium 103: Vincenzo Marcolongo Celebration - Milestones in Travel Medicine

Convention Center - Room 717 (Level 700)

4 p.m.	INTRODUCTION
4:10 p.m.	MAPPING GLOBAL INFECTIOUS DISEASES IMPORTANT TO TRAVELERS: HISTORICAL ACCOMPLISHMENTS AND FUTURE
4:40 p.m.	THE IMPACT OF CLIMATE ON TRAVELERS' HEALTH
5:10 p.m.	2025 AND BEYOND: TRANSFORMING EDUCATION IN TROPICAL DISEASES AND GLOBAL HEALTH
5:35 p.m.	IAMAT'S LEGACY: TRAVEL MEDICINE SCHOLARSHIPS

Tuesday, November 11 Room Name

		om Large-Scale Implementation of Perennial Malaria Chemoprevention (PMC) Ivoire, Mozambique and Nigeria	Convention Center - Room 718B (Level 700
	4 p.m.	INTRODUCTION	
	4:10 p.m.	OPERATIONAL FEASIBILITY, ACCEPTABILITY AND COVERAGE OF PERENNIAL M	MALARIA CHEMOPREVENTION: THE NIGERIA
	4:20 p.m.	PERENNIAL MALARIA CHEMOPREVENTION (PMC) COVERAGE AND PATHWAYS	TO IMPACT IN BENIN, CAMEROON AND CÔTE
	4:30 p.m.	IMPACT OF PERENNIAL MALARIA CHEMOPREVENTION (PMC) ON CLINICAL MA	LARIA IN CAMEROON AND CÔTE D'IVOIRE
	4:40 p.m.	THE IMPACT OF PERENNIAL MALARIA CHEMOPREVENTION ON KEY HEALTH O	UTCOMES IN CHILDREN AGED 2-18 MONTHS
	4:50 p.m.	IS PERENNIAL MALARIA CHEMOPREVENTION COST-EFFECTIVE? EVIDENCE FR	ROM INTEGRATED DELIVERY WITH ROUTINE
	5 p.m.	COST AND COST-EFFECTIVENESS OF PERENNIAL MALARIA CHEMOPREVENTION	ON IMPLEMENTED AT SCALE IN BENIN
Scientific	Session 106: Schi	stosomiasis: Epidemiology, and Control	Convention Center - Room 801A (Level 800
	4 p.m.	7203: SCOPE-ING OUT SUCCESS: DEVELOPMENT AND OPERATIONAL FEASIBIL	ITY OF THE SMART CAPTURE OF
	4:10 p.m.	7204: LONGITUDINAL IMPACT OF PRAZIQUANTEL ON SCHISTOSOMIASIS INFEC	CTION AMONG PRESCHOOL-AGE CHILDREN
	4:20 p.m.	7205: ELIMINATION OF MEKONG SCHISTOSOMIASIS THROUGH AN INTEGRATEI	D ECO-HEALTH APPROACH: THE CAMBODIA
	4:30 p.m.	7206: SURVEILLANCE FOR PRAZIQUANTEL RESISTANCE IN AFRICAN SCHISTO	SOME POPULATIONS
	4:40 p.m.	7207: INVESTIGATING SOCIAL AND ENVIRONMENTAL PATHWAYS TO GENETIC	RELATEDNESS BETWEEN SCHISTOSOMA
	4:50 p.m.	7208: HARNESSING ENVIRONMENTAL MANAGEMENT AND COMMUNITY ENGAG	SEMENT TO REDUCE SCHISTOSOMIASIS RISK
	5 p.m.	7209: IMPACT OF CHEMICAL SNAIL CONTROL ON INTERMEDIATE HOST SNAIL I	POPULATIONS FOR UROGENITAL
	5:10 p.m.	7210: SEXUAL AND REPRODUCTIVE HEALTH AMONG MEN WITH GENITAL SCHI	STOSOMIASIS IN SOUTHERN TANZANIA

Tuesday, November 11		Room Name
5:20 p.m.	7211: DETECTION OF ANTI-SCHISTOSOMA MANSONI ANTIBODIES	IN INCARCERATED WOMEN IN A LOW ENDEMICITY AREA
5:30 p.m.	7212: HIGH BURDEN OF SCHISTOSOMA AND PROTOZOAN CO-INFE	CTIONS AMONG SCHOOL-AGE CHILDREN IN MALAWI
Symposium 107: Bridging Ac Modelling, and Policy for Cris	ademia and Humanitarian Response: Data, iis-Affected Populations	Convention Center - Room 801B (Level 800)
4 p.m.	INTRODUCTION	
4:10 p.m.	MODELLING THE IMPACT OF DISRUPTIONS TO IMMUNIZATION CO	VERAGE DUE TO CONFLICT
4:25 p.m.	EVALUATING THE EFFECTIVENESS OF EPIDEMIC DETECTION THR	ESHOLDS AND RESPONSE TIMELINES IN CRISIS SETTINGS
4:40 p.m.	THE ROLE OF WASH INTERVENTIONS IN MITIGATING ANTIMICROB	BIAL RESISTANCE AND STRENGTHENING IPC
4:55 p.m.	APPLYING DATA-DRIVEN APPROACHES TO ESTIMATE TRAUMA BU	IRDEN AND OPTIMIZE PREPAREDNESS FOR HOSPITAL
5:10 p.m.	APPLYING DATA-DRIVEN APPROACHES TO PROJECT EXCESS MOR	TALITY IN FIVE DISEASE MODULES AND OPTIMIZE THE
5:30 p.m.	REVIEWS OF METHODS TO ESTIMATE MORTALITY IN CRISIS SETT	INGS AND THE PATTERNS IN AGE AND SEX SPECIFIC
Scientific Session 108: Mosqu	uitoes- Epidemiology and Vector Control II	Convention Center - Room 803 (Level 800)
4 p.m.	7213: PRONET DUO INSECTICIDE-TREATED NET INCORPORATED W	/ITH CHLORFENAPYR AND BIFENTHRIN IS SUPERIOR TO
4:10 p.m.	7214: EVALUATION OF DUAL-ACTIVE INGREDIENT LONG-LASTING	INSECTICIDAL NETS AGAINST WILD RESISTANT
4:20 p.m.	7215: MAPPING CURRENT AND FUTURE LEVELS OF INSECTICIDE	RESISTANCE IN MALARIA VECTORS ACROSS AFRICA
4:30 p.m.	7216: ECOLOGICAL AND INSECTICIDE FREE SIMPLE MOSQUITO TR	APPING-DEVICE AGAINST RESISTANT MALARIA
4:40 p.m.	7217: EFFICACY OF THE BITEBARRIER TRANSFLUTHRIN EMANATO	OR AGAINST SUSCEPTIBLE AND RESISTANT MALARIA
4:50 p.m.	7218: SPATIAL REPELLENTS TO NOT SHRINK THE ASYMPTOMATIC	MALARIA RESERVOIR ACROSS ALL AGE GROUPS IN
5 p.m.	7219: INVESTIGATING OPPORTUNITIES FOR TARGETED LARVAL SO	OURCE MANAGEMENT IN RURAL COMMUNITIES
5:10 p.m.	7220: SUSTAINABILITY OF INDOOR RESIDUAL SPRAYING (IRS) GAI	INS IN UGANDA , PAST AND CURRENT EXPERIENCES

Tuesday, November 11 Room Name 5:20 p.m. 7221: INSECTICIDES CAN KILL THE MOSQUITO VECTOR AND PREVENT TRANSMISSION OF THE PLAS

	5:20 p.m.	7221: INSECTICIDES CAN KILL THE MOSQUITO VECTOR AND PREVENT TRAI	NSMISSION OF THE <i>PLASMODIUM</i> PARASITE
	5:30 p.m.	7222: THE SILENT CONTRIBUTORS TO MALARIA PERSISTENCE IN HIGH-TRA	NSMISSION ENDEMIC AREAS OF BURKINA FASO
Scientific Sess	sion 109: Filaria	sis - Epidemiology and Control	Convention Center - Room 602 (Level 600)
	4 p.m.	7223: ZOONOSIS- A POTENTIAL CATALYST OF THE RE-EMERGENCE OF HUM.	AN BRUGIAN FILARIASIS IN SRI LANKA
	4:10 p.m.	7224: MOLECULAR XENOMONITORING TO MONITOR TRANSMISSION OF ZOO	PHILIC BRUGIA MALAYI FOLLOWING IDA
	4:20 p.m.	7225: ASSESSING IMPACT OF FOUR ROUNDS OF MASS DRUG ADMINISTRAT	TON USING A THREE-DRUG REGIMEN ON
	4:30 p.m.	7226: PARASITE GENOMICS REVEALS LOCALIZED TRANSMISSION OF WUCH	HERERIA BANCROFTI, WHICH CAUSES
	4:40 p.m.	7227: POST-TREATMENT SURVEILLANCE FOR LYMPHATIC FILARIASIS IN HA	ITI AMIDST CHALLENGES: RESULTS FROM
	4:50 p.m.	7228: UTILITY OF LYMPHATIC FILARIASIS ANTIBODY SEROSURVEILLANCE F	FOR POST-VALIDATION SURVEILLANCE IN
	5 p.m.	7229: IMPROVING DRUG COMPLIANCE FOR LYMPHATIC FILARIASIS ELIMINA	ATION IN INDIA: EVIDENCE FROM
	5:10 p.m.	7230: BASELINE ASSESSMENT OF IVERMECTIN ACCEPTABILITY PRIOR TO T	HE ROLLOUT OF MOXIDECTIN MASS DRUG
•	5:20 p.m.	7231: COMPARISON OF EXPOSURE TO ONCHOCERCA VOLVULUS AMONG HC	ST AND REFUGEE POPULATIONS IN GAMBELLA
•	5:30 p.m.	7232: EVALUATION OF A 2% OV16 SEROPREVALENCE THRESHOLD FOR STO	PPING MASS DRUG ADMINISTRATION IN
4 p.m 5:45 p	.m.	Special Session 110: ASTMH Committee on Global Health (ACGH) Interviewing Practice for Global Health Careers	Convention Center - Room 707 (Level 700)
5:15 p.m 6:1	5 p.m.	Mentorship Pop-Up Session: Missing Data, Missed Opportunities: Integrating Sex and Gender in Global Health R&D	Convention Center – Level 600 Lobby (Level 600)

Tuesday, November 11		Room Name
5:45 p.m 6:15 p.m.	Break	
6:15 p.m 8 p.m.	Special Session 111: Speed-Networking with the Experts	InterContinental Hotel - Ballroom B (Lower Level)
6:15 p.m 8 p.m.	Sponsored Symposium: Breaking Dengue's Grip: Epidemiology, Immune Responses and Vaccine Advances	Convention Center - Room 718A (Level 700)
	SPONSORED BY Medscape GLOBAL	

Wednesday, November 12		Room Name
7 a.m 5 p.m.	Registration	Convention Center - Registration Lobby Area (Level 600)
7 a.m 5 p.m.	TropStop - Student/Trainee Lounge	Convention Center - Room 401 (Level 400) (TropStop)
7 a.m 7 p.m.	Speaker Ready Room (Closed 10:30 a.m 11:30 a.m.)	Convention Center - Room 703 (Level 600)
7 a.m 7 p.m.	Meeting Sign-Up Room	Convention Center - Room 711 (Level 700)
7 a.m 7 p.m. Please pick up the room	Nursing Mothers Room key at the Registration Desk, Level 600	Convention Center – Room 702 (Level 700)
7 a.m 7 p.m.	Prayer Room	Convention Center - Room 810 (Level 800)
7 a.m 7:30 a.m.	Poster Session C Set-Up	Convention Center - Hall E (Level 800) (Poster Hall)
7 a.m. – 8:45 a.m.	Sponsored Symposium: Spatial Repellents - A New Frontier in Vector Control SPONSORED BY SC Johnson Healthier World Initiative Healthier World	Convention Center - Room 713 (Level 700)
7 a.m. – 8:45 a.m.	Sponsored Symposium: Malaria Eradication in our Lifetime: Don't Stop Believing SPONSORED BY Medicines for Malaria Venture	Convention Center - Room 717 (Level 700)
7:30 a.m 11 a.m.	Poster Session C Viewing	Convention Center - Hall E (Level 800) (Poster Hall)

Wednesday, November 12		Room Name
7:45 a.m 8:45 a.m.	Scientific Program Committee Meeting	Convention Center - Room 802 (Level 800)
7:45 a.m 5 p.m.	Press Room	Convention Center - Room 704 (Level 700)
8 a.m 9 a.m.	ASTMH Presidents Meeting	Convention Center - Room 604 (Level 600)
8:30 a.m. – 12:30 p.m.	Exhibit Hall Open	Convention Center - Hall D (Level 800) (Exhibit Hall)
8:45 a.m 9:15 a.m.	Coffee Break	Convention Center - Hall D (Level 800) (Exhibit Hall)
8:45 a.m 9:45 a.m.	Mentorship Pop-Up Session: Rotary and Malaria – How Rotary Interacts with Global Malaria Efforts	Convention Center – Level 600 Lobby (Level 600)
10:15 a.m 11:15 a.m.	Mentorship Pop-Up Session: Anchored in Africa: Building Local Leadership in Women's Health R&D	Convention Center – Level 600 Lobby (Level 600)
9:15 a.m. – 11 a.m. (((b)) EDU LIVE STREAMING CONTRE	Symposium 112: Reimagining Global Health and Building Resilience for the Future	Convention Center - Hall F/G (Level 800)
9:15 a.m.	PANEL DISCUSSION	
Symposium 113: From Pilot to Onchocerciasis Elimination Effo	Scale: Implementing Moxidectin Where It Is Needed to Support Countries' orts	Convention Center - Room 701A (Level 700)
9:15 a.m.	INTRODUCTION	
9:25 a.m.	MOMENTUM PROJECT IN GHANA: LEARNINGS FROM THE FIRST IMPLEMENTATION OF MOXIDECTIN AS AN ALTERNATIVE	
9:45 a.m.	FINDINGS FROM AN ACCEPTABILITY STUDY FOLLOWING PILOT COMMUNITY-BASED MASS DRUG ADMINISTRATION OF	
10:05 a.m.	MOXIDECTIN VERSUS IVERMECTIN MASS DRUG ADMINISTRATION FOR THE CONTROL OF ONCHOCERCIASIS AND OTHER	

10:25 a.m.	ASSOCIATIONS OF TREATMENT ACCEPTABILITY FOR ONCHOCERC	CIASIS AND LYMPHATIC FILARIASIS: FINDINGS FROM
10:45 a.m.	PROGRESS TOWARDS ENABLING ACCESS TO MOXIDECTIN FOR OI	NCHOCERCIASIS ELIMINATION PROGRAM
Scientific Session 114: Malar	ia - Diagnosis - Challenges and Innovations	Convention Center - Room 701B (Level 700
9:15 a.m.	7233: ASSESSMENT OF CYTOPHONE, A NON-INVASIVE MALARIA D	DIAGNOSTIC, IN ADULTS WITH UNDIFFERENTIATED FEVER
9:25 a.m.	7234: INTEGRATING PLASMODIUM KNOWLESI-SPECIFIC SEROLOG	GICAL MARKERS OF RECENT EXPOSURE IN A MULTIPLEX
9:35 a.m.	7235: DEEP LEARNING DETECTION OF SUBMICROSCOPIC PLASMO	DDIUM FALCIPARUM INFECTION FROM PARASITE-FREE
9:45 a.m.	7236: FIRST FIELD EVALUATION OF NOVEL LDH- AND HRP2-BASE	D RAPID DIAGNOSTIC TESTS FOR <i>PLASMODIUM VIVAX</i>
9:55 a.m.	7237: DEPLOYING MOLECULAR MALARIA FIELD TESTING TO RURA	AL AFRICA: A LAMP-BASED APPROACH FOR
10:05 a.m.	7238: EVALUATION OF A NOVEL DIRECT-ON-BLOOD MINIPCR NALF	FIA TEST FOR THE DIAGNOSIS OF MALARIA IN TWO
10:15 a.m.	7239: REGIONAL DIFFERENCES IN PFHRP2/3 GENE DELETIONS AN	ND THEIR IMPACT ON MALARIA DIAGNOSIS
10:25 a.m.	7240: EVALUATION OF THE QUALITY OF MALARIA CASE MANAGEN	MENT THROUGH AN ELECTRONIC SUPERVISION AND
10:35 a.m.	7241: PRIVATE MEDICINE RETAILER-BASED TRIAL OF MALARIA TE	STS AND CONDITIONAL TREATMENT SUBSIDIES
10:45 a.m.	LIGHTNING TALKS	
	7492: ULTRASENSITIVE ELECTROCHEMICAL GENOSENSORS FOR S	SPECIES-SPECIFIC DIAGNOSIS OF NON-FALCIPARUM
	7498: PLASMODIUM FALCIPARUM PREVALENCE AND CLINICAL UT	TILITY OF A HIGH-SENSITIVITY RAPID DIAGNOSTIC TEST
	7491: MOLECULAR INVESTIGATION OF PLASMODIUM SPECIES IN	SIERRA LEONE: RECOMMENDATIONS ON
	7490: THE COST-EFFECTIVENESS AND EPIDEMIOLOGICAL IMPACT	OF RAPID SWITCHING TO NON-HRP2-ONLY MALARIA
	7493: ANTIMALARIAL AND DIAGNOSTIC TEST MARKET LANDSCAP	'E IN CAMEROON'S PRIVATE SECTOR

Room Name

Symposium 115: What's Ne	w in Clinical Tropical Medicine Literature?	Convention Center - Room 713 (Level 700)
9:15 a.m.	INTRODUCTION	
9:25 a.m.	WHAT'S NEW IN THE LITERATURE: OROPOUCHE VIRUS?	
9:50 a.m.	WHAT'S NEW IN THE LITERATURE: AVIAN INFLUENZA VIRUS?	
10:15 a.m.	WHAT'S NEW IN THE LITERATURE: DENGUE VIRUS?	
10:35 a.m.	WHAT'S NEW IN THE LITERATURE: MARBURG VIRUS?	
cientific Session 116: Ame Trug Resistance and Parasi	rican Committee of Molecular Cellular and Immunoparasitology (ACMCIP): te Biology	Convention Center - Room 714 (Level 700)
SUPPORTED WITH FUNDIN	WELLCOME FUND®	
9:15 a.m.	7964: SEE MEETING APP FOR PRESENTATION DETAILS	
9:30 a.m.	7965: SEE MEETING APP FOR PRESENTATION DETAILS	
9:30 a.m. 9:45 a.m.	7965: SEE MEETING APP FOR PRESENTATION DETAILS 7242: MEASURING REACTIVE OXYGEN SPECIES (ROS) ACCUMULATION IN F	PLASMODIUM FALCIPARUM GROWN IN HIGH
9:45 a.m.	7242: MEASURING REACTIVE OXYGEN SPECIES (ROS) ACCUMULATION IN F	IM FALCIPARUM: THE BASAL-LEVEL NATIVE
9:45 a.m. 10 a.m.	7242: MEASURING REACTIVE OXYGEN SPECIES (ROS) ACCUMULATION IN F 7243: HEME PROCESSING IN THE HUMAN MALARIA PARASITE, PLASMODIU	IM FALCIPARUM: THE BASAL-LEVEL NATIVE ED WITH ARTEMISININ TOLERANCE
9:45 a.m. 10 a.m. 10:15 a.m.	7242: MEASURING REACTIVE OXYGEN SPECIES (ROS) ACCUMULATION IN F 7243: HEME PROCESSING IN THE HUMAN MALARIA PARASITE, PLASMODIU 7244: MULTI-OMIC PROFILING REVEALS MOLECULAR MARKERS ASSOCIATION	IM FALCIPARUM: THE BASAL-LEVEL NATIVE ED WITH ARTEMISININ TOLERANCE IWER THAN EXPECTED? INSIGHTS
9:45 a.m. 10 a.m. 10:15 a.m. 10:30 a.m. 10:45 a.m.	7242: MEASURING REACTIVE OXYGEN SPECIES (ROS) ACCUMULATION IN F 7243: HEME PROCESSING IN THE HUMAN MALARIA PARASITE, PLASMODIU 7244: MULTI-OMIC PROFILING REVEALS MOLECULAR MARKERS ASSOCIATI 7245: WHY ARE FITNESS COSTS OF MULTIDRUG RESISTANT PARASITES LO	IM FALCIPARUM: THE BASAL-LEVEL NATIVE ED WITH ARTEMISININ TOLERANCE WER THAN EXPECTED? INSIGHTS

9:25 a.m.	7248: SAFETY AND EFFICACY OF PLASMODIUM FALCIPARUM MALARIA T	RANSMISSION-BLOCKING MONOCLONAL
9:35 a.m.	7249: MRNA VACCINES TARGETING MULTIPLE MALARIA ANTIGENS AND S	SPECIES INDUCE BROAD MULTIFUNCTIONAL
9:45 a.m.	7250: PERSISTENCE OF IGG ANTIBODY RESPONSES IN WOMEN IMMUNIZ	ED WITH PRIMVAC PLACENTAL MALARIA VACCINE.
9:55 a.m.	7251: A PHASE 1A CLINICAL TRIAL OF SAFETY, TOLERABILITY AND IMMU	NOGENICITY OF PVS25-IMX313 IN MATRIX
10:05 a.m.	7252: STRATEGIES TO IMPROVE UPTAKE OF FOUR-DOSE MALARIA VACC	INE
10:15 a.m.	7253: A PHASE IB TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF	THE BLOOD-STAGE MALARIA VACCINE
10:25 a.m.	7254: R21/MATRIX-M™ MALARIA VACCINE: THREE-YEAR EFFICACY AND	SAFETY RESULTS FROM A PHASE III CLINICAL TRIA
10:35 a.m.	7255: DURATION OF PROTECTION AND COST-EFFECTIVENESS OF MALAR	IA VACCINE CANDIDATE R21/MATRIX-M
10:45 a.m.	LIGHTNING TALKS	
	7602: USING MOBILE PLATFORMS TO DRIVE MALARIA VACCINE AWAREN	ESS AND BEHAVIOR CHANGE
	7599: MICRONEEDLE-MEDIATED INTRADERMAL VACCINATION TOWARD S	ELF-ADMINISTRABLE AND THERMOSTABLE
	7597: DEVELOPMENT AND EVALUATION OF AN IN VITRO MALARIA PARAS	SITE KILLING ASSAY TO ASSESS NOVEL MALARIA
	7610: BLOOD PATENCY DURING PLASMODIUM FALCIPARUM SPOROZOITE	VACCINATION WITH CONCURRENT ANTI
	7613: LONGITUDINAL MALARIA GENOTYPING INCREASES EFFICACY RES	OLUTION FOR THE MALARIA MONOCLONAL
ntific Session 118: Wat	er, Sanitation, Hygiene and Environmental Health (WaSH-E): Interventions	Convention Center - Room 716 (Level 700)
9:15 a.m.	7256: SEROLOGIC RESPONSES TO VIBRIO CHOLERAE TO ASSESS THE IM	PACT OF A WATER, SANITATION, AND HYGIENE
9:25 a.m.	7257: FORMATIVE RESEARCH FOR ADAPTING THE CHOLERA-HOSPITAL-BASED-INTERVENTION-FOR-7-DAYS (CHOBI7)	

<u> </u>	Room Name
7258: INTERVENTIONS TO IMPROVE HAND HYGIENE IN COMMUNITY SETTI	INGS - A SYSTEMATIC REVIEW OF THEORIES
7259: IMPACT OF A MULTI-COMPONENT TRAINING INTERVENTION (CLEAN	FRONTLINE) ON MICROBIOLOGICAL
7260: HOW MUCH ARE END-USERS WILLING TO INVEST IN HAND HYGIENE	ENABLING TECHNOLOGIES? A PURCHASING
7261: MDA ALONE IS NOT ENOUGH: INTEGRATING WASH AND HEALTH EDU	JCATION TO REDUCE INTESTINAL PARASITES
7262: EFFECT OF WASH INTERVENTIONS ON GIARDIA INFECTION IN BANG	SLADESH: HETEROGENEITY BY EXPOSURE
7263: EFFECTS OF A WATER, SANITATION AND HYGIENE MOBILE HEALTH I	PROGRAM ON RESPIRATORY ILLNESS
7264: ASSESSMENT OF INFRASTRUCTURE HYGIENE BEHAVIOURS AND MA	ANAGEMENT OF EARLY CHILDHOOD
7265: THE EFFECT OF TWO COMMUNITY-BASED INTERVENTIONS ON SANI	TATION AND HYGIENE OUTCOMES IN RURAL
urveillance Approaches for Lymphatic Filariasis in Post-Elimination and	Convention Center - Room 717 (Level 700)
INTRODUCTION	
MONITORING AND EPIDEMIOLOGICAL ASSESSMENT OF MASS DRUG ADMI	NISTRATION IN THE GLOBAL PROGRAM TO
FINDINGS FROM INTEGRATING LF PVS WITH THE WHO STEPWISE APPROA	ACH TO NON-COMMUNICABLE DISEASE RISK
INTEGRATED VECTOR SURVEILLANCE FOR MALARIA AND LF IN CO-ENDEN	MICITY SETTING IN MALI: A PILOT STUDY
INTEGRATION OF MALARIA SURVEILLANCE INTO LF TRANSMISSION ASSE	SSMENT SURVEYS (TAS)
Malaria Deaths: Managing Endemic Malaria While Pursuing Elimination	Convention Center - Room 718A (Level 700)
INTRODUCTION	
SEVERE MALARIA IN THE ELIMINATION ERA: EPIDEMIOLOGICAL INSIGHTS	FOR TARGETED INTERVENTIONS
CARE SEEKING PATTERNS AND THE RISK OF SEVERE MALARIA	
MALARIA COMMUNITY CASE MANAGEMENT AND HOSPITAL MORTALITY IN	NORTHERN ZAMBIA: BRIDGING THE
	7258: INTERVENTIONS TO IMPROVE HAND HYGIENE IN COMMUNITY SETT 7259: IMPACT OF A MULTI-COMPONENT TRAINING INTERVENTION (CLEAN 7260: HOW MUCH ARE END-USERS WILLING TO INVEST IN HAND HYGIENE 7261: MDA ALONE IS NOT ENOUGH: INTEGRATING WASH AND HEALTH EDI 7262: EFFECT OF WASH INTERVENTIONS ON GIARDIA INFECTION IN BANG 7263: EFFECTS OF A WATER, SANITATION AND HYGIENE MOBILE HEALTH 7264: ASSESSMENT OF INFRASTRUCTURE HYGIENE BEHAVIOURS AND M. 7265: THE EFFECT OF TWO COMMUNITY-BASED INTERVENTIONS ON SANI URVEILLANCE Approaches for Lymphatic Filariasis in Post-Elimination and INTRODUCTION MONITORING AND EPIDEMIOLOGICAL ASSESSMENT OF MASS DRUG ADMI FINDINGS FROM INTEGRATING LF PVS WITH THE WHO STEPWISE APPRO INTEGRATED VECTOR SURVEILLANCE FOR MALARIA AND LF IN CO-ENDER INTEGRATION OF MALARIA SURVEILLANCE INTO LF TRANSMISSION ASSE MAIARIA Deaths: Managing Endemic Malaria While Pursuing Elimination INTRODUCTION SEVERE MALARIA IN THE ELIMINATION ERA: EPIDEMIOLOGICAL INSIGHTS CARE SEEKING PATTERNS AND THE RISK OF SEVERE MALARIA

Wednesday, November	12	Room Name
10:10 a.m.	ANTIMALARIAL DRUG RESISTANCE AND THE TREATMENT OF SEVERE MALAR	RIA
10:25 a.m.	EFFICACY OF IV ARTESUNATE FOR PEDIATRIC SEVERE MALARIA IN UGANDA	, A REGION WITH ARTEMISININ PARTIAL
10:40 a.m.	INTERIM RESULTS FROM THE PLATFORM TRIAL: EVALUATING A NOVEL WHO	LE BLOOD TRANSFUSION PROTOCOL FOR
10:50 a.m.	POTENTIAL OPTIONS FOR MANAGING SEVERE MALARIA	
Symposium 121: Ti	opical Medicine Consult: Tissue Helminths	Convention Center - Room 718B (Level 700)
9:15 a.m.	INTRODUCTION	
9:25 a.m.	NEUROCYSTICERCOSIS: EPILEPSY AND INTRACRANIAL HYPERTENSION	
9:50 a.m.	SPARGANOSIS: A NEW YORK EXPERIENCE	
10 a.m.	FASCIOLIASIS AND LIVER DISEASE	
10:20 a.m.	GENITAL SCHISTOSOMIASIS AND INFERTILITY	
10:40 a.m.	ALVEOLAR ECHINOCOCCOSIS: A CANADIAN EXPERIENCE	
	etoplastida and Other Opportunistic and Anaerobic Protozoa: Genomics, Proteomics and Therapeutic Targets, Treatment Drug Delivery, Drug Repurposing and Drug Discovery	Convention Center - Room 801A (Level 800)
9:15 a.m.	7266: EFFECTIVENESS OF BENZNIDAZOLE IN THE TREATMENT OF CHAGAS DI	ISEASE IN CHILDREN AND ADULTS
9:25 a.m.	7267: DIAGNOSIS AND TREATMENT OF T.B. GAMBIENSE HAT PATIENTS WITH	FEXINIDAZOLE AND THE ACTIVE SEARCH
9:35 a.m.	7268: CLINICAL AND DEMOGRAPHIC RISK FACTORS ASSOCIATED WITH MORT	ALITY IN VISCERAL LEISHMANIASIS IN
9:45 a.m.	7269: THE ECONOMIC BURDEN OF VISCERAL LEISHMANIASIS AND BARRIERS)

Wednesday, November	12 Room Name
9:55 a.m.	7270: EVALUATING PRESCRIBER PREFERENCES FOR INDETERMINATE CHAGAS TREATMENTS: AN INTERNATIONAL
10:05 a.m.	7271: NANOENCAPSULATION STRATEGIES OF ANTIMALARIAL AND ANTILEISHMANIAL COMPOUNDS
10:15 a.m.	7272: EFFECT OF LACTOBACILLUS ACIDOPHILUS PROBIOTIC SUPPLEMENTATION ON THE PHYSIOLOGICAL STATUS OF
10:25 a.m.	7273: NEW FOCI OF CUTANEOUS LEISHMANIASIS IN TERRORISM REFUGEE CAMPS IN THE CENTRE WEST OF BURKINA
10:35 a.m.	7274: DIVERSITY OF RNA VIRUSES IN TRYPANOSOMATIDS
10:45 a.m.	7275: INTRASPECIES GENETIC DIVERSITY OF <i>ENDOLIMAX NANA</i> IN SUMBA ISLAND, INDONESIA
Scientific Session 123: Virus	res - Epidemiology Convention Center - Room 801B (Level 800
9:15 a.m.	7276: RELATIVE AND ATTRIBUTABLE RISKS OF NEUROLOGICAL AND PERINATAL ADVERSE OUTCOMES AMONG CHILDREN
9:25 a.m.	7277: HUMAN PARVOVIRUS B19 AS A HIDDEN CAUSE OF DENGUE-LIKE ILLNESS IN NICARAGUAN CHILDREN: INSIGHTS
9:35 a.m.	7278: CLIMATE CHANGE AND WEST NILE VIRUS: EXTENDING TRANSMISSION SEASONS IN NEW YORK STATE
9:45 a.m.	7279: MODELLING OPTIMAL DEPLOYMENT STRATEGIES FOR NIPAH VACCINES AND MONOCLONAL ANTIBODIES
9:55 a.m.	7280: IDENTIFICATION OF MULTIPLE ARBOVIRUS INFECTIONS OR EXPOSURE IN BRAZIL USING A MULTIPLEX
10:05 a.m.	7281: WEEKLY PROBABILISTIC EPIDEMIC BANDS FOR DENGUE MONITORING: A STATISTICAL MODELING TOOL
10:15 a.m.	7282: TROPICAL OCEAN TEMPERATURE ANOMALIES PREDICT DENGUE TRENDS IN ASIA AND THE AMERICAS
10:25 a.m.	7283: AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF 12 COHORTS IN THE ZIKA BRAZILIAN COHORTS CONSORTIUM.
10:35 a.m.	7284: KINETICS OF THE NEUTRALIZING AND BINDING ANTIBODY RESPONSES FOLLOWING ZIKA VIRUS INFECTION
10:45 a.m.	LIGHTNING TALKS
	7425: THE CHANGING EPIDEMIOLOGY OF DENGUE IN NICARAGUA IN THE POST-PANDEMIC PERIOD
	7424: MONITORING GHANA'S PROGRESS TOWARDS ELIMINATING HEPATITIS B AS A PUBLIC HEALTH THREAT: A BASELINE

7426: THE POTENTIAL IMPACT OF A CHIKUNGUNYA VACCINE IN BRAZIL

Wednesday, November 12

	TARE INCIDENCE OF A CUTE CACEDOENTEDITIC AND MODOWIDUS INFECT	IONS IN 1 000 DEDCOMS (F TO 100 VDS OF D
		<u> </u>
	7431: SOCIO-ECOLOGICAL DRIVERS OF FLAVIVIRUS EXPOSURE IN A RUR.	AL DISTRICT OF MADAGASCAR
ssion 124: Mosq	uitoes- Biology and Genetics of Insecticide Resistance	Convention Center - Room 803 (Level 800)
9:15 a.m.	7285: MAPPING OF INSECTICIDE RESISTANCE VARIANTS IN MALARIA VEC	CTORS IN BURKINA FASO
9:25 a.m.	7286: ENTOMOLOGICAL SURVEY IN AN AGRO-ECOLOGICAL SETTING IN SC	OUTHERN GHANA REVEAL HIGH MALARIA
9:35 a.m.	7287: THE RIFT VALLEY AS A BARRIER TO GENE FLOW AND ASSOCIATION	I WITH INSECTICIDE RESISTANCE PROFILES
9:45 a.m.	7288: GENOMIC SURVEILLANCE REVEALS GEOGRAPHICAL HETEROGENEI	TY AND DIFFERENCES IN KNOWN AND NOVEL
9:55 a.m.	7289: ASSESSING THE PERFORMANCE OF NOVEL ITNS AGAINST PYRETHI	ROID-RESISTANT ANOPHELES GAMBIAE S.L. IN
10:05 a.m.	7290: WHOLE TRANSCRIPTOMIC ANALYSIS REVEALS KEY METABOLIC GE	NES INVOLVED IN INSECTICIDE-RESISTANT
10:15 a.m.	7291: TRANSCRIPTOMIC INSIGHTS INTO INSECTICIDE RESISTANCE IN AE	DES AEGYPTI FROM KINGSTON AND
10:25 a.m.	7292: CYP6Z-PYRETHROID RESISTANCE GENES CONFERS CROSS-RESISTA	ANCE TO A RANGE OF INSECTICIDES IN THE
10:35 a.m.	7293: A SINGLE MUTATION IN THE CARBOXYLESTERASE GENE COEAE80 (COUPLED WITH P450 SUPPRESSION DRIVE
10:45 a.m.	7294: PERMETHRIN ELICITS CHEMORECEPTIVE RESPONSES ON DIFFERE	NT ANOPHELES GAMBIAE SENSORY APPENDAGES
ssion 125: Bacte	riology: Trachoma, Systemic Infections, and Other Bacterial Infections	Convention Center - Room 602 (Level 600)
9:15 a.m.	7295: A LONGITUDINAL COHORT IN SOUTHEAST BRAZIL HIGHLIGHTS BIO	MARKERS AND RISK FACTORS PREDICTIVE OF
9:25 a.m.	7296: SCRUB TYPHUS: A SIGNIFICANT AND UNDERRECOGNIZED CAUSE O	OF ACUTE FEBRILE ILLNESS IN KATHMANDU
9:35 a.m.	7297: ANTI-PGL-I IGM POSITIVITY IN HOUSEHOLD CONTACTS OF PATIENT	'S WITH HANSEN'S DISEASE IN THE
	9:15 a.m. 9:25 a.m. 9:35 a.m. 9:45 a.m. 9:55 a.m. 10:05 a.m. 10:15 a.m. 10:25 a.m. 10:35 a.m. 10:45 a.m. 10:45 a.m. 9:15 a.m.	9:15 a.m. 7290: WHOLE TRANSCRIPTOMIC ANALYSIS REVEALS KEY METABOLIC GE 10:15 a.m. 7291: TRANSCRIPTOMIC INSIGHTS INTO INSECTICIDE RESISTANCE ONFERS CROSS-RESIST 10:35 a.m. 7292: CYP6Z-PYRETHROID RESISTANCE GENES CONFERS CROSS-RESIST 10:45 a.m. 7292: A SINGLE MUTATION IN THE CARBOXYLESTERASE GENE COCAEASO (10:45 a.m. 7292: A SINGLE MUTATION IN THE CARBOXYLESTERASE GENE COCAEASO (10:45 a.m. 7292: CYP6Z-PYRETHROID RESISTANCE GENES CONFERS CROSS-RESIST 10:35 a.m. 7293: A SINGLE MUTATION IN THE CARBOXYLESTERASE GENE COCAEASO (10:45 a.m. 7291: TRANSCRIPTOMIC IN IN THE CARBOXYLESTERASE GENE COCAEASO (10:45 a.m. 7292: CYP6Z-PYRETHROID RESISTANCE GENES CONFERS CROSS-RESIST 10:35 a.m. 7293: A SINGLE MUTATION IN THE CARBOXYLESTERASE GENE COCAEASO (10:45 a.m. 7294: PERMETHRIN ELICITS CHEMORECEPTIVE RESPONSES ON DIFFERE SSION 125: Bacteriology: Trachoma, Systemic Infections, and Other Bacterial Infections 9:15 a.m. 7295: A LONGITUDINAL COHORT IN SOUTHEAST BRAZIL HIGHLIGHTS BIO 9:25 a.m. 7296: SCRUB TYPHUS: A SIGNIFICANT AND UNDERRECOGNIZED CAUSE (10:45 a.m. 7296: SCRUB TYPHUS: A SIGNIFICANT AND UNDERRECOGNIZED CAUSE (10:45 a.m. 7296: SCRUB TYPHUS: A SIGNIFICANT AND UNDERRECOGNIZED CAUSE (10:45 a.m. 7296: SCRUB TYPHUS: A SIGNIFICANT AND UNDERRECOGNIZED CAUSE (10:45 a.m. 7296: SCRUB TYPHUS: A SIGNIFICANT AND UNDERRECOGNIZED CAUSE (10:45 a.m. 7296: SCRUB TYPHUS: A SIGNIFICANT AND UNDERRECOGNIZED CAUSE (10:45 a.m. 7296: SCRUB TYPHUS: A SIGNIFICANT AND UNDERRECOGNIZED CAUSE (10:45 a.m. 7296: SCRUB TYPHUS: A SIGNIFICANT AND UNDERRECOGNIZED CAUSE (10:45 a.m. 7296: SCRUB TYPHUS: A SIGNIFICANT AND UNDERRECOGNIZED CAUSE (10:45 a.m. 7296: SCRUB TYPHUS: A SIGNIFICANT AND UNDERRECOGNIZED CAUSE (10:45 a.m. 7296: SCRUB TYPHUS: A SIGNIFICANT AND UNDERRECOGNIZED CAUSE (10:45 a.m. 7296: SCRUB TYPHUS: A SIGNIFICANT AND UNDERRECOGNIZED CAUSE (10:45 a.m. 7296: SCRUB TYPHUS: A SIGNIFICANT AND UNDERRECOGNIZED CAUSE (10:45 a.m. 7296: SCRUB TYPHUS: A SIGNIFICANT AND UNDERRECOGNIZED CAUSE (10:45 a.m. 7296: SCRUB TYPHUS: A SIGNIFICANT AND UNDERRECOGNI

9:45 a.m.	7298: ANTIBODY-OMICS REVEALS DISTINCT IMMUNOLOGICAL STATES ACROSS	THE INFECTION AND DISEASE SPECTRUM
9:55 a.m.	7299: COMPARISON OF MOLECULAR ASSAYS FOR BURKHOLDERIA PSEUDOMAL	LEI DETECTION IN CLINICAL ISOLATES
10:05 a.m.	7300: MODELING ANTIBODY DECAY TO STRENGTHEN MELIOIDOSIS SURVEILLAN	CE AND DIAGNOSTIC TOOLS
10:15 a.m.	7301: CLUSTER RANDOMIZED CONTROLLED TRIAL OF DOUBLE-DOSE AZITHROM	YCIN MASS DRUG ADMINISTRATION
10:25 a.m.	7302: THE BURDEN OF LATE ONSET SEPSIS AMONG LOW BIRTH WEIGHT NEONA	TES IN SOUTH AFRICA, 2013-2020
10:35 a.m.	7303: PERSISTENT TRACHOMA IN AL RAHAD LOCALITY, SUDAN: EVALUATING CI	HLAMYDIA TRACHOMATIS INFECTION
10:45 a.m.	LIGHTNING TALKS	
	7635: DIAGNOSTIC AND TREATMENT PRACTICES FOR BACTERIAL MENINGITIS A	MONG HEALTHCARE PROVIDERS IN GHANA
	7643: PREVALENCE AND FACTORS ASSOCIATED WITH PREHOSPITAL DELAYS IN	SEEKING CARE AMONG SEPSIS PATIENTS
	7624: ANTIBIOTIC USE IN CHILDREN LESS THAN FIVE YEARS OF AGE IN A PERI-	URBAN COMMUNITY OF LIMA, PERU
	7626: INVESTIGATION OF MICRONUTRIENT AND ENERGY METABOLISM DIFFERE	NCES IN LATENT AND CLINICAL LEPROSY
	7625: "BENEATH THE TROPICAL CALM: MAPPING THE CLINICAL SPECTRUM AND	DISEASE BURDEN OF LEPTOSPIROSIS
10:45 a.m 12:45 p.m.	Exhibit Hall - Light Lunch	Convention Center - Hall D (Level 800) (Exhibit Hall)
11 a.m 12:45 p.m.	Poster Session 126: Poster Session C Presentations	Convention Center - Hall E (Level 800) (Poster Hall)
11:15 a.m 12:15 p.m.	Clinical Group (ACCTMTH) Past Presidents Meeting	Convention Center - Room 604 (Level 600)
11:15 a.m 12:15 p.m.	Diploma Course Certification Committee Meeting	Convention Center - Room 606 (Level 600)
11:15 a.m 12:30 p.m.	Meet the Professors Session 127: Meet the Professors: Same Story, Different Faces	Convention Center - Room 801B (Level 80

Wednesda	y, November 12		Room Name
11:15 a.m	12:30 p.m.	Late-Breaker Abstract Session 128: Late-Breakers in Malaria I	Convention Center - Room 801A (Level 800)
11:15 a.m	12:30 p.m. (((▶))-	Late-Breaker Abstract Session 129: Late-Breakers in Virology	Convention Center - Hall F/G (Level 800)
12:30 p.m	1:30 p.m.	Mentorship Pop-Up Session: Equitable Partnership in Health and Beyond	Convention Center – Level 600 Lobby (Level 600)
12:45 p.m	2:30 p.m.	Poster Session C Viewing	Convention Center - Hall E (Level 800) (Poster Hall)
Symp	oosium 130: Innovat	ion in Countering Substandard and Falsified Medicines	Convention Center - Hall F/G (Level 800)
	12:45 p.m.	INTRODUCTION	
	12:55 p.m.	SUBSTANDARD AND FALSIFIED ONCOLOGY MEDICINES	
	1:10 p.m.	INNOVATION FOR DEVICES FOR DETECTING SUBSTANDARD AND FALSIFIED L	IQUID MEDICINES AND VACCINES
	1:25 p.m.	PHARMACEUTICAL FORENSICS: A MULTIDISCIPLINARY ANALYTICAL APPROA	CH TO TRACING FALSIFIED MEDICINES
	1:40 p.m.	A SOCIAL NETWORK ANALYSIS OF THE TRADE IN SF MEDICINES	
	1:55 p.m.	MODELLING THE IMPACT OF SF ANTIMICROBIALS ON PATIENT OUTCOME AND	D AMR
	2:10 p.m.	STAKEHOLDER INSIGHTS ON SUBSTANDARD AND FALSIFIED MEDICINES AS	DRIVERS OF ANTIMICROBIAL RESISTANCE
	131: The Data Revo	lution: Harnessing AI, Geospatial Science, and ase Eradication	Convention Center - Room 701A (Level 700
	12:45 p.m.	INTRODUCTION	

12:50 p.m.	THE EVOLVING EPIDEMIOLOGY OF GUINEA WORM DISEASE IN SOUTH SUDAN
12:55 p.m.	HIGH-RESOLUTION RISK MAPPING OF GUINEA WORM DISEASE: HARNESSING REMOTE SENSING, GEOSTATISTICS, AND
1:10 p.m.	TURNING DATA INTO ACTION: THE USE SURVEILLANCE DATA FOR REAL-TIME RESPONSE IN GUINEA WORM ERADICATION
1:25 p.m.	ACCELERATING GUINEA WORM ERADICATION EFFORTS BY LEVERAGING GENERATIVE AI MODELS
1:40 p.m.	SOLVING THE GEOCODE PUZZLE: MAPPING GUINEA WORM TRANSMISSION DESPITE DATA GAPS
Scientific Session 132: M	alaria - Getting to Zero and Staying There: Successes and Challenges in Malaria Elimination Convention Center - Room 701B (Level 700)
12:45 p.m.	7741: DEVELOPING A NOVEL AND SUSTAINABLE STRATIFICATION FOR THE PREVENTION OF RE-ESTABLISHMENT OF
12:55 p.m.	7742: FROM DEMONSTRATION TO SUSTAINABILITY: EVALUATING THE POST-ELIMINATION PHASE OF THE MALARIA
1:05 p.m.	7743: INTEGRATING VILLAGE MALARIA WORKERS INTO CAMBODIA'S HEALTH SYSTEM: A PATHWAY TO SUSTAIN MALARIA
1:15 p.m.	7744: REGIONAL NETWORKS IN ASIA-PACIFIC DRIVING MALARIA ELIMINATION
1:25 p.m.	7745: TOWARDS MALARIA ELIMINATION IN MALAWI: DEVELOPING FORECASTING MODELS FOR A MALARIA EARLY
1:35 p.m.	7746: MAPPING LOCAL EFFECTIVENESS OF MASS DRUG ADMINISTRATION FOR MALARIA IN SENEGAL
1:45 p.m.	7747: RESULTS OF THE CUREMA PROJECT: LEVERS AND OBSTACLES TO THE REACH AND EFFECTIVENESS OF A COMPLEX
1:55 p.m.	7748: COMMUNITY PATIENT FOLLOW-UP AS A PART OF PLASMODIUM VIVAX CASE MANAGEMENT IN CAMBODIA
2:05 p.m.	7749: COMMUNITY CO-CREATION: AN UNTAPPED APPROACH FOR ADVANCING TOWARDS MALARIA ELIMINATION
2:15 p.m.	7750: MALARIA IN AFRICA - FOUR POSSIBLE ENDGAMES
Symposium 133: Strike \	While the Iron is Hot: How Outbreak Research Response Efforts Can Address Critical Convention Center - Room 713 (Level 700)

 Knowledge and Programmatic Gaps in Our Understanding of Emerging Infectious Diseases

 12:45 p.m.
 INTRODUCTION

 12:55 p.m.
 THE ROLE OF RESEARCH IN EMERGING INFECTIOUS DISEASE OUTBREAK PREPAREDNESS AND RESPONSE EFFORTS

1:15 p.m.	THE SPREAD OF OROPOUCHE VIRUS IN BRAZIL AND BEYOND	
1:35 p.m.	UNDERSTANDING CLINICAL SEQUELAE AND IMMUNOLOGY OF SUDAN	EBOLAVIRUS IN A COHORT OF SURVIVORS
1:55 p.m.	LASSA FEVER OUTBREAKS IN WEST AFRICA AND THE IMPORTANCE O	F NEUROLOGICAL SEQUELAE IN SURVIVORS
2:15 p.m.	OUTBREAK RELATED RESEARCH AND LESSONS LEARNED FROM 5-YEA	ARS OF CREID NETWORK-SUPPORTED GLOBAL EID
Scientific Session 134: Wa	ter, Sanitation, Hygiene and Enviromental Health (WaSH-E): Outcomes	Convention Center - Room 714 (Level 700)
12:45 p.m.	7751: ASSESSING THE RELATIVE IMPORTANCE OF HOUSEHOLD-LEVEL	VERSUS COMMUNITY TRANSMISSION OF
12:55 p.m.	7752: HIGH PREVALENCE OF ANTIMICROBIAL RESISTANCE GENES IN V	WASTEWATER BIOFILMS AN EVIDENCE OF
1:05 p.m.	7753: PRENATAL AND POSTNATAL ENVIRONMENTAL INFLUENCES ON	CHILD GROWTH TRAJECTORIES: AN ANALYSIS OF A
1:15 p.m.	7754: ASSOCIATION BETWEEN SANITATION TYPE AND SOIL CONTAMIN	IATION WITH CULTURABLE E. COLI IN A RURAL
1:25 p.m.	7755: HIGH BLOOD LEAD LEVELS IN CHILDREN LIVING NEAR ABANDON	NED LEAD-ACID BATTERY RECYCLING SITES IN
1:35 p.m.	7756: HOUSEHOLD-LEVEL ENVIRONMENTAL RISK FACTORS FOR ANIM	AL AND HUMAN FECAL CONTAMINATION IN
1:45 p.m.	7757: INTER-RATER AGREEMENT OF METHODS TO EVALUATE HAND CL	LEANLINESS TO STUDY TRACHOMA RISK IN RURAL
1:55 p.m.	7758: COMPARATIVE EVALUATION OF ENVIRONMENTAL SURVEILLANC	CE METHODS FOR DETECTING SALMONELLA TYPHI
2:05 p.m.	7759: CHARACTERIZATION OF CEFOTAXIME-RESISTANT KLEBSIELLA F	PNEUMONIAE FROM COURTYARD AND HOME
2:15 p.m.	7760: ANIMAL EXPOSURE AND SANITATION ARE ASSOCIATED WITH DI	ARRHEA AMONG YOUNG CHILDREN IN THE
Symposium 135: Cabamiq	ine: A Decade of Antimalarial Drug Development	Convention Center - Room 715 (Level 700,
12:45 p.m.	INTRODUCTION	

Wednesday, Noven	nber 12		Room Name
12:50 p.	m.	OVERVIEW AND VISION OF CABAMIQUINE CLINICAL DRUG DEVELOPME	ENT
1:10 p.m	ո.	NON-CLINICAL DEVELOPMENT SUMMARY	
1:30 p.m	n.	SUMMARY OF PHASE 1 STUDIES	
1:50 p.m	n.	DISCLOSURE OF PHASE2A STUDIES	
2:10 p.m	า.	MODELLING AND CLINICAL TRIAL SIMULATION	
12:45 p.m 1:45 p.m.		Session 136: ASTMH Annual Business Meeting	Convention Center - Room 716 (Level 700)
Symposium 137: Host Across Sub-Saharan A		ers to Predict Severe Febrile Illness in Community Settings Asia	Convention Center - Room 717 (Level 700)
12:45 p.	m.	INTRODUCTION	
12:55 p.	m.	TRANSFORMING FEVER MANAGEMENT: NEW TOOLS TO SAVE LIVES, BI	RAINS AND MONEY
1:10 p.m	n.	URIC ACID AS A BIOMARKER OF SEVERE MALARIA PATHOGENESIS, PR	OGNOSIS, AND A PATHWAY FOR INTERVENTION
1:25 p.m	า.	PROGNOSTIC MARKERS IN DENGUE VIRUS INFECTION	
1:40 p.m	ո.	HOST SEVERITY MARKERS TO RISK-STRATIFY MALARIA AND NON-MAL	ARIAL FEBRILE ILLNESS IN SUB-SAHARAN AFRICA
1:55 p.m	n.	SPOT SEPSIS - GUIDING REFERRAL OF FEBRILE CHILDREN FROM RESC	DURCE-LIMITED COMMUNITY SETTINGS
2:10 p.m	า.	PROGNOSTIC BIOMARKERS FOR THE TRIAGE AND RISK STRATIFICATION	ON OF NEWBORNS AND CHILDREN IN SUB-SAHARAN
Symposium 138: Doin Cost-effectiveness of		ith Less: The Opportunity of Sub-national Tailoring to Maximize the ector Control	Convention Center - Room 718A (Level 700)
12:45 p.	m.	INTRODUCTION	
12:55 p.	m.	"FROM EFFICACY TO ENDURANCE", EVALUATING THE DURABILITY OF I	DUAL ACTIVE INGREDIENTS ITNS AND COMMUNITY
1:10 p.m	ղ.	THE COST-EFFECTIVE ALLOCATION OF ITNS - LOOKING AT CASES/DALY	YS/DEATHS

	1:25 p.m.	EXPLORING AVENUES TO IMPACT IN INSECTICIDE-TREATED-NET CAMPAI	IGNS: A MODELING EXERCISE
	1:40 p.m.	ENTOMOLOGICAL SURVEILLANCE PLANNING TOOL (ESPT) - TO SUPPOR	T EVIDENCE-BASED VECTOR CONTROL
	1:55 p.m.	THE GHANAIAN EXPERIENCE OF DESIGNING AND IMPLEMENTING AN SN	T STRATEGY FOR MALARIA VECTOR CONTROL
Scientific	Session 139: Cesto	des: Epidemiology, Pathogenesis, and Treatment	Convention Center - Room 718B (Level 700
	12:45 p.m.	7761: UNREVEALING TISSUE REMODELING IN NEUROCYSTICERCOSIS: PI	3K-AKT DEPENDENT REGULATION OF
	12:55 p.m.	7762: EXPLORATORY STUDY ON GENETIC VARIANTS RELATED TO CYSTIC	ECHINOCOCCOSIS SUSCEPTIBILITY AND
	1:05 p.m.	7763: LONG-TERM DATA COLLECTION ON PATIENTS WITH CYSTIC ECHING	OCOCCOSIS: THE PAVIA EUROPEAN REGISTER
	1:15 p.m.	7764: INTER-CLUSTER TRANSMISSION OF CYST ECHINOCOCCUS IN RURA	AL PERUVIAN COMMUNITIES. A CASE-CONTROL
	1:25 p.m.	7765: FREQUENCY OF NEUROCYSTICERCOSIS AMONG PEOPLE WITH NEU	JROLOGICAL CLINICAL MANIFESTATIONS
	1:35 p.m.	7766: UNRECOGNIZED AT-RISK POPULATIONS FOR CYSTIC ECHINOCOCC	OSIS IN PERU
	1:45 p.m.	7767: LIVER CYST ECHINOCOCCOSIS CUMULATIVE INCIDENCE OVER A 10)-YEAR PERIOD IN A RURAL PERUVIAN
	1:55 p.m.	7768: PREVALENCE OF LIVER CYSTIC ECHINOCOCCOSIS IN FOUR COMMU	JNITIES LOCATED IN PERUVIAN CENTRAL
	2:05 p.m.	7769: EXTRACELLULAR VESICLES OF TAENIA SOLIUM SUPPRESSES REA	CTIVE OXYGEN SPECIES PRODUCTION IN
	2:15 p.m.	7770: IMMUNOREACTIVITY OF NLRP3, CASPASE 1, GASDERMIN D, AND IL	-1β IN RAT BRAIN TISSUE WITH
12:45 p.m	n 2:30 p.m.	Late-Breaker Abstract Session 140: Late-Breakers in Malaria II	Convention Center - Room 801A (Level 800
Scientific	Session 141: Virus	es - Evolution and Genomic Epidemiology	Convention Center - Room 801B (Level 800
	12:45 p.m.	7771: INTEGRATING FINE SCALE MOLECULAR EPIDEMIOLOGY AND SURV	EILLANCE OF WEST NILE VIRUS TO IDENTIFY

12:45 p.m.

12:55 p.m.	7772: NOT ALL VARIANTS SMELL AND TASTE THE SAME: GREATER CHEMOSENSORY DYSFUNCTION IN LAMBDA VS
1:05 p.m.	7773: RETROSPECTIVE GENOMIC SURVEILLANCE OF ST. LOUIS ENCEPHALITIS VIRUS IN TEXAS, USA FROM 2009-2024
1:15 p.m.	7774: GENOMIC ECOLOGY: EXPLORING THE ECOLOGICAL AND BIOLOGICAL FITNESS OF WEST NILE VIRUS DURING THE
1:25 p.m.	7775: EPIDEMIOLOGICAL AND GENOMIC INSIGHTS INTO THE EMERGENCE AND SPREAD OF CLADE IB MPOX VIRUS
1:35 p.m.	7776: WHOLE-GENOME CHARACTERIZATION OF CHIKUNGUNYA VIRUS IN PAKISTAN A COMPARATIVE STUDY
1:45 p.m.	7777: CHARACTERIZATION OF CIRCULATING VIRAL ISOLATES OF POWASSAN VIRUS LINEAGE II
1:55 p.m.	7778: GENOMIC AND EPIDEMIOLOGICAL CHARACTERIZATION OF DENV AND CHIKV IN MINAS GERAIS, BRAZIL, 2024
2:05 p.m.	7779: DETECTION OF TRACE DENGUE VIRUS IN NEW YORK STATE THROUGH WASTEWATER SURVEILLANCE
2:15 p.m.	7780: USING PHYLOGENIES TO EVALUATE DENGUE FITNESS IN THAILAND

Symposium 142: Bytes Against Bites: Building a Unified Digital Framework for Vector Surveillance and Control

Convention Center - Room 803 (Level 800)

2:05 p.m.	DIGITAL SOLUTIONS FOR VECTOR CONTROL: IMPLEMENTATION SUCCESSES AND COMPLEMENTARY NEEDS
1:45 p.m.	ACCELERATING THE DATA CYCLE WITH THE HYRIS SYSTEM GENETIC SURVEILLANCE NETWORK
1:25 p.m.	ZZAPP MALARIA: OPTIMIZING VECTOR CONTROL STRATEGIES THROUGH AI
1:10 p.m.	VBDS360: A COMPREHENSIVE SURVEILLANCE SYSTEM FOR MONITORING, CONTROL, AND ELIMINATION OF VECTOR-BORNE
12:55 p.m.	VECTORCAM: TRANSFORMING MOSQUITO SURVEILLANCE THROUGH AI-POWERED IDENTIFICATION
12:45 p.m.	INTRODUCTION
	12:55 p.m. 1:10 p.m.

7781: EFFECTS OF EXTREME WEATHER EVENTS ON CHOLERA IN THE DEMOCRATIC REPUBLIC OF THE CONGO...

	10.55	FEON CACE AREA TARRETER INTERVENTIONS TO RARIEN Y CONTAIN THE CRREAD	OF OLIOLEDA A DECORECTIVE
	12:55 p.m.	7782: CASE-AREA TARGETED INTERVENTIONS TO RAPIDLY CONTAIN THE SPREAD	
	1:05 p.m.	7783: GENOMIC CHARACTERIZATION OF <i>VIBRIO CHOLERAE</i> ISOLATED FROM CLINIC	CAL AND ENVIRONMENTAL SOURCES
	1:15 p.m.	7784: EFFECTIVENESS OF SINGLE-DOSE ORAL CHOLERA VACCINE AND GENOMIC S	SURVEILLANCE OF VIBRIO CHOLERAE
	1:25 p.m.	7785: PREDICTORS OF CHOLERA-RELATED MORTALITY IN HAITI, 2022-2024	
	1:35 p.m.	7786: CHOLERA OUTBREAK RESULTING FROM UNTREATED WATER CONSUMPTION	: A CASE-CONTROL STUDY AND
	1:45 p.m. 7787: A COLORIMETRIC METHOD TO DETECT VIRULENT BACTERIOPHAGE TO VIBRIO		CHOLERAE IN FECAL AND
	1:55 p.m. 7788: ORAL CHOLERA VACCINATION CAMPAIGNS IN HUMANITARIAN CRISES: IMPLEMENTATION AMONG ROHIN		EMENTATION AMONG ROHINGYA
	2:05 p.m.	7789: OPTIMIZING BOIL EXTRACTION AND QPCR FOR VIBRIO CHOLERAE DETECTIO	N IN STOOL: FROM LAB VALIDATION
	2:15 p.m.	7790: 5-YEAR EFFECTIVENESS OF AN ORAL CHOLERA VACCINE IN A CHOLERA OUT	BREAK IN RURAL HAITI
2 p.m 3 p.m.		Career Chats: Scientific Job Hunting in Industry: Differentiating Yourself from the Crowd	Convention Center Level 600 Lobby (Level 600)
2:30 p.m.	3 p.m.	Break	
2:30 p.m 5:15 p.m.		Poster Session C Dismantle	Convention Center - Hall E (Level 800) (Poster Hall)
3 p.m. – 4 p.m.		Mentorship Pop-Up: Clinical Syndromes Around the World	Convention Center – Level 600 Lobby (Level 600)
4 p.m. – 5 p.m.		Mentorship Pop-Up: Youth Voices Driving Advocacy Impact: Making the Case for Noma	Convention Center – Level 600 Lobby (Level 600)

Symposium 144: Th	e Changing Epidemiology of Oropouche Virus in South and Central America	Convention Center - Hall F/G (Level 800)	
3 p.m.	INTRODUCTION		
3:10 p.m.	ENVIRONMENTAL AND EPIDEMIOLOGICAL DRIVERS OF OROPOUCHE VIRUS	S TRANSMISSION IN LETICIA	
3:25 p.m.	DYNAMICS AND ECOLOGY OF A MULTI-STAGE EXPANSION OF OROPOUCHE	VIRUS IN BRAZIL	
3:40 p.m.	MODELING OROPOUCHE VIRUS AND VECTOR ENVIRONMENTAL SUITABILITY	TY: SEASONAL DYNAMICS AND TRANSMISSION	
3:55 p.m.	EMERGENCE OF OROPOUCHE OUTBREAK IN THE DARIEN GAP, PANAMA		
4:10 p.m.	UNRAVELING OROPOUCHE: DISEASE DYNAMICS AND PUBLIC HEALTH IMP	LICATIONS IN BRAZIL	
4:25 p.m.	PHYLOGEOGRAPHIC ANALYSIS OF OROPOUCHE VIRUSES IN COLOMBIA DURING THE 2024 OUTBREAK		
4:35 p.m.	A GROWING THREAT: LESSONS LEARNED FROM OROPOUCHE AND OTHER EMERGENT ORTHOBUNYAVIRUSES		
Symposium 145: Vector-bo The Case of the Shire Valle	orne Diseases at the Interface Between Irrigation and Climate Change: ey in Southern Malawi	Convention Center - Room 701A (Level 700)	
3 p.m.	INTRODUCTION		
3:10 p.m.	EXPLORING THE IMPACTS OF LARGE-SCALE IRRIGATION ON FARMING PRA	ACTICES AND VECTOR-BORNE DISEASE RISK	
3:25 p.m.	PRELIMINARY RESULTS OF CROSS-SECTIONAL PARASITOLOGICAL SURVE	YS FOR MALARIA AND SCHISTOSOMIASIS IN	
3:40 p.m.	UNDERSTANDING MOSQUITO POPULATION DYNAMICS IN THE LOWER SHIF	RE VALLEY PRIOR TO LARGE-SCALE IRRIGATION	
3:55 p.m.	IDENTIFYING AND CHARACTERIZING MALARIA VECTORS AND SCHISTOSON	MIASIS INTERMEDIATE HOSTS BREEDING SITES	
4:10 p.m.	ASSESSING THE SUITABILITY OF ATTRACTIVE TARGETED SUGAR BAITS TO	CONTROL ANOPHELES MOSQUITOES	
Scientific Session 146: Mal	aria - Prevention II	Convention Center - Room 701B (Level 700)	
3 p.m.	7792: ASPIRE TRIAL: EFFECTS OF METRONIDAZOLE PLUS INTERMITTENT F	PREVENTIVE TREATMENT OF MALARIA WITH	

3:55 p.m.

4:10 p.m.

3:10 p.n	7793: PREVENTING POSTPARTUM MALARIA: A STUDY OF ARTEMISININ COMBINATION THERAPY AT TIME OF DELIVERY		
3:20 p.n	7794: KEY LESSONS FROM INTEGRATING SMC AND A COMMUNITY-BASED CATCH-UP STRATEGY FOR PREGNANT WOMEN		
3:30 p.n	7795: STRATEGIC EXPANSION OF SEASONAL MALARIA CHEMOPREVENTION IN SUB-SAHARAN AFRICA: INSIGHTS FROM		
3:40 p.n	7796: UNDERSTANDING AND MAXIMIZING THE COMMUNITY IMPACT OF SEASONAL MALARIA CHEMOPREVENTION		
3:50 p.n	7797: DO PIPERONYLBUTOXIDE-PYRETHROID NETS WORK IN WEST AFRICA? RESULTS FROM A 3-ARM, CLUSTER		
4 p.m.	7798: EVALUATING THE IMPACT OF VECTOR CONTROL SERVICE INTERRUPTIONS: AN INTERRUPTED TIME SERIES		
4:10 p.n	7799: DELIVERY STRATEGIES TO OPTIMIZE ADHERENCE OF POST-DISCHARGE MALARIA CHEMOPREVENTION (PDMC)		
4:20 p.n	7800: ECONOMIC BENEFITS OF MALARIA CONTROL		
•	H Committee on Global Health (ACGH) Symposium I: The Melting Frontier: Convention Center - Room 713 (Level 700, Arctic and Its Global One Health Implications		
3 p.m.	INTRODUCTION		
3:10 p.n	CLIMATE CHANGE IMPACT ON ARCTIC ONE HEALTH		
3:25 p.n	FROM CLIMATE CHANGE TO ARCTIC SUPERBUGS: WHY SHOULD WE FEEL THREATENED?		
3:40 p.n	PANDEMIC THREAT TO ARCTIC INDIGENOUS COMMUNITIES IN CHANGED ENVIRONMENT-A CASE STUDY FROM SÁMI		

INDIGENOUS GENDER PERSPECTIVE AND CLIMATE JUSTICE AMID ARCTIC CLIMATE CHANGE

ROLE OF ACGH AND GTF IN PROMOTING GLOBAL HEALTH AND CLIMATE CHANGE IMPACT IN ASTMH COMMUNITY

Symposium 148: Aspartyl Protease Inhibitors for *Plasmodium* and other Apicomplexan Parasites: From Screening Hits to Clinical Proof of Biology for Malaria

Convention Center - Room 714 (Level 700)

3 p.m.	INTRODUCTION	
3:10 p.m.	3:10 p.m. PHASE 1 CLINICAL TRIALS OF THE ASPARTYL PROTEASE INHIBITOR MK-7602 IN HUMANS 3:30 p.m. ACTIVITY OF MK-7602 AGAINST BLOOD-STAGE <i>P. FALCIPARUM</i> IN A CONTROLLED HUMAN MALARIA INFECTION S	
3:30 p.m.		
3:50 p.m.	MODE OF ACTION AND INHIBITION OF TRANSMISSION BY ASPARTIC F	PROTEASE INHIBITORS IN <i>P. FALCIPARUM</i>
4:10 p.m.	ACTIVITY AND MODE OF ACTION OF ASPARTYL PROTEASE INHIBITOR	S IN TOXOPLASMA AND CRYPTOSPORIDIUM
4:30 p.m.	ACTIVITY AND MODE OF ACTION OF ASPARTYL PROTEASE INHIBITOR	S IN THE APICOMPLEXAN PARASITE BABESIA
Symposium 149: Next-ger New Determinants, and In	eration Antimalarial Drug Resistance: Molecular Approaches, pplications for the Field	Convention Center - Room 715 (Level 700)
3 p.m.	INTRODUCTION	
3:10 p.m.	THE RESISTANCE PROFILE OF THE ANTIMALARIAL CANDIDATE ZY194	89
3:25 p.m.	ANTIMALARIAL DRUG RESISTANCE IN EASTERN AFRICA	
3:40 p.m.	HIGH-THROUGHPUT YEAST-BASED DIRECTED EVOLUTION TO EXPLOR	RE THE MUTATIONAL LANDSCAPE OF <i>PLASMODIUM</i>
3:55 p.m.	OVERCOMING HALOFUGINONE RESISTANCE: UNCOVERING NEXT GEN	IERATION <i>PLASMODIUM FALCIPARUM</i> PROLYL-TRNA
4:10 p.m.	BREAKING BARRIERS IN MALARIA RESEARCH: GENOMICS, RESISTAN	CE AND HUMAN SUSCEPTIBILITY
4:25 p.m.	NEW GENETIC APPROACHES FOR ANTIMALARIAL TARGET DISCOVER	Y AND VALIDATION
Scientific Session 150: Res	spiratory Infections I	Convention Center - Room 716 (Level 700)
3 p.m.	7801: QUANTIFYING UNDETECTED TUBERCULOSIS IN ETHIOPIA USIN	G A NOVEL GEOSPATIAL MODELLING APPROACH

Wednesday, November 12 Room Name

3:10 p.m.	7802: EVALUATION OF CRISPR-BASED DETECTION OF CELL-FREE BACTERIAL DNA IN PLASMA FOR DIAGNOSIS OF
3:20 p.m.	7803: FEASIBILITY OF USING FOCUSED ULTRASOUND TECHNOLOGY FOR RAPID RELEASE OF MYCOBACTERIUM DNA IN
3:30 p.m.	7804: RISK OF DEATH FOLLOWING TUBERCULOSIS DIAGNOSIS AND TREATMENT COMPLETION IN THE 100 MILLION
3:40 p.m.	7805: HOST PLASMA PROTEIN BIOMARKERS FOR DIAGNOSING TUBERCULOSIS DISEASE IN FEBRILE ADULTS PRESENTING
3:50 p.m.	7806: TOWARD ENHANCEMENT OF TUBERCULOSIS DETECTION: EVALUATING LAM POC TESTS WITH EXHALED BREATH
4 p.m.	7807: TRAJECTORIES OF LUNG FUNCTION RECOVERY IN GAMBIAN CHILDREN AND ADOLESCENTS FOLLOWING
4:10 p.m.	7808: MAPPING BCG VACCINATION COVERAGE IN AFRICA, 1990-2022: A NOVEL SPATIOTEMPORAL MODELLING STUDY
4:20 p.m.	7809: EVALUATING SOCIAL CAPITAL AND SUPPORT NETWORKS OF 2382 PEOPLE WITH TUBERCULOSIS (PTB): A CROSS
4:30 p.m.	7810: EVALUATING LINEAGE SPECIFIC RESPONSE TO TUBERCULOSIS TREATMENT REGIMENS USING
C 4 E 4 . I I	

Symposium 151: Uncovering the Hidden Burden of Acute Febrile Illness and Their Infectious Causes in Rural South and Southeast Asia Convention Center - Room 717 (Level 700)

3 p.m.	INTRODUCTION
3:10 p.m.	AN INTRODUCTION TO THE SOUTH AND SOUTHEAST ASIAN COMMUNITY-BASED TRIALS NETWORK (SEACTN)
3:15 p.m.	USING SERO-DIAGNOSIS TO DETERMINE BURKHOLDERIA PSEUDOMALLEI AS A CAUSE OF ACUTE FEBRILE ILLNESS
3:30 p.m.	ILLUSTRATING THE BURDEN OF SCRUB TYPHUS IN RURAL COMMUNITIES THROUGH INTER-CONNECTED HOUSEHOLD
3:45 p.m.	CHARACTERIZING DEATHS ASSOCIATED WITH FEBRILE ILLNESS IN RURAL SOUTH AND SOUTHEAST ASIA, FINDINGS FROM
4 p.m.	PREDICTORS OF SEVERITY IN CHILDREN WITH FEBRILE ILLNESS
4:15 p.m.	DEVELOPMENT AND ASSESSMENT OF NOVEL POINT-OF-CARE DIAGNOSTICS IN LOW-RESOURCE SETTINGS

Symposium 152: Delaye	d (Post-Intervention) Malaria - Should This Be a Concern?	Convention Center - Room 718A (Level 700)
3 p.m.	INTRODUCTION	
3:10 p.m.	A BRIEF REVIEW OF THE EVIDENCE THAT DELAYED (POST-INTERVE	NTION) MALARIA SHOULD BE A CONCERN
3:20 p.m.	THE INCIDENCE OF MALARIA IN CHILDREN WHO PARTICIPATED IN A	A FIVE-YEAR TRIAL OF RTS,S/AS01E AND SMC
3:40 p.m.	EXPLORATION OF THE FACTORS THAT INFLUENCED THE RISK OF M	IALARIA IN CHILDREN WHO PARTICIPATED IN A FIVE
4 p.m.	SEROLOGICAL FINDINGS IN CHILDREN WHO PARTICIPATED IN A FIV	/E-YEAR TRIAL OF RTS,S/AS01E AND SMC
4:20 p.m.	OPTIONS OF MEASURES TO CONTROL DELAYED (POST-INTERVENT)	ON MALARIA IN CHILDREN
Scientific Session 153: N	Nematodes: Epidemiology, Diagnostics, and Treatment	Convention Center - Room 718B (Level 700,
3 p.m.	7811: DEVELOPMENT OF NOVEL DIAGNOSTIC TARGETS FOR DRACU	NCULUS MEDINENSIS
3:10 p.m.	7812: EFFICACY OF ANTHELMINTICS AND GENETIC RESISTANCE MA	ARKERS OF BENZIMIDAZOLES IN HUMAN AND CANINE
3:20 p.m.	7813: LONGITUDINAL HIGH PREVALENCE OF INTESTINAL PARASITE	S IN PRESCHOOL CHILDREN DESPITE ANTI-PARASITIC
3:30 p.m.	7814: SOIL-TRANSMITTED HELMINTHS (STH) AND SCHISTOSOMIASI	S (SCH) PREVALENCE AND INTENSITY IN CROSS
3:40 p.m.	7815: ASSESSING THE BURDEN OF HOOKWORM SPECIES AND STRO	ONGYLOIDES STERCORALIS IN VANUATU: THE ROLE OF
3:50 p.m.	7816: SOIL TRANSMITTED HELMINTHES (STHS) AND URINARY TRAC	CT INFECTIONS (UTIS) AMONGST PRE-SCHOOL
4 p.m.	7817: GEOSTATISTICAL ANALYSIS OF NATIONAL SOIL-TRANSMITTED	HELMINTH SURVEYS IN TIMOR-LESTE 2012-2021
4:10 p.m.	7818: OPTIMIZING COMMUNITY HEALTH WORKERS AND NON-BIOME	EDICAL APPROACHES TO ASSESS THE BURDEN
4:20 p.m.	7819: IMPACT OF MASS DRUG ADMINISTRATION FOR PARASITIC WO	ORM INFECTION ON IRON-DEFICIENCY ANEMIA
4:30 p.m.	7820: HOW DOES DUNG BURIAL BY COPROPHAGOUS BEETLES MOD	DIFY INFECTIOUS STRONGYLE NEMATODE LARVAE?

Wednesday, November 12

Wednesday, November 12 Room Name

	3 p.m.	INTRODUCTION	
	3:10 p.m.	PRO: TRAVELERS WITH A HIGH ENOUGH BENEFIT-RISK RATIO FOR PREVENT	ION OF DISEASE SHOULD RECEIVE A
	3:25 p.m.	CON: TRAVELERS WITH A HIGH ENOUGH BENEFIT-RISK RATIO FOR PREVENT	ION OF DISEASE SHOULD RECEIVE A
	3:40 p.m.	AMPHOTERICIN IS THE PREFERRED THERAPY FOR NEW WORLD LEISHMANIA	SIS
	3:55 p.m.	MILTEFOSINE IS THE PREFERRED THERAPY FOR NEW WORLD LEISHMANIAS	S
	4:10 p.m.	MODERATOR: CLINICAL TROPICAL MEDICINE DEBATES	
Scientif	ic Session 155: Virus	ses - Transmission Biology Pathogenesis and Animal Models	Convention Center - Room 801B (Level 800
	3 p.m.	7821: VECTOR COMPETENCE OF ST. LOUIS ENCEPHALITIS VIRUS IN CALIFOR	NIA CULEX TARSALIS AND CULEX
	3:10 p.m.	7822: RHESUS MACAQUES MODEL HUMAN MAYARO VIRUS DISEASE AND TRA	NSMIT TO AEDES AEGYPTI MOSQUITOES
	3:20 p.m.	7824: PRESENCE AND PERSISTENCE OF MONKEYPOX VIRUS DNA IN ANATOM	IC SITES AND BODY FLUIDS
	3:30 p.m.	7825: THE GOOD, THE BATV, AND THE UGLY: FIRST REPORT OF BATV VECTOR	COMPETENCE IN CULEX
	3:40 p.m.	7826: CHARACTERIZING THE ROLE OF VIRAL GENOTYPE AND TICK POPULATI	ON IN POWASSAN-TICK INTERACTIONS
	3:50 p.m.	7827: ACUTE KIDNEY INJURY AND ELECTROLYTE ABNORMALITIES IN EBOLA	VIRUS DISEASE: RETROSPECTIVE ANALYSIS
	4 p.m.	7828: SOLUBLE TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1 IS	ASSOCIATED WITH HEMOCONCENTRATION
	4:10 p.m.	7829: CONSERVED RESIDUES IN THE ORTHOFLAVIVIRUS ENVELOPE PROTEIN	SERVE A DUAL PURPOSE: TO CONTROL
	4:20 p.m.	7830: GENDER DIFFERENCES IN A MOUSE MODEL OF CHRONIC CHIKUNGUNY	A VIRUS DISEASE

	3 p.m.	7831: THE MALARIA VECTOR GENOME OBSERVATORY - DATA AND TOOLS	TO SUPPORT GENOMIC SURVEILLANCE AND
	3:10 p.m.	7832: POPULATION GENETICS OF AEDES AEGYPTI POPULATIONS ACROSS	S WEST AFRICA: A PILOT PROJECT FROM THE
	3:20 p.m.	7833: INTRONIC HOMING GENE DRIVES: A NOVEL STRATEGY FOR FEMALE	E-SPECIFIC LETHALITY OR STERILITY BASED
	3:30 p.m.	7834: THE ARGININOSUCCINATE LYASE GENE EXACERBATES PYRETHROI	D RESISTANCE IN THE MAJOR AFRICAN
	3:40 p.m.	7835: WHOLE GENOME SEQUENCE DATA REVEALS EVIDENCE OF INSECTI	CIDE RESISTANCE SELECTION IN AN
	3:50 p.m.	7836: MOSQUITO SALIVA ENHANCES PRO-VIRAL VASCULAR BARRIER LE	AKAGE THROUGH DIRECT MODULATION OF
	4 p.m.	7837: TRACKING THE SPREAD OF ANOPHELES STEPHENSI P47REC VECT	OR-PARASITE COMPATIBILITY PROTEIN VARIANT
	4:10 p.m.	7838: INTEGRATING GENOMICS, REMOTE SENSING, AND MACHINE LEARN	IING TO PREDICT THE ENVIRONMENTAL
	4:20 p.m.	7839: COMBINED POPULATION DIVERSITY OF WOLBACHIA STRAINS AND	THEIR HOST, ANOPHELES DEMEILLONI
	4:30 p.m.	7840: MATCHING ANOPHELES MOSQUITO BLOOD MEALS TO HUMAN HOS	TS TO IDENTIFY IMPORTANT TRANSMISSION
ientifi	c Session 157: Bact	eriology: AMR and Other Enteric Infections	Convention Center - Room 602 (Level 600)
	3 p.m.	7841: ENVIRONMENTAL DETERMINANTS OF CAMPYLOBACTER INFECTION	N IN CHILDREN UNDER AGE 5: A BAYESIAN
	3:10 p.m.	7842: ADDRESSING ANTIMICROBIAL RESISTANCE RESEARCH GAPS IN SU	JB-SAHARAN AFRICA - A ONE HEALTH APPROACH
	3:20 p.m.	7843: WEATHER VARIABLES AS PREDICTORS OF CRYPTOSPORIDIUM-ATT	TRIBUTED ACUTE DIARRHEA AMONGST CHILDREN.
	3:30 p.m.	7844: CLINICAL PREDICTION MODEL FOR VIRAL ETIOLOGY OF ACUTE DIA	RRHEA IN US CHILDREN PRESENTING FOR
	3:40 p.m.	7845: CHARACTERIZATION OF THE ENZYMATIC ACTIVITIES OF CULTURED	HUMAN FECAL BACTERIA AND THEIR
	3:50 p.m.	7846: ANTIMICROBIAL-RESISTANT BACTERIA FROM POST-MORTEM CULT	URE ISOLATES IN CHILD HEALTH AND
	4 p.m.	7847: ANTIBIOTIC USE AND ADHERENCE TO THE WHO AWARE GUIDELINE	ES AMONG PATIENTS WITH INFLUENZA-LIKE

Wednesday, November 12			Room Name	
	4:10 p.m.	7848: BURDEN AND ANTIBIOTIC RESISTANCE OF KLEBSIELLA PNEUMONIAE	IN INVASIVE AND FATAL PEDIATRIC	
	4:20 p.m. 7849: INCREASED COLONIZATION WITH ANTIBIOTIC RESISTANT BACTERIA IN THE GENITOURINARY TRACT OF		THE GENITOURINARY TRACT OF PREGNANT	
	4:30 p.m.	7850: PROCALCITONIN GUIDED ANTIBIOTIC DE-ESCALATION IN ADULT SEPSI	S PATIENTS IN AN LMIC WITH A HIGH	
4:45 p.m 5:	15 p.m.	Break		
CIVE STREAMING	osium 158: Advanc	es in the Diagnosis and Treatment of Congenital Chagas Disease	Convention Center - Hall F/G (Level 800)	
	5:15 p.m.	INTRODUCTION		
	5:25 p.m.	MOLECULAR MECHANISMS OF VERTICAL TRYPANOSOMA CRUZI TRANSMISS	ION	
	5:40 p.m.	THE IMPACT OF TRYPANOSOMA CRUZI DTUS ON MOLECULAR DIAGNOSIS FO	R PREGNANT WOMEN, NEONATES AND THE	
	5:55 p.m.	TREATING CONGENITAL CHAGAS DISEASE IN THE NEWBORN AND MISSED PE	EDIATRIC CASES: LESSONS LEARNED	
	6:10 p.m.	CONTEMPORARY AND CHANGING CLINICAL EPIDEMIOLOGY OF CONGENITAL	CHAGAS DISEASE: FINDINGS FROM ~20 YEARS	
	6:25 p.m.	NEXT GENERATION DIAGNOSTICS FOR CONGENITAL CHAGAS DISEASE: PREL	IMINARY FINDINGS FROM A TWO-YEAR STUDY	
	6:40 p.m.	ACCESSING DIAGNOSIS AND TREATMENT FOR CONGENITAL CHAGAS DISEAS	E	
Symposium	159: Climate Chang	e and Neglected Tropical Diseases: Challenges and Solutions	Convention Center - Room 701A (Level 700)	
	5:15 p.m.	INTRODUCTION		
	5:25 p.m.	OVERVIEW OF CLIMATE CHANGE AND NEGLECTED TROPICAL DISEASES: A SY	YSTEMATIC REVIEW	
	5:45 p.m.	OVERVIEW OF CLIMATE CHANGE AND NEGLECTED TROPICAL DISEASES: A SY	YSTEMATIC REVIEW	
	6:05 p.m.	CLIMATE CHANGE AND INFECTIOUS DISEASE: THE INTERNATIONAL TASK FO	RCE	

Wednesday, November 12	2	Room Name
6:25 p.m.	PREVENTION AND MANAGEMENT STRATEGIES FOR NTDS IN A CHANGING	WORLD
6:45 p.m.	NTDS IN POLYCRISIS SETTINGS: EARLY INSIGHTS FROM THE PREPARE-CO	PROJECT
Scientific Session 160: Malari	a - Pathogenesis of the Brain, Blood and Beyond	Convention Center - Room 701B (Level 700)
5:15 p.m.	7851: NOVEL SPATIAL OMICS AND DATA-DRIVEN TOOLS TO STUDY HOST-P	PARASITE INTERACTIONS IN THE PLASMODIUM
5:25 p.m.	7852: ALL ROADS LEAD TO ROME: REGULATION OF MALARIA EXACERBATION	ON BY THE GUT MICROBIOTA
5:35 p.m.	7853: NEUREGULIN-1 MITIGATES HEME-INDUCED INJURY IN IPSC-DERIVE	D ENDOTHELIAL CELLS FROM CHILDREN
5:45 p.m.	7854: ANTIBODY RESPONSES REVEAL INSIGHTS INTO VAR2CSA EXPRESSI	ION AND CEREBRAL MALARIA PATHOGENESIS
5:55 p.m.	7855: CEREBROSPINAL FLUID TAU ASSOCIATION WITH PROLONGED COMA	A AND NEUROLOGICAL DEFICIT AT DISCHARGE
6:05 p.m.	7856: SPATIALLY RESOLVED CELL ATLASES OF THE BM AND SPLEEN REVE	EAL MARKED HETEROGENEITY IN TISSUE
6:15 p.m.	7857: IMPAIRED JAK2 SIGNALING CONTRIBUTES TO INEFFECTIVE ERYTHR	ROPOIESIS IN CHILDHOOD SEVERE MALARIAL
6:25 p.m.	7858: UNDERSTANDING THE COMPLEX FORMATION OF FALSTATIN; AN END	DOGENOUS MACROMOLECULAR INHIBITOR
6:35 p.m.	7859: NEGLECTED PATHOGEN PLASMODIUM MALARIAE: HOST PARASITAE	MIA AND RED BLOOD CELL INVASION
6:45 p.m.	7860: ROSETTING OF PLASMODIUM KNOWLESI-INFECTED RED BLOOD CEL	LS
	MH Committee on Global Health (ACGH) Symposium II: Advancing mRNA obal South - Opportunities, Challenges, and Pathways to Equitable Access	Convention Center - Room 713 (Level 700)
5:15 p.m.	INTRODUCTION	
5:25 p.m.	OPENING KEYNOTE: CURRENT STATE OF MRNA TECHNOLOGIES IN THE GL	OBAL SOUTH
5:40 p.m.	MRNA TECHNOLOGY AND ITS POTENTIAL FOR GLOBAL SOUTH	
5:55 p.m.	LEVERAGING GLOBAL HEALTH DIPLOMACY TO PROMOTE CONDUCIVE MRN	NA POLICY AND REGULATORY FRAMEWORK

Wednesday, November 12 Room Name

	6:10 p.m.	POTENTIAL OF MRNA IN ADDRESSING COUNTRY DISEASE BURDENS	
	6:25 p.m.	ACGH BUSINESS MEETING	
	6:40 p.m.	NETWORKING RECEPTION	
		the Fight Against NTDs: Financing, Local Investment, or Long-Term Impact	Convention Center - Room 714 (Level 700
	5:15 p.m.	INTRODUCTION	
	5:25 p.m.	STRATEGIES FOR SECURING LONG-TERM INVESTMENT IN NTD PROGRA	MS IN LMICS
	5:40 p.m.	BEYOND DONOR FUNDING: STRENGTHENING DOMESTIC RESOURCE MO	BILIZATION AND NEW LEADERSHIP FOR NTDS
	5:55 p.m.	IDENTIFYING ALTERNATIVE AND INNOVATIVE APPROACHES TO FUND N	IEW PRODUCTS BEYOND THE DRUG DONATION
	6:10 p.m.	POLICY AND INNOVATIONS FOR FINANCING AND SUSTAINING NTD PRO	GRAMS
cientif	ıc Session 163: Mala	ria- Drug Development and Clinical Trials	Convention Center - Room 715 (Level 700
	5:15 p.m.	7861: A HIGH-THROUGHPUT PLATFORM TO IDENTIFY NEW ANTIMALARI	AL COMPOUNDS TARGETING MOSQUITO STAGES
	5:25 p.m.	7862: PRECLINICAL CHARACTERIZATION OF A POTENT ANTIMALARIAL A	AGAINST LIVER, BLOOD, AND MOSQUITO STAGES
	5:35 p.m.	7863: AN EFFECTIVE ANTIMALARIAL KALIHINOL ANALOG TARGETS PLA	SMODIUM FALCIPARUM APICOPLAST AND
	5:45 p.m.	7864: MULTI-OMICS ELUCIDATION OF THE TARGETS OF NEW ANTIMALA	RIAL CANDIDATES FROM MALARIA LIBRE
	5:55 p.m.	7865: NOVEL COMBINATION OF PFCYTB INHIBITORS SHOWS PROMISE F	FOR TREATMENT OF BLOOD STAGE PLASMODIUM
	6:05 p.m.	7866: EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF I	V CIPARGAMIN
	6:15 p.m.	7867: AN INVESTIGATION OF INE963 FOR THE SINGLE DOSE TREATMEN	T OF UNCOMPLICATED <i>PLASMODIUM</i>

6:25 p.m.	7868: AN INVESTIGATION OF SINGLE DOSE TREATMENT OF UNCOM	IPLICATED MALARIA USING A NON-ARTEMISININ
6:35 p.m.	7869: FIRST-IN-HUMAN, SINGLE CENTRE, OPEN-LABEL, DOSE-ESCA	ALATION PHASE 1 STUDY IN HEALTHY ADULTS TO
6:45 p.m.	7870: KALUMA - A PIVOTAL PHASE III TRIAL TO EVALUATE THE EFF	FICACY, SAFETY AND TOLERABILITY OF THE NOVEL
ientific Session 164: Res	piratory Infections II	Convention Center - Room 716 (Level 70
5:15 p.m.	7871: SOLAR POWERED COMPRESSED OXYGEN CYLINDER FILLING	TO ADDRESS MEDICAL OXYGEN INSECURITY IN UGAND
5:25 p.m.	7872: BREAD: A PRE-PROCESSING PIPELINE AND R PACKAGE TO A	DDRESS TECHNICAL VARIATION IN SEROLOGICAL DATA
5:35 p.m.	7873: ANTHROPOMETRIC INDICES OF UNDERNUTRITION AS PREDI	CTORS OF MORTALITY IN UGANDAN CHILDREN WITH
5:45 p.m.	7874: DEEP LEARNING-GUIDED CARTOGRAPHY METHOD FOR ANAL	YZING PATTERNS AND MOLECULAR DETERMINANTS
5:55 p.m.	7875: EFFECTIVENESS OF A CLINICAL DECISION SUPPORT ALGORI	THM ON DECREASING UNNECESSARY ANTIBIOTIC USE.
6:05 p.m.	7876: ANTIBIOTIC USE ACCORDING TO THE WORLD HEALTH ORGAN	NIZATION AWARE CLASSIFICATION AND ANTIMICROBIAL
6:15 p.m.	7877: ASSESSING POLICY DECISIONS AND IMPLEMENTATION IMPA	CT OF THE PNEUMOCOCCAL CONJUGATE VACCINE
6:25 p.m.	7878: PNEUMOCOCCAL SEROTYPE REPLACEMENT IN THE POST-PC	CV ERA: IMPLICATIONS FOR VACCINE POLICY IN
6:35 p.m.	7879: EVALUATION OF A MEASLES IGM RAPID DIAGNOSTIC TEST FO	OR USE IN MEASLES SURVEILLANCE PROGRAMS:

5:15 p.m.	INTRODUCTION	
5:25 p.m.	INTRODUCTION TO MELIOIDOSIS PART 1 AND EPIDEMIOLOGY OF MELIOIDOSIS IN SOUTH ASIA (INDIA)	
5:35 p.m.	INTRODUCTION TO MELIOIDOSIS- PART 2	
5:45 p.m.	EPIDEMIOLOGY IN SOUTH ASIA- NEPAL	

Wednesday	, November 1	12	Room Name
	5:55 p.m.	EPIDEMIOLOGY IN SOUTH ASIA- SRI LANKA	
	6:05 p.m.	MELIOIDOSIS IN SOUTH ASIA- BANGLADESH	
	6:15 p.m.	CLINICAL PROFILE AND DIAGNOSIS OF MELIOIDOSIS	
	6:35 p.m.	TREATMENT OF MELIOIDOSIS	
		fass Vaccination with the Pre-erythrocytic Vaccine R21 rica: Early Results	Convention Center - Room 718A (Level 700)
	5:15 p.m.	INTRODUCTION	
	5:25 p.m.	TRIAL DESIGN AND STATISTICAL ANALYSIS	
	5:35 p.m.	SAFETY AND EFFICACY OF MASS VACCINATION WITH R21 IN THE GAMBIA	
	5:45 p.m.	SAFETY AND EFFICACY OF MASS VACCINATION WITH R21 IN BURKINA FASO	
	5:55 p.m.	PERCEPTION AND ACCEPTABILITY OF MASS VACCINATION WITH R21	
	6:10 p.m.	MODELLING THE IMPACT OF MASS VACCINATION WITH R21	
	6:25 p.m.	COST AND COST-EFFECTIVENESS OF MASS VACCINATION WITH R21	
Scientific Ses	sion 167: Helm	inth Infections: Immunology, Diagnostics and Treatment	Convention Center - Room 718B (Level 700)
	5:15 p.m.	7881: A PHASE II PROOF-OF-EFFICACY TRIAL OF SM-TSP-2/ALHYDROGEL FOR	R INTESTINAL SCHISTOSOMIASIS IN
	5:25 p.m.	7882: SOLUBLE EGG ANTIGEN OF SCHISTOSOMA JAPONICUM AMELIORATES	ANDROGENETIC ALOPECIA IN MICE VIA
	5:35 p.m.	7883: SCHISTOSOMA JAPONICUM PROTEIN 40 ATTENUATES GRAFT REJECTIO	ON AND PROLONGS GRAFT SURVIVAL

6:35 p.m.	7889: UNDERSTANDING TRANSMISSION VERSUS INFECTION DYNAMICS OF SCHISTOSOMA MANSONI PRE- AND POST
6:25 p.m.	7888: NEXT GENERATION DRUG TO TREAT SCHISTOSOMIASIS
6:15 p.m.	7887: PHARMACOLOGICAL AND COMPUTATIONAL PROFILING OF A SEROTONIN-RESPONSIVE GPCR REVEALS A NOVEL
6:05 p.m.	7886: SCHISTO-SCORE: DEVELOPMENT OF A MULTIVARIABLE PREDICTION MODEL FOR THE DIAGNOSIS OF SCHISTOSOMA
5:55 p.m.	7885: A CAS13-BASED ASSAY FOR DETECTION OF CIRCULATING MICRORNAS (MIRNAS) ASSOCIATED WITH
5:45 p.m.	7884: CHANGING THE PARADIGM: DEVELOPMENT AND VALIDATION OF A SEROLOGICAL POINT-OF-CARE TEST

Scientific Session 168: Global Health: Ensuring Rigorous Research and Its Impact (Research Ethics, Training, Translation, Policy, and Decolonization)

Convention Center - Room 801A (Level 800)

, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
5:15 p.m.	7891: POWER IMBALANCES IN TROPICAL MEDICINE JOURNALS: AN ANALYSIS OF EDITORIAL BOARD REPRESENTATION
5:25 p.m.	7892: RESEARCH OPPORTUNITIES AND BARRIERS FOR MEDICAL STUDENTS IN SUB-SAHARAN AFRICA: A FOCUS ON NIGERIA
5:35 p.m.	7893: EVALUATION OF THE BANGKOK HEALTH RESEARCH AND ETHICS INTEREST GROUP: EXPERIENCES OF GROUP
5:45 p.m.	7894: DEVELOPING AN INNOVATION AND ENTERPRISE FRAMEWORK FOR TRANSLATING UK-DRIVEN GLOBAL HEALTH
5:55 p.m.	7895: ADAPTING THE CRANKY UNCLE VACCINE GAME FOR PAKISTAN - A CO-DESIGN APPROACH TO COMBAT
6:05 p.m.	7896: LASTING IMPACT OF INCLUSION: WHAT IF PARTICIPATORY CO-CREATION APPROACHES HOLD THE KEY TO
6:15 p.m.	7897: DECOLONIZING HIV STIGMA REDUCTION: A COMMUNITY-BASED, CULTURALLY GROUNDED INTERVENTION
6:25 p.m.	7898: APPLYING AN EQUITY-GENDER LENS TO ADDRESS THE MALARIA BURDEN IN LIBERIA: INSIGHTS FROM THE 2024
6:35 p.m.	7899: COMPARATIVE ANALYSIS OF SOCIAL AND DIGITAL VULNERABILITY INDICES IN ETHIOPIA AND UGANDA: GENDER
6:45 p.m.	7900: BEHIND THE SILENCE: EXPLORE MENTAL HEALTH INEQUITIES AND HUMAN RIGHTS AMONG RURAL WOMEN

Wednesday, November 12 Room Name

	5:15 p.m.	INTRODUCTION	
	5:25 p.m.	PANEL DISCUSSION	
Scienti	hc Session 170: Mos	quitoes- Biology, Physiology and Immunity	Convention Center - Room 803 (Level 800)
	5:15 p.m.	7901: DECODING MOSQUITO FEEDING FOR VECTOR CONTROL	
	5:25 p.m.	7902: THE IMPLICATION OF SAMSP1, SPOROZOITE-ASSOCIATED MOSQUI	TO SALIVA PROTEIN, AS A HOST FACTOR FOR
	5:35 p.m.	7903: INCORPORATING MULTIPLE BLOOD MEALS TO ESTIMATE REALIZED	D BITING RATES AND DENGUE TRANSMISSION
	5:45 p.m.	7904: REAL-TIME MOSQUITO BITING BEHAVIOR ABOVE AND BELOW HUM	IAN HOST SKIN
	5:55 p.m.	7905: PERIPHERAL AND DERMAL IMMUNE RESPONSES FOLLOWING SEG	QUENTIAL ANOPHELES/AEDES MOSQUITO BITE
	6:05 p.m.	7906: IMPACT OF HUMIDITY AND TEMPERATURE FLUCTUATIONS ON THE	E EXPRESSION OF ANOPHELES GENETIC TARGET
	6:15 p.m.	7907: ASSESSING VERTICAL TRANSFER OF A GENE DRIVE TARGETING D	OUBLESEX AMONG SIBLING SPECIES OF
	6:25 p.m.	7908: ANOPHELES MOSQUITOES EXPOSED TO LONG-ACTING ANTIMALAR	RIALS VIA DRUG-SPIKED BLOODMEAL ABSORB
	6:35 p.m.	7909: A PILOT STUDY TO DETERMINE THE IMPACT OF DIRECT ORAL ANTI	ICOAGULANT TREATMENT ON THE PHYSIOLOGY
	6:45 p.m.	7910: HIJACKING MOSQUITOES: INFECTION DYNAMICS OF DENGUE VIRU	JS IN THE MOSQUITO BRAIN
Scienti	nc Session 171: Bact	eriology: Shigella and Salmonella	Convention Center - Room 602 (Level 600)
	5:15 p.m.	7911: VACCINES TO PREVENT ANTIMICROBIAL RESISTANCE - THE IMPAC	CT OF TYPHOID CONJUGATE VACCINES ON

7:15 p.m 9 p.	m.	Special Session 173: Clinical Pub Trivia Night	InterContinental Hotel - Ballroom A (Lower Level)
6 p.m 7 p.m.		Ben Kean Fellowship Reception - By Invitation Only	Convention Center - Room 707 (Level 700)
6	6:45 p.m.	7920: GENOMIC CHARACTERIZATION OF CEFTRIAXONE RESISTANCE AN	ND ATYPICAL LACTOSE FERMENTATION
6	6:35 p.m.	7919: THE THREAT OF INVASIVE NON-TYPHOIDAL SALMONELLA IN GHA	ANA: EVIDENCE FROM EIGHT YEARS OF
6	6:25 p.m.	7918: PERIOD PREVALENCE AND RISK FACTORS OF RESPIRATORY TRA	CT INFECTIONS IN THE 3 MONTHS FOLLOWING
6	6:15 p.m.	7917: AN UPDATED GLOBAL SYSTEMATIC REVIEW ON SALMONELLA TY	'PHI ANTIMICROBIAL RESISTANCE
6	6:05 p.m.	7916: SAFETY PROFILE, CLINICAL RESPONSES AND OUTCOMES FROM	A FIRST-IN-HUMAN <i>SALMONELLA TYPHIMURIUM</i>
-	5:55 p.m.	7915: PERFORMANCE OF FECAL INFLAMMATORY BIOMARKERS TO IDE	NTIFY WATERY SHIGELLOSIS: FINDINGS FROM
-	5:45 p.m.	7914: SAFETY AND IMMUNOGENICITY OF LOCALLY PRODUCED TYPHOI	D CONJUGATE VACCINE IN BANGLADESH: A
5	5:35 p.m.	7913: PERSISTENCE OF IMMUNE RESPONSE AT 4-5 YEARS FOLLOWING	A SINGLE DOSE TYPHOID CONJUGATE VACCINE
5	5:25 p.m.	7912: POST-INTRODUCTION IMPACT OF THE TYPHOID CONJUGATE VAC	CINE ON TYPHOID FEVER IN MALAWI - MITIMA

Thursday, November 13		Room Name
7 a.m. – 10:30 a.m.	Registration	Convention Center - Registration Lobby Area (Level 600)
7 a.m Noon	Speaker Ready Room	Convention Center - Room 703 (Level 600)
7 a.m 1 p.m.	Meeting Sign-Up Room	Convention Center - Room 711 (Level 700)
7 a.m 1 p.m.	Nursing Mothers Room Please pick up the room key at the Registration Desk, Level 6	Convention Center – Room 702 (Level 700)
7 a.m 1 p.m.	Prayer Room	Convention Center - Room 810 (Level 800)
7 a.m 8 a.m.	ASTMH Board of Directors Meeting	Convention Center - Room 709 (Level 700)
	Onchocerciasis Elimination is in Sight: A Multi-country Snapshot of Progress ion of Transmission in Africa and Lessons for the Road Ahead	Convention Center - Hall F/G (Level 800)

8 a.m.	INTRODUCTION	
8:10 a.m.	SESSION OVERVIEW - TRIALS, TRIBULATIONS AND CELEBRATIONS ALONG THE ROAD TO OV ELIMINATION	
8:15 a.m.	PROGRESSING TOWARDS ONCHOCERCIASIS ELIMINATION THRESHOLDS IN AREAS WITH EXTREMELY HIGH BASELINE	
8:25 a.m.	ONCHOCERCIASIS ELIMINATION MAPPING IN GUINEA: RESULTS AND DECISIONS FROM FIVE HEALTH DISTRICTS	
8:35 a.m.	RESULTS FROM ONCHOCERCIASIS ELIMINATION MAPPING: THE FIRST EVER 0V16 SURVEY COMPLETED IN MOZAMBIQUE	
8:45 a.m.	ELIMINATION OF ONCHOCERCIASIS IN BENIN: THE COUNTRY'S LONG ROAD TO AN UPDATED EPIDEMIOLOGICAL	
8:55 a.m.	ELIMINATION OF ONCHOCERCIASIS IN BENIN: THE COUNTRY'S LONG ROAD TO AN UPDATED EPIDEMIOLOGICAL	

ANSMISSION FIVE YEARS AFTER ELIMINATION THRESHOLD WERE THOUGHT TO HAVE
ANSMISSION FIVE YEARS AFTER ELIMINATION THRESHOLD WERE THOUGHT TO HAVE
: Multi-modal Insights Convention Center - Room 701A (Level 700)
VERS OF ZOONOSES OF PANDEMIC POTENTIAL NEAR CONSERVATION AREAS IN
ISIONING ON THE EPIDEMIOLOGICAL OUTCOMES OF RODENT-BORNE DISEASES
RIVERS OF PUUMALA HANTAVIRUS IN BANK VOLES
FORESTS AND EMERGING INFECTIOUS DISEASES: SHOULD WE WORRY?
/IRUS SPILLOVER IN HUMAN-DRIVEN ECOSYSTEMS
Convention Center - Room 701B (Level 700)
A CHEMOPREVENTION ON IMMUNOGENICITY OF PNEUMOCOCCAL VACCINATION
IMMUNOREGULATORY RESPONSES TO MALARIA IN KENYAN CHILDREN AND ADULTS
LONAL DYNAMICS SHAPE ASYMPTOMATIC DRY-SEASON PLASMODIUM FALCIPARUM
THE IMMUNE EVASION PHENOTYPIC IMPACT OF MABS TO RH5 IN THE CONTEXT
ENT MEMORY T CELL FORMATION AND FUNCTION FOLLOWING GENETICALLY
W MICROENVIRONMENT FOLLOWING PLASMODIUM INFECTION IMPAIR THE
L SUBSETS IN INDIVIDUALS WITH PERSISTENT ANTIBODY RESPONSE
ONS BETWEEN PLASMODIUM INFECTIONS AND AUTOIMMUNITY IN SUB-SAHARAN

Thursday, November 13 Room Name

	9:20 a.m.	7929: CHARACTERIZING IGG RESPONSES TO 1,307 P. FALCIPARUM PROTEINS IN YOUNG CHILDREN IN BURKINA FASO		
	9:30 a.m.	7930: IGM IS PROMINENT AND ACTIVATES COMPLEMENT IN ACQUIRED TRAI	NSMISSION-BLOCKING IMMUNITY	
Symposium 1	77: Viral Genom	ics and Global Health in the Age of Artificial Intelligence	Convention Center - Room 713 (Level 700	
	8 a.m.	INTRODUCTION		
	8:05 a.m.	HOW AI CAN HELP PREDICT VIRAL EVOLUTION TO ACCELERATE VACCINE AI	ND THERAPEUTIC DESIGN	
	8:25 a.m.	DEEP LEARNING-GUIDED ANTIGENIC MAPPING OF INFLUENZA AND DENGUE	VIRUS	
	8:40 a.m.	INTEGRATING MACHINE LEARNING AND PHYLOGENETIC TOOLS TO PREDICT	NOVEL SARS-COV-2 LINEAGE-DEFINING	
	8:55 a.m.	LEVERAGING AI TO OPTIMIZE DISEASE SURVEILLANCE FOR PANDEMIC SCA	LE GENOMIC EPIDEMIOLOGY	
EDO-		halmic Manifestations of Ebola, Mpox, and Emerging Infectious Diseases: , and Scientific Perspectives	Convention Center - Room 714 (Level 70)	
	8 a m	INTRODUCTION		



8 a.m. INTRODUCTION 8:10 a.m. GENOMIC EPIDEMIOLOGY OF MPOX: STATUS OF THE OUTBREAK AND OCULAR IMPLICATIONS, DEMOCRATIC REPUBLIC... 8:20 a.m. OCULAR MANIFESTATIONS OF MPOX: DISEASE SPECTRUM AND MANAGEMENT, DEMOCRATIC REPUBLIC OF THE CONGO 8:30 a.m. MPOX-ASSOCIATED EYE DISEASE: CLINICAL FINDINGS AND OUTCOMES IN ACUTE AND POST-ACUTE PHASES... 8:40 a.m. IMPACT OF WEATHER VARIABLES ON PATHOGEN DETECTION IN VIRAL CONJUNCTIVITIS WORLDWIDE 8:50 a.m. OCULAR IMMUNE RESPONSES IN EBOLA AND EMERGING INFECTIOUS DISEASES. ONE HEALTH PERSPECTIVES ON OCULAR MANIFESTATIONS OF EMERGING INFECTIOUS DISEASES. 9 a.m.

Thursday, November 1	13	Room Name	
9:10 a.m.	9:10 a.m. EBOLA AND THE EYE: FROM DISEASE UNDERSTANDING TO VISION HEALTH SYSTEMS STRENGTHENING		
9:20 a.m.	POST-ACUTE OCULAR SEQUELAE: OPEN QUESTIONS FOR HOS	T-VIRUS INTERACTIONS	
Symposium 179: Malaria in the Metropolis: Building Global Networks to Address the Expanding Risk of Urban Transmission		Convention Center - Room 715 (Level 700)	
8 a.m.	INTRODUCTION		
8:10 a.m.	BUILDING A GLOBAL NETWORK TO TACKLE MOSQUITO-BORNE	DISEASE RISKS IN AFRICAN CITIES	
8:25 a.m.	URBAN ECOLOGY AND CONTROL OF ANOPHELES STEPHENSI I	N ETHIOPIA: INSIGHTS AND CHALLENGES	
8:40 a.m.	VECTOR BIONOMICS AND TRANSMISSION DYNAMICS OF ANOF	PHELES STEPHENSI IN URBAN AREAS OF GUJARAT, INDIA	
8:55 a.m.	URBAN MALARIA UNDER THE LENS: EPIDEMIOLOGICAL AND E	NTOMOLOGICAL INSIGHTS FROM FIELD STUDIES	
9:10 a.m.	BRIDGING CONTINENTS: LEVERAGING INDIA'S MALARIA AND D	DENGUE SURVEILLANCE AND CONTROL STRATEGIES FOR	
9:25 a.m.	BRIDGING THE EXISTING KNOWLEDGE GAPS AND FORGING NE	W OPPORTUNITIES FOR COLLABORATION	
	nerican Committee of Molecular Cellular and Immunoparasitology (ACMC Vaccines and Treatments	Convention Center - Room 716 (Level 700)	
SUPPORTED WITH FUND	DING FROM BURROUGHS WELLCOME FUND®		

8 a.m.	7931: CHARACTERIZATION OF THE IMMUNE RESPONSES INDUCED BY THE BLOOD-STAGE VACCINE CANDIDATE RH5.2/
8:15 a.m.	7932: ANTIBODY RESPONSES IN CHILDREN RECEIVING SEASONAL MALARIA CHEMOPREVENTION, RTS,S/AS01E
8:30 a.m.	7933: DISTINCT AND CONTRASTING NEUTROPHIL PHENOTYPES AND FUNCTIONAL PROFILES IN HUMAN INFECTIONS WITH

Thursday, November 13	Room Name

	8:45 a.m.	7934: CHARACTERIZATION AND DEVELOPMENT OF SCHISTOSOMA HAEMATOBIUM	CALPAIN-BASED VACCINES: NEXT
	9 a.m. 7935: BMA-LAD-2 AS A POSSIBLE NOVEL THERAPEUTIC AND VACCINE TARGET FOR LYMPHATIC FILARIASIS		R LYMPHATIC FILARIASIS
	9:15 a.m.	7936: CRY-CRY PROTEIN COMBINATIONS AS A NOVEL THERAPEUTIC STRATEGY A	GAINST GASTROINTESTINAL NEMATODES
	9:30 a.m.	7937: SPLEEN-SPARING MANAGEMENT OF SPLENIC ECHINOCOCCOSIS: A SINGLE-	CENTRE EXPERIENCE
8 a.m 9:4	45 a.m.	Late-Breaker Abstract Session 181: Late-Breakers in Clinical and Applied Sciences II	Convention Center - Room 717 (Level 700)
		nectin Mass Drug Administration for Malaria Elimination: andomized Trials in Sub-Saharan Africa	Convention Center - Room 718A (Level 700
	8 a.m.	INTRODUCTION	
	8:10 a.m.	IVERMECTIN AND DIHYDROARTEMISININ-PIPERAQUINE MDA FOR MALARIA CONT	ROL IN THE GAMBIA: RESULTS FROM
	8:25 a.m.	IVERMECTIN AND DIHYDROARTEMISININ-PIPERAQUINE MDA FOR MALARIA CONT	ROL IN THE GAMBIA: RESULTS FROM
	8:40 a.m.	ADJUNCTIVE IVERMECTIN MDA FOR MALARIA CONTROL ON THE BIJAGOS ARCHIF	PELAGO OF GUINEA-BISSAU: RESULTS
	8:55 a.m.	IVERMECTIN MDA WITH COMBINED SEASONAL MALARIA CHEMOPROPHYLAXIS FO	OR MALARIA CONTROL IN BURKINA FASO
	9:10 a.m.	IVERMECTIN MDA WITH COMBINED SEASONAL MALARIA CHEMOPROPHYLAXIS FO	OR MALARIA CONTROL IN BURKINA FASO
	9:25 a.m.	IMPACT OF IVERMECTIN MDA FOR MALARIA IN MOZAMBIQUE AND KENYA: RESUL	TS FROM THE BOHEMIA TRIAL
Symposiur	m 183: Use of Car	diac Evaluation Modalities for Management of Patients with Chagas Disease	Convention Center - Room 718B (Level 700)
	8 a.m.	INTRODUCTION	
	8:05 a.m.	ELECTROCARDIOGRAPHIC CHANGES IN CHAGAS DISEASE: A JOURNEY FROM TYP	PICAL TO ATYPICAL PRESENTATIONS

Thursday, November 13		Room Name
8:25 a.m.	USING ECHOCARDIOGRAPHY IN THE STAGING AND MANAGEMENT OF CH	IAGAS DISEASE PATIENTS
8:45 a.m.	CHARACTERISTICS OF CHAGAS CARDIOMYOPATHY BY CARDIAC MAGNET	FIC RESONANCE IMAGING (CMRI)
9:05 a.m.	ASSESSING MYOCARDIAL INFLAMMATION USING PET-CT TO EVALUATE I	BENZNIDAZOLE TREATMENT RESPONSE
Scientific Session 184: Globa	al Health: Extreme Weather and Climate Change as Global Health Issues	Convention Center - Room 801A (Level 800)
8 a.m.	7938: ADOLESCENT PSYCHOLOGICAL HEALTH, TEMPORAL DISCOUNTING	, AND CLIMATE DISTRESS UNDER INCREASED
8:10 a.m.	7939: SAFEGUARDING COMMUNITY HEALTH WORKERS' MENTAL HEALTH	AND WELLBEING IN THE FACE OF EXTREME
8:20 a.m.	7940: IMPACT OF EXTREME WEATHER EVENTS ON LEPTOSPIROSIS BURE	DEN IN THE CARIBBEAN REGION
8:30 a.m.	7941: EFFECT OF EXTREME HEAT EXPOSURE ON ELECTROLYTE LOSS, DE	HYDRATION, AND HYPOTENSION AMONG
8:40 a.m.	7942: HISTORICAL HEALTHCARE BURDENS ASSOCIATED WITH EXTREME	WEATHER EVENTS AT THE BELAU NATIONAL
8:50 a.m.	7943: EXTREME HEAT AND TEMPERATURE VARIATION TRIGGER STILLBIF	RTH RISK: EVIDENCE FROM CHAMPS
9 a.m.	7944: THE POSSIBLE INFLUENCE OF CLIMATE CHANGE IN THE INCIDENC	E OF PARATUBERCULOSIS
9:10 a.m.	7945: RISING DENGUE RISK WITH INTENSIFIED CLIMATE MODES AND TE	LECONNECTIONS UNDER GREENHOUSE WARMING
9:20 a.m.	7946: DENGUE FEVER TRENDS IN KATHMANDU, NEPAL: A DECADE OF EP	PIDEMIOLOGICAL INSIGHTS FROM A HIGH
9:30 a.m.	7947: PREDICTING DENGUE CASES AND RISK USING HYBRID DEEP LEAR	NING MODELS AND CLIMATE DATA
Symposium 185: Advances i	n HEV Outbreak Detection and Burden Estimation	Convention Center - Room 801B (Level 800)
8 a.m.	INTRODUCTION	
8:10 a.m.	INTRODUCTION: WHY HEV BURDEN MATTERS AND APPROACHES TO GEN	NERATE NEW DATA
8:25 a.m.	ESTIMATING FATAL BURDEN OF HEPATITIS E VIRUS (HEV) USING NATUF	RAL HISTORY VS CAUSES OF DEATH APPROACHES
8:40 a.m.	PERFORMANCE OF RAPID AND CONVENTIONAL DIAGNOSTIC TESTS FOR	HEPATITIS E: INSIGHTS FROM A FIELD

Thursday, November 13 Room Name

	8:55 a.m.	VALIDATION OF A RAPID DIAGNOSTIC TEST (RDT) FOR DETECTION OF HEI	PATITIS E VIRUS (HEV) IN URINE SAMPLES
	9:10 a.m.	THE USE OF SEROLOGICAL DATA TO BETTER UNDERSTAND THE TRANSM	ISSION AND BURDEN OF HEPATITIS E VIRUS.
	9:25 a.m.	HEPATITIS E SURVEILLANCE IN WASTEWATER SAMPLES COLLECTED DU	RING HEPATITIS E OUTBREAKS IN SOUTH SUDAN
		pellents to Prevent Dengue and Malaria: overy to Policy and Rollout Evaluations	Convention Center - Room 803 (Level 800)
	8 a.m.	INTRODUCTION	
	8:10 a.m.	SPATIAL REPELLENTS: FROM ACTIVE INGREDIENT DISCOVERY TO POLICY	Y AND ROLLOUT EVALUATIONS
	8:20 a.m.	SEMI-FIELD SCREENING OF NOVEL NON-PYRETHROID ACTIVE INGREDIEN	ITS FOR SECOND GENERATION SPATIAL
	8:30 a.m.	DATA SYNTHESIS ON SPATIAL REPELLENTS: ENTOMOLOGY, EPIDEMIOLOG	GY, INSECTICIDE RESISTANCE
	8:40 a.m.	SPATIAL REPELLENT SUITABILITY AND EFFECTIVENESS FOR PROTECTIN	G DISPLACED PEOPLE AGAINST VECTOR-BORNE
	8:50 a.m.	TRANSLATING SPATIAL REPELLENT TRIAL EVIDENCE TO NATIONAL SCAL	E-UP IN KENYA, AS WELL AS PRODUCT
	9 a.m.	CHALLENGES TO SPATIAL REPELLENT SCALE-UP AND OPERATIONAL USE	AND MITIGATION STRATEGIES BEING CONSIDERED
	9:10 a.m.	CLINICAL TRIALS IN NIGERIA THAT EXPLORE THE OPERATIONAL USE OF	SPATIAL REPELLENTS IN RURAL AREAS WITH
	9:20 a.m.	ENABLING THE ADOPTION OF SPATIAL EMANATORS WITH MULTIPLE ACT	IVE INGREDIENTS
Sympos	ium 187: From Negl	ect to Action: Results from the Multi-Country Assessment of	Convention Center - Room 602 (Level 600)

Prevalence for Female Genital Schistosomiasis (MAP-FGS)

8 a.m.	INTRODUCTION
8:10 a.m.	DESIGN AND IMPLEMENTATION OF A NOVEL PREVALENCE STUDY ON FEMALE GENITAL SCHISTOSOMIASIS

Thursday, November 13			Room Name
8:2	20 a.m.	MAPPING PREVALENCE OF FGS ACROSS SIX COUNTRIES	
8:4	40 a.m.	MAP-FGS APPROACH TO DIAGNOSIS FOR FGS AND CONCURRENT INFECTIONS	
9:0)5 a.m.	BARRIERS TO FGS INTEGRATION INTO REPRODUCTIVE HEALTH SERVICES: LESSON	IS LEARNED FROM MAP-FGS
9:2	25 a.m.	PERSPECTIVES ON FGS INTEGRATION FROM A NTD PROGRAM MANAGER	
9:45 a.m 10:15	a.m.	Coffee Break	Convention Center - Level 700 Meeting Room Corridor
10:15 a.m 11:15	5 a.m. r (((>)) LIVE STREAMING	Plenary Session 188: Plenary Session IV: Commemorative Lecture	Convention Center - Hall F/G (Level 800)
10:	:15 a.m.	COMMEMORATIVE LECTURE: GLOBAL HEALTH INNOVATION THROUGH NETWORKS OF	PARTNERSHIPS
11:15 a.m 11:30	0 a.m.	Break	
CATION CONTENT	mposium 189: M	Ipox Without Borders: Global Trends, Breakthroughs, and Preparedness	Convention Center - Hall F/G (Level 800)
11:	:30 a.m.	INTRODUCTION	
11:	:40 a.m.	MPOX RESURGENCE: UNDERSTANDING THE SHIFTING EPIDEMIOLOGY AND GLOBAL	IMPACT
11:	:55 a.m.	BREAKING BARRIERS IN MPOX DIAGNOSTICS: INNOVATIONS FOR EARLY DETECTION	N AND RESPONSE
12:	:10 p.m.	FROM TREATMENT TO CARE: ADVANCING CLINICAL MANAGEMENT OF MPOX	
12:	:25 p.m.	MPOX VACCINATION: CHALLENGES, OPPORTUNITIES, AND THE PATH FORWARD	
12:	:40 p.m.	MPOX AND BEYOND: RESEARCH PRIORITIES AND STRENGTHENING GLOBAL PREPA	REDNESS

Thursday, November 13 Room Name

11:30	a.m.	INTRODUCTION	
11:40	a.m.	DESIGN CONSIDERATIONS FOR MULTI-STAGE MALARIA VACCINES	
11:55	a.m.	LATEST ADVANCES IN BLOOD-STAGE AND MULTI-STAGE MALARIA VACCIN	NE TRIALS
12:10	p.m.	TRANSMISSION BLOCKING VACCINES: STRATEGIES AND CONSIDERATION	S FOR INTEGRATION INTO MULTISTAGE MALARIA
12:25	p.m.	OPPORTUNITIES AND CHALLENGES FOR MULTI-STAGE MALARIA VACCINE	TRIALS IN AFRICA
12:40	p.m.	ROLE OF MODELLING TO SUPPORT DECISIONS AND UNDERSTAND IMPAC	T OF MULTI-STAGE MALARIA VACCINES
12:50	p.m.	WHO MALARIA VACCINE PRIORITIES - FROM DEVELOPMENT TO IMPLEME	NTATION
1 p.m	١.	ADDITIONAL PANELISTS	
entific Session 1	91: Malar	ia - Parasite Transmission Biology	Convention Center - Room 701B (Level 700
11:30	a.m.	7948: ANTIMALARIAL RESISTANCE IN PLASMODIUM FALCIPARUM IMPACT	S THE MOSQUITO STAGES IN INSECTICIDE
11:40	a.m.	7949: GAMETOCYTE PRODUCTION AND INFECTIVITY AMONG UGANDAN UI	NCOMPLICATED MALARIA PATIENTS
11:50	a.m.	7950: THE ROLE OF PLASMODIUM FALCIPARUM GAMETOCYTOGENESIS IN	THE SPREAD OF RESISTANCE TO
Noon		7951: IT'S COMPLICATED: IDENTIFYING DRIVERS OF INVESTMENT IN SEXU	JAL REPRODUCTION IN COMPLEX PLASMODIUM
12:10	p.m.	7952: DETERMINANTS OF HUMAN-TO-MOSQUITO TRANSMISSION FROM T	HE ASYMPTOMATIC MALARIA RESERVOIR IN
12:20	p.m.	7953: UNRAVELING THE COMPLEXITIES OF PLASMODIUM FALCIPARUM A	ND <i>PLASMODIUM VIVAX</i> MIXED INFECTIONS
12:30	p.m.	7954: EVALUATION OF ATOVAQUONE'S BLOCKING ACTIVITY ON CLINICAL	ISOLATES OF PLASMODIUM FALCIPARUM

Thursda	y, November 13		Room Name
	12:40 p.m.	7955: PFAPIAT2 MEDIATES PROLINE TRANSPORT AND IS ESSENTIAL FOR O	OCYST DEVELOPMENT AND TRANSMISSION OF
	12:50 p.m.	7956: TRANSCRIPTOMIC PROFILE OF ANOPHELES GAMBIAE MOSQUITOES IN	NFECTED WITH THE NEGLECTED MALARIA
	1 p.m.	7957: MALARIA PARASITE DEVELOPMENT IN THE URBAN MALARIA VECTOR	ANOPHELES STEPHENSI UNDER VARIABLE
	mposium 192: Enhan aluating mhGAP's Im	cing Mental Health and Neglected Tropical Disease Program Integration: spact in West Africa	Convention Center - Room 713 (Level 700)
	11:30 a.m.	INTRODUCTION	
	11:35 a.m.	STATE OF THE FIELD: MENTAL HEALTH AND NTDS	
	11:55 a.m.	CASE STUDY 1: MHGAP IMPLEMENTATION IN LIBERIA	
	12:25 p.m.	CASE STUDY 2: MHGAP IMPLEMENTATION IN NIGERIA	
	12:55 p.m.	ADVOCACY AND LIVED EXPERIENCE: ELEVATING COMMUNITY VOICES	
EDU- CATION CONTENT	mposium 193: Innov	ations in Tropical Medicine and Global Health (TMGH) Education	Convention Center - Room 714 (Level 700,
	11:30 a.m.	INTRODUCTION	
	11:40 a.m.	DEVELOPMENT AND APPLICATION OF TMGH PROGRAMS: LESSONS LEARNE	D FROM TRAVEL MEDICINE RESIDENCY IN
	12:05 p.m.	A DEBATE AND UPDATE ABOUT INCLUDING A HANDS-ON LABORATORY IN D	TM COURSES: DOING AWAY WITH THE
	12:30 p.m.	LEVERAGING ARTIFICIAL INTELLIGENCE FOR TROPICAL MEDICINE EDUCATI	ON
	12:55 p.m.	USING "GAMIFICATION" PLATFORMS TO ENGAGE LEARNERS	
Symposic	ım 194: The Paradox	of IPTp: Balancing Malaria Control and Maternal and Infant Health Outcomes	Convention Center - Room 715 (Level 700)
	11:30 a.m.	INTRODUCTION	
	11:40 a.m.	SAFETY AND EFFICACY OF INTERMITTENT PREVENTIVE TREATMENT IN PRE	GNANCY WITH DIHYDROARTEMISININ

3	Room Name
EFFICACY OF DIHYDROARTEMISININ-PIPERAQUINE PLUS SULFADOX	INE-PYRIMETHAMINE ON INFANT MALARIA RISK
IMPACT OF INTERMITTENT PREVENTIVE TREATMENT IN PREGNANCY	ON PLASMODIUM FALCIPARUM DRUG RESISTANCE
DOES REPEATED DOSING OF DIHYDROARTEMISININ-PIPERAQUINE D	URING PREGNANCY HAVE A NEGATIVE IMPACT ON
SP, DP, OR DP+SP? WHICH REGIMEN DELIVERS MOST BENEFITS FOR	MATERNAL HEALTH, PREGNANCY OUTCOMES
ntimicrobial Resistance: Prevention and Control in LMIC Settings	Convention Center - Room 716 (Level 700)
INTRODUCTION	
AMR IN LMIC SETTING: AN OVERVIEW	
IDENTIFYING CONTEXT-SPECIFIC DETERMINANTS TO INFORM IMPRO	VEMENT OF ANTIMICROBIAL STEWARDSHIP
IMPACT OF THE FIRST NATIONAL ANTIMICROBIAL PRESCRIBING GUI	DELINES ON ANTIMICROBIAL PRESCRIPTIONS AMONG
DIVERSIFYING THE RESPONSE TO ANTIMICROBIAL STEWARDSHIP: S	TRATEGIES TO ADDRESS DISTINCTIVE BARRIERS
DIVERSIFYING THE RESPONSE TO ANTIMICROBIAL STEWARDSHIP: S	TRATEGIES TO ADDRESS DISTINCTIVE BARRIERS IN
DIVERSIFYING THE RESPONSE TO ANTIMICROBIAL STEWARDSHIP: S	TRATEGIES TO ADDRESS DISTINCTIVE BARRIERS IN
ANTIMICROBIAL STEWARDSHIP EFFORTS IN NEPAL	
r Xenomonitoring: A Game Changer for Eliminating Vector Borne tic Filariasis, Visceral Leishmaniasis, and Malaria	Convention Center - Room 717 (Level 700)
INTRODUCTION	
INTEGRATED VECTOR SURVEILLANCE: STRENGTHENING CONTROL, E	LIMINATION AND OUTBREAK DETECTION THROUGH
	EFFICACY OF DIHYDROARTEMISININ-PIPERAQUINE PLUS SULFADOX IMPACT OF INTERMITTENT PREVENTIVE TREATMENT IN PREGNANCY DOES REPEATED DOSING OF DIHYDROARTEMISININ-PIPERAQUINE D SP, DP, OR DP+SP? WHICH REGIMEN DELIVERS MOST BENEFITS FOR INTERIOR OF THE FIRST NATIONAL ANTIMICROBIAL PRESCRIBING GUI DIVERSIFYING THE RESPONSE TO ANTIMICROBIAL STEWARDSHIP: S DIVERSIFYING THE RESPONSE TO ANTIMICROBIAL STEWARDSHIP: S ANTIMICROBIAL STEWARDSHIP EFFORTS IN NEPAL IT XENOMORIOTING: A Game Changer for Eliminating Vector Borne tic Filariasis, Visceral Leishmaniasis, and Malaria

Thursday, Nover	mber 13		Room Name
11:55	5 a.m.	LEVERAGING MOLECULAR XENOMONITORING TO DETECT SUB-PATENT AND RARE	MALARIA PARASITE TRANSMISSION
12:10	0 p.m.	ENHANCING MOLECULAR XENOMONITORING FOR ACCELERATED LYMPHATIC FILAF	RIASIS ELIMINATION
12:25	5 p.m.	MOLECULAR XENOMONITORING IN LF ELIMINATION: FROM MAPPING HIDDEN HOTS	SPOTS TO POST-MDA SURVEILLANCE
12:40) p.m.	NEXT-GEN SURVEILLANCE: MULTIPLEXED REAL-TIME PCR FOR MOLECULAR XENOI	MONITORING OF VECTOR-BORNE
12:55	5 p.m.	APPLYING STATISTICAL PRECISION IN MOLECULAR XENOMONITORING: OPTIMIZING	G SURVEILLANCE FOR ELIMINATING
1:05	p.m.	HARNESSING MOLECULAR XENOMONITORING OF AEDES VECTORS FOR EARLY WAI	RNING AND SURVEILLANCE OF
		rst Non-artemisinin Combinations for falciparum Malaria: ng in WANECAM2 and Beyond	Convention Center - Room 718A (Level 700)
11:30	a.m.	INTRODUCTION	
11:40	a.m.	DEVELOPMENT OF CLINICAL TRIAL CAPACITY IN NIGER TO EXPAND THE MALARIA I	RESEARCH FOOTPRINT IN SSA
Noon	1	RESULTS OF THE KALUMA STUDY: PHASE 3 STUDY RESULTS OF GANAPLACIDE-LU	IMEFANTRINE SDF COMBINATION
12:20) p.m.	TRANSMISSION BLOCKING METHODOLOGY AND RESULTS	
12:40) p.m.	BEYOND WANECAM2: NEX-GENERATION COMBINATIONS AND APPROACHES FOR SI	NGLE-DOSE CURE
		ated Pathways: Key Regulators of Immune Response and ections and Potential Targets for Intervention	Convention Center - Room 718B (Level 700
11:30	O a.m.	INTRODUCTION	
11:40	a.m.	HYPOXIA AND T CELLS IN CUTANEOUS LEISHMANIASIS	
12:05	5 p.m.	PARASITIC INFECTIONS, HYPOXIA, AND B CELL FUNCTION: A COMPLEX IMMUNOLO	GICAL INTERPLAY
10.00) n m	HYPOXIA DRIVES THE IMMUNE RESPONSE AGAINST TRYPANOSOMA CRUZI INFECT	ION TO PROMOTE CHRONIC DISEASE
12:30	J p.111.	THE ONLY DRIVES THE IMPORE RESIDENCE AGAINST THE ANGSOLIA CHOZENIN EST	TOTAL TO THORSE OF THORSE DISEASE

Thursday, November 13	Room Name
-----------------------	-----------

	11:30 a.m.	INTRODUCTION	
	11:40 a.m.	INTEGRATING CLIMATE AND HEALTH DATA FOR EARLY WARNING OF INFE	ECTIOUS DISEASES IN BANGLADESH
	Noon	HOW TO IMPROVE THE USEFULNESS OF EWARS IN PRACTICE	
	12:20 p.m.	EXPANDING VECTOR-BORNE EARLY WARNING SYSTEM CAPACITY IN LATI	N AMERICA
	1 p.m.	BUILDING EWARS FOR CLIMATE-SENSITIVE DISEASES IN BANGLADESH: I	IMPLEMENTATION EXPERIENCE
· U-		sting Endemic Countries Today: Essential Components for Eliminating	Convention Center - Room 801B (Level 800
ITENT U		ns from Niger and Beyond	
TENT C	11:30 a.m.	INTRODUCTION	IATION
UENT U	11:30 a.m. 11:40 a.m.	INTRODUCTION NIGER: THE BUILDING BLOCKS OF SUCCESS IN ONCHOCERCIASIS ELIMIN	
U C	11:30 a.m.	INTRODUCTION	
TENT C	11:30 a.m. 11:40 a.m.	INTRODUCTION NIGER: THE BUILDING BLOCKS OF SUCCESS IN ONCHOCERCIASIS ELIMIN	IG THE INTERRUPTION OF ONCHOCERCIASIS
TIENT U	11:30 a.m. 11:40 a.m. Noon	INTRODUCTION NIGER: THE BUILDING BLOCKS OF SUCCESS IN ONCHOCERCIASIS ELIMIN SENEGAL: PRIORITIZING ENTOMOLOGICAL EVALUATIONS IN DETERMININ	IG THE INTERRUPTION OF ONCHOCERCIASIS ERRUPTION OF ONCHOCERCIASIS TRANSMISSION
TENT O	11:30 a.m. 11:40 a.m. Noon 12:20 p.m.	INTRODUCTION NIGER: THE BUILDING BLOCKS OF SUCCESS IN ONCHOCERCIASIS ELIMIN SENEGAL: PRIORITIZING ENTOMOLOGICAL EVALUATIONS IN DETERMININ PRIORITIZING ENTOMOLOGICAL EVALUATIONS IN DETERMINING THE INTE	IG THE INTERRUPTION OF ONCHOCERCIASIS ERRUPTION OF ONCHOCERCIASIS TRANSMISSION CALLY DRIVEN SOLUTIONS AND ADAPTIVE
TENT C	11:30 a.m. 11:40 a.m. Noon 12:20 p.m. 12:35 p.m. 12:50 p.m.	INTRODUCTION NIGER: THE BUILDING BLOCKS OF SUCCESS IN ONCHOCERCIASIS ELIMIN SENEGAL: PRIORITIZING ENTOMOLOGICAL EVALUATIONS IN DETERMININ PRIORITIZING ENTOMOLOGICAL EVALUATIONS IN DETERMINING THE INTE TACKLING ONCHOCERCIASIS IN VAST, UNSTABLE REGIONS THROUGH LOG	IG THE INTERRUPTION OF ONCHOCERCIASIS ERRUPTION OF ONCHOCERCIASIS TRANSMISSION CALLY DRIVEN SOLUTIONS AND ADAPTIVE
TENT O	11:30 a.m. 11:40 a.m. Noon 12:20 p.m. 12:35 p.m. 12:50 p.m.	INTRODUCTION NIGER: THE BUILDING BLOCKS OF SUCCESS IN ONCHOCERCIASIS ELIMIN SENEGAL: PRIORITIZING ENTOMOLOGICAL EVALUATIONS IN DETERMININ PRIORITIZING ENTOMOLOGICAL EVALUATIONS IN DETERMINING THE INTE TACKLING ONCHOCERCIASIS IN VAST, UNSTABLE REGIONS THROUGH LOG LEVERAGING COMMUNITY KNOWLEDGE AND THE HEALTH SYSTEM STRU	IG THE INTERRUPTION OF ONCHOCERCIASIS ERRUPTION OF ONCHOCERCIASIS TRANSMISSION CALLY DRIVEN SOLUTIONS AND ADAPTIVE CTURE TO ENHANCE THE PLANNING AND

Thursday, November 13 Room Name 11:50 a.m. THE DEVELOPMENT OF ESPERANZA WINDOW TRAPS: REFLECTIONS AND LESSONS LEARNED Noon OPTIMUM TRAPPING METHODOLOGIES FOR ADULT SIMULIUM VECTORS OF ONCHOCERCIASIS VARY ACCORDING TO... OPTIMIZING COLLECTION OF PAROUS BLACKFLIES USING BELLEC TRAPS 12:10 p.m. EXPERIENCES FROM DISSECT: BLACKELY TRAP DEVELOPMENT AND DEPLOYMENT IN WEST AND EAST AFRICAN... 12:20 p.m. FEASIBILITY OF ALTERNATIVE BLACKFLY COLLECTION METHODS FOR ONCHOCERCIASIS ELIMINATION PROGRAMS 12:30 p.m. 12:40 p.m. A ROADMAP TO SUPPORT THE USE OF BLACKFLY SURVEILLANCE METHODS IN ONCHOCERCIASIS ELIMINATION Symposium 202: Integrating Female Genital Schistosomiasis (FGS) into Health Systems: Convention Center - Room 602 (Level 600) Transformative Approaches to Advocacy, Training, and Service Delivery 11:30 a.m. INTRODUCTION

RECENT PROGRESS AROUND GLOBAL ADVOCACY AND CROSS-SECTORAL COLLABORATION IN FGS.

MAI AWI'S INTEGRATION OF EGS AND MGS INTO NATIONAL GUIDELINES FOR THE SYNDROMIC MANAGEMENT OF...

INTEGRATING A MINIMUM SERVICE PACKAGE (MSP) FOR FGS INTO REPRODUCTIVE HEALTH SERVICES IN KENYA...

CAPACITY- BUILDING TO ADDRESS FGS: INNOVATIVE DIGITAL PEFR-L FARNING PLATFORMS TO FQUIP HEALTHCARE...

1:15 p.m.

ASTMH 2025 Annual Meeting Adjourns

11:40 a.m.

12:05 p.m.

12:30 p.m. 12:55 p.m.


See you next year at the ASTMH 2026 Annual Meeting

November 18-22, 2026 (Wednesday through Sunday)

Gaylord National Harbor


National Harbor, MD, USA (adjacent to Washington, DC)


Metro Toronto Convention Centre — South Building Level 400




Metro Toronto Convention Centre — South Building Level 500











InterContinental Toronto





Thank You to #TropMed25 Sponsors



Gates Foundation





COLUMBIA UNIVERSITY

College of Physicians and Surgeons







Malaria Research Institute

Travel Grants

Gates Foundation

GiveWell





All individuals who made a donation during registration and throughout the year.

Friends of the Young Investigators

William A. Petri, Jr. in memory of William A. Petri Sr.
All individuals who made a donation during
registration and throughout the year.

Supporters





Partners



Become an Affiliate Member of ASTMH

Affiliate Membership offers a cost-effective way for universities, university programs, NGOs, research groups and professional societies throughout the world that have an interest in clinical and basic tropical medicine, infectious diseases and global public health to join and lend their voice to a Society that is a leader in its field.



Visit **astmh.org** to learn more about ASTMH membership.






Affiliate membership within these organizations and institutions is particularly focused on bringing together students, trainees and early-career professionals, and enabling them to take advantage of ASTMH benefits. For universities and other programs with few resources to devote to advocacy, this category offers the opportunity to join in the messaging of a trusted and respected scientific society.

It is expected that Affiliates around the globe will develop a sense of community around shared goals of global health equity.

BENEFITS OF AFFILIATE MEMBERSHIP

- Membership for the designated university faculty member, program director or NGO representative
- ▶ Membership for up to 15 pre- or post-doctoral students
- ▶ Visit astmh.org for benefits and access to the membership application



GOTropMEd, the ASTMH Global Online Tropical

Medical Education website, is a members-only benefit offering webinars, policy updates and presentations from world experts in tropical medicine, hygiene and global health. Researchers, clinicians, students, trainees and health professionals can access more than 300 resources curated especially for the Society's digital education efforts.

Free and unlimited access to GOTropMEd is a benefit of membership to ASTMH. Non-members will need to **join ASTMH** to access **GOTropMEd**.

GOTropMEd.astmh.org

Notes	
	_

Z
0
÷
ന
S

Notes	
	•
	-
	_
	-
	_
	_
	_
	-
	-

Z
0
=
מו


Notes				

Notes	
	•
	-
	_
	-
	_
	_
	_
	-
	-



The American Journal of Tropical Medicine and Hygiene publishes 1-3 supplemental issues a year that are dedicated to a specific topic in tropical medicine.









To view all supplements, visit ajtmh.org and click on Issues.

Interested in producing a supplement? Contact Alison Jaeb, Managing Editor and Publisher at journal@ajtmh.org.

Medscape EDUCATION GLOBAL



Breaking Dengue's Grip

Epidemiology, Immune Responses, and Vaccine Advances

TUESDAY, NOVEMBER 11, 2025 | 6:15 PM − 8:00 PM ET IN-PERSON (*)

CONVENTION CENTRE | ROOM: 718A | Dinner buffet will be served!

Moderator/Course Director: Davidson H. Hamer, MD | Boston, Massachusetts, United States

AGENDA

- Welcome and Introductions
- · Medscape Quiz Show: Dengue, A Public Health Concern
- · Immune Responses During Dengue Infection
- Overview of the Currently Available Dengue Vaccines
- Bridging the Gap: Understanding Risk and Vaccine Acceptance
- Panel Discussion
- Summary and Audience Q&A



This sponsored symposium is held in conjunction with the 2025 ASTMH Annual Meeting

For more information and to register, visit: www.medscape.org/symposium/dengue-epidemiology-ir-vaccination

Supported by an independent educational grant from Takeda.

Mark Your Calendar





ASTMH 2026 ANNUAL MEETING

November 18-22, 2026

(Wednesday through Sunday)

Gaylord National Harbor

National Harbor, MD, USA (adjacent to Washington, DC)

ASTMH 2027 ANNUAL MEETING

November 7-11, 2027 (Sunday through Thursday)
Gaylord Rockies

Denver, CO, USA

ASTMH 2028 ANNUAL MEETING

October 18-22, 2028 (Wednesday through Sunday)

Seattle Convention Center

Seattle, WA, USA